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Tobacco smoking is a major risk factor in the development of oesophageal squamous cell 
carcinoma (OSCC). Benzo[a]pyrene (BaP) is a tobacco smoke procarcinogen that is 
metabolically activated into the carcinogenic benzo[a]pyrene diol-epoxide (BPDE) by the 
CYP1 family of cytochrome P450 enzymes. BaP is a ligand for the aryl hydrocarbon 
receptor (AhR) which activates CYP1 gene transcription. Polymorphisms in these genes 
affect enzyme activity and therefore BaP bioactivation.  
 
The effects of BaP on expression of CYP1A1, CYP1B1 and the AhR and cell 
proliferation were compared between a normal oesophageal epithelial cell line (EPC-2) 
and an OSCC cell line (WHCO1). Transcriptional profiling f the effects of BaP 
treatment on global gene expression in WHCO1 and EPC-2 cells was carried out using an 
Illumina microarray system and the data analyzed using Ingenuity Pathways Analysis 
(IPA) software. Treatment with BaP induced CYP1A1 and CYP1B1 mRNA and protein 
to a greater extent in WHCO1 compared to EPC-2 cells, and their levels remained 
elevated when BaP was removed. Nuclear translocation and exit of AhR and ARNT was 
more rapid in EPC-2 cells during BaP treatment and withdrawal than in WHCO1 cells. 
Genes involved in inflammation and xenobiotic metabolism were differentially expressed 
in WHCO1 cells, while genes involved in cell cycle regulation and the DNA damage 
response were differentially expressed in EPC-2 cells.  
 
These results suggest that WHCO1 cells are more efficient at CYP1 induction and 
therefore BaP bioactivation than normal cells. Prolonged CYP1 induction and nuclear 
AhR-ARNT signaling events in WHCO1 cells may contribute to cancer maintenance or 
promotion, while reduced CYP1 induction in EPC-2 cells may result in less efficient BaP 
detoxification and subsequent accumulation of DNA-damaging metabolites which cause 


















1.1 Incidence of Oesophageal Cancer (OC) and Oesophageal Squamous Cell 
Carcinoma (OSCC) 
 
OC is the eighth most common cancer worldwide and the sixth most common cause of cancer-
related deaths worldwide (Ferlay et al., 2010). In 2008, there were an estimated 482 000 new OC 
cases and 407 000 deaths worldwide, with more than 80% of cases and deaths occurring in 
developing countries (Ferlay et al., 2010). The global incidence and mortality of OC are highest 
along the “oesophageal cancer belt” from Southern and Eastern Africa to the Middle East and 


























Figure 1.1 Global incidence and mortality of OC. The estimated age-standardized incidence and 
mortality rates of oesophageal cancer in males and females according to global region. Incidence and 
mortality rates are higher in Southern and Eastern Africa and Asia, and less developed areas of the world 












The incidence of OC is two to four times higher in males than females, with age-standardized 
incidence rates (ASIR) in males varying from 1.4 to 22.3 per 100 000, depending on the region 




















Figure 1.2 Global distribution of OC ASIR per 100 000 males. Global regions with highest 
incidence rates of OC include Southern and Eastern Africa and Asia, with ASIR exceeding 20 per 100 000 
(dark red areas). OC incidence is two to four times higher in males than females. (Taken from IARC 
Globocan 2008: http://globocan.iarc.fr/) 
 
 
There are two histological types of OC: adenocarcinoma, which is more prevalent in developed 
countries; and squamous cell carcinoma (OSCC), which comprises 90% of OC cases in 
developing countries (Pisani et al., 1999).  Adenocarcinoma and Barret’s oesophagus occur in the 
lower third of the oesophagus mainly at the gastroesophageal junction, whereas OSCC occurs in 
the upper two thirds of the oesophagus (Fig. 1.3). 
 
In South Africa, OSCC is the third leading cancer in Black males, who have a lifetime risk of 1 in 
59 for developing the disease (Hendricks and Parker, 2002, Mqoqi et al., 2004, Pickens and 
Orringer, 2003). The ASIR is 32.7/100 000 for males and 20.2/100 000 for females (Somdyala et 
al., 2010). The mortality rate is very high: 75% of patients die within the first year after diagnosis 
and the 5-year survival rate is less than 10% (Hendricks and Parker, 2002, Hiyama et al., 2007). 
This is due to the fact that patients are asymptomatic until the disease has progressed to an 

























Figure 1.3 Positions of the histological types of OC. Oesophageal adenocarcinoma occurs in the 
lower third of the oesophagus, mainly at the gastroesophageal junction, whereas OSCC develops in 
epithelial cells from the upper two thirds of the oesophagus (Taken from http://www.sts.org/patient-
information/esophageal-surgery/esophageal-cancer)).   
 
 
1.2 Risk Factors for the Development of OSCC 
 
Epidemiological evidence has suggested that the major risk factors for the development of OSCC 
include tobacco smoking, alcohol consumption and defects in the genes encoding enzymes 
involved in their metabolism. Gene-environment interactions therefore play an important role in 
oesophageal carcinogenesis. Several minor risk factors have also been identified; however they 
will not be the focus of this study. Minor risk factors include infection with the human papilloma 
virus (HPV) (Matsha et al., 2002), a diet lacking in fruit and vegetables (Franceschi et al., 2000), 
reduced dietary vitamin D intake (Lipworth et al., 2009), contamination of food with aflatoxins 
and fumonisin (Marasas, 2001, Wild and Gong, 2010), exposure to smoke while cooking on open 
fires (Pacella-Norman et al., 2002) and physical injury due to consumption of hot beverages 
(Islami et al., 2009) or forced vomiting, which is a form of ritual cleansing in some cultures 
(Matsha et al., 2006).  
 
1.2.1 Genetic Polymorphisms 
 
Inter-individual genetic differences can explain why susceptibility to cancer varies despite similar 
exposures to environmental carcinogens. These genetic differences occur as a result of 
polymorphic genes within the genome. Polymorphisms are variations in a gene that occur with a 
frequency of at least 1% within a population. The gene’s two copies, or alleles, could therefore 











common allele (which has the highest frequency within a population) or a polymorphic variant. 
For example, this can be represented by the notation CYP1A1 4889A>G, which indicates that at 
base pair 4889 in the CYP1A1 gene, the common A allele can be replaced by the polymorphic 
variant, the G allele. 
 
Polymorphic variants in detoxification genes or xenobiotic metabolism give rise to enzymes with 
altered specificity, increased, reduced or abolished catalytic activity, or altered regulation and 
expression (Ingelman-Sundberg, 2001). In the case where polymorphic variants result in 
increased enzyme activity, the common allele can be referred to as the “slow” or “low activity” 
allele, and the polymorphic allele is referred to as the “fast” or “high activity” allele. These 
alterations can influence the enzyme’s detoxification efficiency and therefore also susceptibility 
to cancer.  
 
The frequency of polymorphic alleles may also vary between ethnic groups, thereby contributing 
to inter-ethnic variation. Several case-control studies have shown that genetic polymorphisms in 
various genes are associated with increased or decreased risk of developing OSCC. 
Polymorphisms in several xenobiotic metabolism genes are associated with increased risk for the 
development of OSCC (Li et al., 2005, Dandara et al., 2005, Dandara et al., 2006, Li et al., 2008, 
Li et al., 2010). Furthermore, this effect on OSCC risk is often enhanced by smoking or alcohol 
consumption, which highlights their roles as major risk factors for OSCC (Table 1.1). 
 
Mutations in important cell cycle regulatory genes, such as p53, can also play a role in the 
development of OSCC. p53, a known tumour suppressor gene, is a transcription factor that 
regulates the transcription of genes involved in cell cycle progression, DNA repair and apoptosis 
(Levine, 1997). p53 is mutated in more than 50% of human tumours, including lung cancers 
(Hahn and Weinberg, 2002, Hainaut and Pfeifer, 2001). Mutations in p53 have been identified in 




















Table 1.1 Polymorphisms in xenobiotic metabolism genes and their association with OSCC 
development in South African populations. CYP: cytochrome P450, SULT: sulfotransferase, 
GST: glutathione S-transferase, ADH: alcohol dehydrogenase, ALDH: aldehyde dehydrogenase 
 
Gene Polymorphism Association with 
OSCC 
Smoking/ alcohol 
consumption and risk 
Reference 





Li et al., 
2005 




reduced OSCC risk 
AA or AG genotype 
associated with increased 




SULT1A1*2 638G>A Associated with 
OSCC 




GSTP1 341 C>T T allele associated 
with increased risk 
Higher risk in tobacco 
smokers and alcohol 
consumers 
Li et al., 
2010 
GSTT1*0 Deletion Increased risk - Li et al., 
2010 
GSTM1*0 Deletion Decreased risk in 
Mixed Ancestry 
subjects 




Increased risk in 
Black subjects 
Higher frequency in non-
alcohol consumers 




Increased risk in 
Black subjects 




1.2.2 Alcohol Consumption 
 
Alcohol consumption is a major risk factor for the development of OSCC. In South Africa, 
consumption of traditional home-brewed beer in rural high-incidence areas may be a major 
contributory factor to the risk of alcohol consumption-associated OSCC (Matsha et al., 2006). 
 
Alcohol dehydrogenases (ADH) in the liver metabolize ethanol to acetaldehyde and aldehyde 
dehydrogenases (ALDH) then metabolize acetaldehyde to acetate. Acetaldehyde is carcinogenic 
and forms mutagenic adducts with DNA (Seitz and Stickel, 2007). Genetic polymorphisms that 
result in acetaldehyde accumulation, such as reduced or abolished ALDH activity, are associated 
with increased OSCC risk (Yokoyama et al., 2003, Li et al., 2008). Alcohol metabolism also 
increases levels of reactive oxygen species (ROS) through the action of cytochrome P450 (CYP) 
2E1, which can lead to DNA damage and lipid peroxidation. The role of ethanol metabolism in 















Figure 1.4 Schematic representation of ethanol 
metabolism and its role in carcinogenesis. Ethanol is 
metabolized by ADH and CYP2E1 in the liver to the 
carcinogenic acetaldehyde, which is metabolized to acetate by 
ALDH, thereby completing the ethanol detoxification pathway. 
Acetaldehyde, however, also binds DNA and forms DNA 
adducts. Increased CYP2E1 activity results in increased ROS, 
which together with DNA adduct formation, increase the DNA 
damage that leads to carcinogenesis. ADH: alcohol 
dehydrogenase, ALDH: aldehyde dehydrogenase, CYP2E1: 
cytochrome P450 2E1, ROS: reactive oxygen species. (Adapted 








1.2.3 Tobacco Smoking 
 
Tobacco smoking is the major risk factor for the development of OSCC, lung, kidney, bladder, 
pharyngeal, laryngeal, pancreatic, breast and oral cancers (Hecht, 2006). About 4800 compounds 
have been identified in tobacco smoke (Green & Rodgman, 1996) including more than 60 known 
carcinogens (IARC, 2004). The most important groups of carcinogens in cigarette smoke are the 
polycyclic aromatic hydrocarbons (PAHs) and N-nitrosamines, although aromatic amines, 
formaldehyde, organic compounds, metals and other chemicals are also listed as carcinogens 
(Hecht, 2006). Some of the toxic and carcinogenic compounds in cigarette smoke are indicated in 
Figure 1.5. 
 
Many intermediates generated during the metabolism of compounds in tobacco smoke are highly 
reactive with DNA. Their molecular mechanism of action is via their ability to bind covalently to 
DNA and form mutagenic adducts (Toh et al., 2010). The role of cigarette smoke compounds in 


















Figure 1.5 Compounds present in 
cigarettes. Known carcinogenic chemicals are 
indicated by *. PAHs are products of combustion 
formed during tobacco and cigarette smoking. 










Figure 1.6 Schematic representation of the 
role of cigarette smoke compounds in 
carcinogenesis. Compounds in cigarette smoke, e.g. 
PAHs or N-nitrosamines, are metabolically activated 
by cytochrome P450s into metabolites that bind 
DNA. Increased DNA adducts enhance DNA 
damage and the genetic mutations that precede 
carcinogenesis. PAH: polycyclic aromatic 
hydrocarbon, GST: glutathione S-transferase, UDP-
GT: uridine diphosphate glucuronosyltransferase. 





PAHs are combustion products in tobacco smoke and require metabolic activation by xenobiotic 
metabolizing enzymes to generate their carcinogenic intermediates. Exposure to PAHs has been 
associated with lung, bladder and breast cancer (Bostrom et al., 2002). The hydrophobic ring 
structure common to all PAHs allows their passive entry through cell membranes and into cells, 
where they can accumulate and exert their carcinogenic effects. One of the 10 PAHs identified in 
















1.3      Benzo[a]pyrene (BaP) 
 
1.3.1 BaP Sources and History 
 
BaP is a five-ring hydrophobic PAH (Fig. 1.7) found in tobacco smoke, burning wood, fuel 
exhaust emissions, environmental pollution and charred meat (Bostrom et al., 2002, Phillips, 
1999). It has been estimated that there is 25ng of BaP per one cigarette (Schmeltz et al., 1974) 
and that the average daily environmental BaP intake is 600ng/day (Scherer et al., 2000). It is the 
prototypic and most commonly studied PAH, probably because it is a good indicator for levels of 
exposure to all PAHs (Fertmann et al., 2002). BaP was first isolated from coal tar in the 1930s 
(Cook et al., 1933) and shown to form papillomas and tumours when repeatedly applied to mouse 
skin and rabbit ears (Yamagiwa and Ichikawa, 1977, Rubin, 2001, Baird et al., 2005). BaP can act 
as both an initiator and promoter of tumorigenesis (Rubin, 2001) and is a procarcinogen that 
requires metabolic activation to form its carcinogenic metabolites. 
 
1.3.2 BaP Metabolism: Detoxification and Metabolic Activation 
 
BaP is metabolized in a two-phase reaction by several xenobiotic metabolizing enzymes (XMEs), 
generating more than a dozen metabolites (Fig. 1.7). Phase I metabolism is carried out by 
cytochrome P450 (CYP) enzymes and epoxide hydrolase, generating intermediate metabolites 
such as diols, oxides and phenols. These intermediates are then conjugated to endogenous 
compounds by the phase II enzymes UDP-glucuronosyltransferases (UGTs), sulfotransferases 
(SULTs), glutathione S-transferases (GSTs), aldo-keto reductases (AKRs) and NADPH quinone 
oxidoreductases (NQO1s). The products formed by these conjugation reactions are sufficiently 
water-soluble to allow easy excretion from the body (Guengerich and Shimada, 1998, Nebert and 
Dalton, 2006). 
 
While this system usually results in efficient BaP detoxification, highly reactive intermediates are 
formed during phase I metabolism (which in this case is called metabolic activation). CYP1A1, 
CYP1B1 and epoxide hydrolase enzymes metabolically activate BaP to form 
anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE), the ultimate carcinogen generated by BaP 
metabolism. BPDE has four isomers, ± anti and ± syn, of which the + isomer of anti-BPDE is the 
most active (Fig. 1.8, Miller and Ramos, 2001). In cases where phase II metabolism is absent or 






























Figure 1.7 Metabolism of BaP by phase I and II enzymes and the metabolites generated. See text for 
discussion. Phase I enzymes: P450, EH; Phase II enzymes: UGT, SULT, GST, NQO1, AKR. P450: 
cytochrome P450 (CYP), EH: epoxide hydrolase, SULT: sulfotransferase, UGT: UDP-
glucuronosyltransferase, GST: glutathione S-transferase, AKR: aldo-keto reductase, NQO1: NADPH 




1.3.3 BaP Mechanism of Carcinogenicity 
 
BaP exposure is believed to contribute to carcinogenesis in two ways: by enhancing oxidative 
stress during its metabolism and by forming adducts with cellular components. Carcinogen-DNA 
adducts have been identified in human oesophagus (Harris et al., 1979). 
 
The generation of oxidized BaP metabolites during phase I metabolism increases cellular ROS 
levels, which promote oxidative and genotoxic stress, including lipid peroxidation and DNA 
damage. Increased ROS, oxidative stress and inflammation have been linked to cancer (Coussens 
and Werb, 2002, Valko et al., 2006). ROS like the BaP-quinones (BPQ) 1,6-BPQ and 3,6-BPQ 
generated during BaP metabolism form the superoxide anion (O2-) and hydrogen peroxide (H2O2) 
in breast epithelium (Burdick et al., 2005). BaP metabolism also forms ˙OH (hydroxyl radical, 




































Figure 1.8 Mechanism of metabolic activation of BaP. During phase I metabolism, CYP1A1, 
CYP1B1 and epoxide hydrolase metabolically activate BaP and form anti BPDE-1 and -2. The + isomer of 
anti-BPDE is the most active BPDE isomer (+(BPDE)-2). EH: epoxide hydrolase, P450: cytochrome P450 
(CYP). (Taken from Shimada, 2006). 
 
 
Most studies have focused on the formation of DNA adducts by the carcinogenic BaP metabolite, 
BPDE. Covalent binding of BPDE to DNA residues results in the formation of bulky BPDE-N2-
deoxyguanosine (BPDE-N2-dG, Fig. 1.9) and BPDE-N6-deoxyadenosine (BPDE-N6-dA) adducts 
(Cheng et al., 1989). The BPDE-N2-dG adduct occurs more frequently and results in G>T 
transversion mutations (Glick et al., 2009, Chiapperino et al., 2002), especially in mutational 
hotspots of the p53 tumour suppressor gene (Denissenko et al., 1996, Chen et al., 1998, Hainaut 
and Pfeifer, 2001) and in other genes, such as the c-Ha-ras1 proto-oncogene (Yang et al., 1999). 
The BPDE-N2-dG adduct occurs in the minor groove of B-DNA and is 5-oriented along the 
modified strand, resulting in a bulky change in DNA conformation (Fig. 1.10, Kropachev et al., 
2009). The formation of mutations is influenced by the DNA sequence context around the adduct 
(Miller and Ramos, 2001, Kropachev et al., 2009), the conformational change caused by the 
adduct (Kozack et al., 2000) and the state of methylation of CpG sites (Glick et al., 2009, Chen et 
al., 1998). The removal of BPDE-DNA adducts occurs through the nucleotide excision repair 
(NER) mechanism, however, mutations can be introduced during DNA replication if low fidelity 
polymerases bypass the adduct without repairing the mutation (Jia et al., 2008). For example, 
while pol  accurately repairs BPDE-DNA lesions, pol  is error-prone (Chiapperino et al., 2002, 


























Figure 1.9 Chemical structure of the BPDE-N2-dG adduct. BPDE binds to either deoxyadenosine or 
deoxyguanosine residues in DNA. BPDE-N2-dG is the major BPDE-DNA adduct which, if not correctly 
repaired, results in G>T transversion mutations, especially in the p53 gene. Mutations caused by BPDE-














Figure 1.10 Conformation of the BPDE-N2-dG adduct in the minor groove of DNA. The bulky 
structure of BPDE causes a conformational change in the double helix. Error-prone DNA polymerases 




1.3.4 Effect of BaP and BPDE on the Cell and Signal Transduction Pathways 
 
BaP has been shown to be carcinogenic, cytotoxic, mutagenic and teratogenic (Uno et al., 2004). 
Both BaP and BPDE induce apoptosis (Solhaug et al., 2004b). BaP affects DNA methylation in 
breast cancer cells (Sadikovic and Rodenhiser, 2006) which is interesting in light of the evidence 
that BPDE preferentially targets methylated CpG sites for G>T mutations (Yoon et al., 2001). 
BaP has been shown to affect the normal function of signal transduction cascades, including Ca2+ 
signaling, epidermal growth factor (EGF) signaling, protein kinase C (PKC) signaling and 
phosphorylation (Miller and Ramos, 2001) and insulin-like growth factor signaling (Tannheimer 
et al., 1998). BaP has also been shown to affect the expression of various genes, for example, 












involved in inflammation and frequently upregulated in OSCC (Shamma et al., 2000). BaP 
exposure has been shown to cause altered expression of nuclear proteins and alternative mRNA 
splicing in response to DNA damage (Yana et al., 2010). 
 
BPDE has been shown to induce aberrations in chromosome 9p21 in bladder cancer (Hazra et al., 
2004, Gu et al., 2008), chromosome 3p21.3 in lung cancer (Wu et al., 1998) and chromosome 
instability and the amplification of centromeres in lung cancer (Shinmura et al., 2008). BPDE 
affects the expression of various genes, including repression of the retinoic acid receptor beta 2 
gene (Song et al., 2005). 
 
BaP is able to regulate the expression of some genes by activating the aryl hydrocarbon receptor 
(AhR). BaP, along with other PAHs and the environmental pollutant 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD), is a ligand for the AhR. Ligand-activated AhR is a transcription factor that 
regulates the transcription of several genes, including some phase I xenobiotic metabolism genes. 
The influence of xenobiotics such as BaP on abnormal cell growth and cancer through the AhR 
and increased ROS is summarized in Figure 1.11. PAHs can also induce gene expression in an 













Figure 1.11 Xenobiotic exposure as a risk factor for cancer development. Xenobiotics such as BaP 
contribute to abnormal cell growth and cancer by affecting the expression and regulation of cancer-related 
genes, including RB1 and NFB, and increasing DNA damage through ROS and inflammation. CYP1: 
cytochrome P450 1 family, AHR: aryl hydrocarbon receptor, RB1: retinoblastoma protein, NFB: nuclear 
factor kappa B, ESR1: estrogen receptor 1, PAHs: polycyclic aromatic hydrocarbons, PHAHs: polycyclic 
halogenated aromatic hydrocarbons, PCBs: polychlorinated biphenyls, ROMs: reactive oxygenated 















1.4 Xenobiotic Metabolizing Enzymes (XMEs) 
 
1.4.1 Xenobiotic Exposure as a Risk for Cancer  
 
Humans are exposed to xenobiotics or foreign compounds through many sources including 
environmental pollution, pharmaceutical drugs, tobacco smoke, alcohol, preservatives and 
insecticides in food and petrol exhaust emissions. The oesophagus is a target organ for most of 
these xenobiotics. Many of these chemicals are harmful to the body if they accumulate during 
prolonged exposure, which may result in toxicity and eventually, cancer. XMEs evolved in order 
to detoxify and eliminate these foreign chemicals from the body and thereby protect against 
carcinogenesis. 
 
1.4.2 Mechanism of Xenobiotic Metabolism 
 
Metabolism of xenobiotics such as BaP occurs in a two-phase reaction catalyzed by phase I and II 
XMEs (Fig. 1.12). Phase III XMEs are responsible for the transport and removal of the detoxified 
product. 
 
1.4.2.1 Phase I XMEs 
 
Phase I metabolism is carried out primarily by cytochrome P450 (CYP) enzymes that catalyze the 
oxidation, reduction or hydrolysis of the xenobiotic substrate, to form an electrophilic 
intermediate (Nebert and Dalton, 2006). Metabolic activation of procarcinogens such as BaP 
occurs during Phase I metabolism (Fig. 1.8). Other phase I XMEs include epoxide hydrolase 
(EPHX). Polymorphisms in EPHX1 have been associated with increased risk of lung and 
oesophageal cancers (Gsur et al., 2003, Jain et al., 2008, Ihsan et al., 2010). 
 
1.4.2.2 Phase II XMEs 
 
Phase II metabolism is carried out by conjugation enzymes that catalyze the conjugation of the 
intermediate from Phase I metabolism to an endogenous compound, such as glutathione, uridine 
diphosphate (UDP)-glucuronic acid or sulfate groups. These XMEs include glutathione S-
transferase (GST), UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), N-
acetyltransferase (NAT), aldo-keto reductase (AKR) and NADPH quinone oxidoreductase 
(NQO1) (Nebert and Dalton, 2006). Conjugated products are more water-soluble and are easily 
excreted from the body. Conjugation of BaP intermediates is catalyzed by all of the 











1.4.2.3 Phase III XMEs 
 
Phase III XMEs are transporter proteins expressed in the liver and intestine that play a role in 
absorption, distribution and excretion of the detoxified xenobiotic (Bozina et al., 2009). 
Transporters include P-glycoprotein, organic anion transporting polypeptide 2 and multi-drug 


























Figure 1.12 Mechanism of xenobiotic metabolism. Phase I XMEs oxidize the xenobiotic to form a 
reactive electrophilic intermediate. Phase II XMEs then conjugate the intermediate to an endogenous 
compound such as glutathione, rendering the product more water-soluble to facilitate elimination from the 
body. Increased activity of Phase I XMEs and decreased activity of phase II XMEs results in deregulated 
xenobiotic metabolism and an accumulation of carcinogenic intermediates that contribute to the 
development of cancer. 
 
 
1.4.3 Deregulated Xenobiotic Metabolism as a Risk for Cancer Development 
 
While the two-phase system normally functions efficiently to detoxify and remove xenobiotics, 
deregulated xenobiotic metabolism can lead to an imbalance of the intermediates and products 
formed and may contribute to the development of cancer when the xenobiotic is a procarcinogen.  
Increased activity of Phase I XMEs and decreased or abolished activity of phase II XMEs can 
result in an accumulation of carcinogenic intermediates such as BPDE because the rate of phase I 
metabolism exceeds that of phase II metabolism (Fig. 1.12). Polymorphisms in phase I and II 
























increased, decreased or abolished enzyme activity or different substrate specificity (Ingelman-
Sundberg, 2001). 
 
1.5      Cytochrome P450 enzymes (CYPs) 
 
CYPs are haem-thiolate monooxygenases that form 70-80% of all phase I XMEs (Ingelman-
Sundberg, 2004). They are membrane-bound microsomal enzymes that function, with an NADPH 
cytochrome P450 reductase as a two-step electron donor, to catalyze reactions involving the 
incorporation of one atom of molecular oxygen into its substrate (Bernhardt, 2006). These 
reactions include hydroxylation, epoxidation, N, S and O-dealkylation and oxygenation. All 
CYPs have a conserved peptide motif – Phe-X(6-9)-Cys-X-Gly, where X is any amino acid – in the 
iron-binding thiol group (Nebert and Dalton, 2006). The nomenclature of all human CYPs is 
maintained by the Human CYP Allele Nomenclature Committee, which is accessible at 
http://www.cypalleles.ki.se/ (Ingelman-Sundberg et al.). 
 
1.5.1 Role of CYPs in Xenobiotic Metabolism 
 
CYPs are classified according to amino acid sequence similarity, with families and subfamilies 
sharing 40% and 55% sequence identity, respectively (Nebert and Russell, 2002). While 57 CYP 
genes have been identified and classified int  18 families and 42 subfamilies, only the CYP1, 
CYP2, CYP3 and CYP4 families are involved in xenobiotic metabolism (Kawajiri and Fuji-
Kuriyama, 2007). Of these, important xenobiotic metabolizing CYPs include CYP1A1, CYP1B1, 
CYP1A2, CYP2E1, CYP3A4, CYP3A5 and CYP2D6. Since these CYP enzymes are responsible 
for most phase I xenobiotic metabolism, they also play a role in metabolic activation of 
procarcinogens. The CYP1 family is particularly interesting because of their role in metabolism 
of BaP. Tissue-specific expression of one or more of these CYPs may influence procarcinogen 
activation and therefore susceptibility to xenobiotic-associated cancer. 
 
1.5.2 CYP1 Family 
 
The CYP1 family plays an important role in xenobiotic metabolism and comprises three highly 
conserved isomers: CYP1A1, CYP1A2 and CYP1B1. The expression of the CYP1 genes is 
induced by PAHs such as BaP; the current understanding of PAH-inducible CYP1 gene 














CYP1A1 is located on chromosome 15q22-24 and consists of 6 introns and 7 exons, encoding a 
protein consisting of 512 amino acids (Jaiswal et al., 1985). CYP1A1 is primarily expressed in 
extrahepatic tissues including the oesophagus (Nakajima et al., 1996, Lechevral et al., 1999). 
CYP1A1 is responsible for the metabolism of many xenobiotics including theophylline, caffeine, 
7-ethoxyresorufin and chlorzoxazone and various PAHs (Bozina et al., 2009, Shimada, 2006). 
CYP1A1 mRNA and protein are present at very low, almost undetectable basal levels, but are 
highly inducible by various compounds (Nebert et al., 2004, Ma and Lu, 2007). These include 
PAHs such as BaP and the classical inducer of CYP1A1, TCDD (Whitlock, 1999). CYP1A1 
induction has been linked to the toxicity and resulting cell death from BaP treatment in cultured 
cells (Ma and Lu, 2007). 
 
Several polymorphic variants of CYP1A1 have been identified, including CYP1A1*2B, *2C, *3, 
*4, *5, *6, *7, *8, *9, *11 that result in amino acid changes (Bozina et al., 2009). Several 
CYP1A1 polymorphisms have been associated with cancer susceptibility in smoking-associated 
cancers including lung, oral, oesophageal, breast and colon cancers (Taioli et al., 2003, Kao et al., 
2002, Nimura et al., 1997, Miyoshi et al., 2002, Pande et al., 2010). While some studies have 
linked these polymorphic gene variants to enzymes with different catalytic activities, it remains 
unclear whether polymorphisms can be linked to increased enzyme activity in all cases. For 
example, there is contradictory data implicating the CYP1A1*2C allele (4889A>G in exon 7 or 
Ile462Val) with increased risk of lung cancer (Landi et al., 2005, Houlston, 2000, Le Marchand et 
al., 2003). CYP1A1*2C is also associated with increased enzyme activity and mRNA induction 
(London et al., 2000, Agudo et al., 2009). Differences in polymorphism frequencies between 
populations may influence inter-population differences in cancer susceptibility, especially in 
cancers where CYP1A1 plays a role in carcinogen metabolism. For example, the frequency of the 
CYP1A1 4889A/A genotype is highest in Africans (94.8%) and Caucasians (90.2%), while the 
A/G genotype occurs with the highest frequency in Asians (36%). The 4889G/G genotype occurs 
with highest frequency in Asians (4.9%) but is very rare in Caucasians (0.6%) and does not occur 
in Africans (0%) (http://www.ncbi.nlm.nih.gov/SNP/). Since CYP1A1 is involved in PAH 
metabolism and therefore metabolic activation, the high-inducibility of the CYP1A1*2C 
















CYP1B1 is located on chromosome 2p21 and consists of 2 introns and 3 exons, of which exons 2 
and 3 encode a protein of 543 amino acids (Sutter et al., 1994). CYP1B1 shares 40% amino acid 
homology with CYP1A1 (Shimada et al., 1996) and while they have overlapping substrate 
specificity, they differ in metabolic efficiency (Shimada and Fujii-Kuriyama, 2004). CYP1B1 has 
higher basal levels than CYP1A1 and is also inducible by PAHs, but to a lesser extent (Nebert et 
al., 2004).  
 
CYP1B1 is expressed in extrahepatic tissues including the oesophagus (Nakajima et al., 1996, 
Lechevral et al., 1999), lung, kidney, heart and brain (Bozina et al., 2009). CYP1B1 is 
responsible for the metabolism of xenobiotics such as 7,12-dimethylbenz[a]anthracene (DMBA), 
PAHs and other diverse procarcinogens as well as endogenous compounds (Shimada et al., 
1996). The 4-hydroxylation of estradiol by CYP1B1 variants has been associated with breast 
cancer (Li et al., 2000).  
 
At least 26 polymorphisms have been identified in the human CYP1B1 gene and 19 of these 
variants confer amino acid changes (Ingelman-Sundberg et al, http://www.cypalleles.ki.se/). The 
A4390G polymorphism (Asn453Ser) has been associated with increased degradation of CYP1B1 
protein (Bandiera et al., 2005). The variants in codons 119 (Ala119Ser) and 432 (Leu432Val) are 
associated with different catalytic activities of the enzymes (Shimada et al., 1999, Li et al., 2000) 
and have been shown to have higher 4-hydroxylation activities than the wild type enzyme (Hanna 
et al., 2000). Inter-ethnic differences in polymorphism frequencies may affect susceptibility to 
cancer. For example, Asians have the highest frequency of the CYP1B1 4326 C/C genotype 
(73.3-84.1%), while Caucasians have the highest frequency of the C/G genotype (41.7-45%) and 
Africans have the highest frequency of the G/G genotype (73.3%) 
(http://www.ncbi.nlm.nih.gov/SNP). 
 
CYP1B1 has been suggested to play a role in carcinogenesis. In addition to its role in carcinogen 
activation (Shimada et al., 1996), CYP1B1 is frequently overexpressed in human cancers (Port et 
al., 2004), and CYP1B1 variants have been associated with cancers such as breast (Paracchini et 
al., 2006), lung (Watanabe et al., 2000), endometrial (Sasaki et al., 2003), prostate (Tanaka et al., 
2002), ovarian (Goodman et al., 2001), head and neck (Ko et al., 2001) and colorectal cancer 
(Fritsche et al., 1999, Gibson et al., 2003). Accordingly, CYP1B1 has been suggested as a 











cancer (Wen and Walle, 2007) and CYP1B1 inhibitors have been suggested as potential anti-




CYP1A2 is located on chromosome 15 and consists of 6 introns and 7 exons, while the 515 
amino acid protein is translated from exon 2 (Ikeya et al., 1989). CYP1A2 shares 72% amino acid 
sequence similarity with CYP1A1 (Bartsch et al., 2000). CYP1A2 is a hepatic enzyme that is 
responsible for the metabolism of aryl, heterocyclic aromatic and nitroaromatic amines and 
pharmaceutical drugs such as 2-aminoanthracene and 2-acetylaminofluorene, acetaminophen, 
antipyrine, caffeine, 7-ethoxyresorufin, lidocaine, phenacetin, aflatoxin B1, theophylline, and R-
warfarin (Bozina et al., 2009). CYP1A2 metabolizes BaP only to a limited degree (Shimada et 
al., 1996) and while CYP1A2 is inducible in rodent lungs, it is not clear whether it is significantly 
expressed in human extrahepatic tissues (Uno et al., 2006). 
 
At least 16 polymorphic variants have been identified in CYP1A2, both in coding and 
untranslated regions (Ingelman Sundberg et al., http://www.cypalleles.ki.se/). The CYP1A2*1F 
allele (-163C>A) is associated with higher inducibility of CYP1A2 in smokers than non-smokers 
(Bozina et al., 2009). In addition, CYP1A2*1F (-163C>A) is associated with increased enzyme 
activity, while CYP1A2*1C (-3860G>A) is associated with decreased enzyme activity (MacLeod 
et al., 1998, Nakajima et al., 1999). Differences in CYP1A2 enzyme activities may contribute to 
inter-individual and inter-ethnic variations in xenobiotic metabolism and cancer susceptibility.  
For example, the frequency of the CYP1A2 -163C>A polymorphism is 18.3% in Africans, 6.5% 
in Caucasians (6.5%) and 4.2-15.9% among Asians (http://www.ncbi.nlm.nih.gov/SNP).  The 
frequencies of the CYP1A2 -163C>A and 63C>G SNPs have been determined in Zimbabwean 
and Tanzanian populations but not yet in South African populations (Dandara et al., 2004). 
 
Less is known about the role of CYP1A2 in cancer risk, although some studies have shown 
CYP1A2 variants to be associated with colorectal, pancreatic and lung cancer (Bozina et al., 
2009). Since the effects of CYP1A2 variants on cancer susceptibility are modified by smoking, 















1.5.2.4      CYP1 Knockout Mouse Models 
 
Since the establishment of the Cyp1a1(-/-) knockout mouse model (Dalton et al., 2000), studies 
using either intraperitoneal (i.p.) or oral doses of BaP have shown that the Cyp1a1(-/-) mouse has 
lower survival, lower blood BaP clearance rates and higher levels of BaP-DNA adducts than the 
Cyp1a1(+/+) wild type mouse (Uno et al., 2001, Uno et al., 2004). These findings suggest that 
CYP1A1 plays more of a protective role in the intact mouse (Uno et al., 2004). Since CYP1B1 
levels increase when CYP1A1 is absent, there may be a compensatory role by CYP1B1 in BaP 
metabolism (Uno et al., 2006). 
 
Studies on the cyp1b1(-/-) knockout mouse line (Buters et al., 1999) showed that tissue damage 
and DNA adduct formation were similar between cyp1b1(-/-) and wild type mice, and the authors 
concluded that CYP1B1 is more responsible for the metabolic activation of BaP than its 
detoxification (Uno et al., 2006). The effects of oral BaP on the cyp1a1/1b1(-/-) double knockout 
mouse were similar to the cyp1a1(-/-) mouse, further highlighting the importance of CYP1A1 in 
detoxification and CYP1B1 in metabolic activation (Uno et al., 2006). 
 
The establishment of a cyp1a2(-/-) knockout mouse line (Liang et al., 1996) allowed the effects of 
i.p. TCDD or oral BaP administration on CYP1A1 induction to be investigated (Liang et al., 
1997, Uno et al., 2006). While hepatic CYP1A1 levels decreased after oral BaP administration 
(Uno et al., 2006), there was no difference in CYP1A1 inducibility after i.p TCDD treatment 
(Liang et al., 1997), which suggests different effects between BaP and TCDD metabolism or 
route of administration (Uno et al., 2006). 
 
The effects of oral BaP administration in the cyp1a2/1b1(-/-) double knockout mouse showed 
DNA adduct levels similar to wild type mice, suggesting a rescued phenotype due to the presence 
of CYP1A1. The authors concluded that basal and inducible CYP1A2 plays a negligible role in 
the tissue damage induced by BaP (Uno et al., 2006). The cyp1a1/1a2(-/-) double knockout 
mouse exhibited the same severity of immunosuppression after oral BaP administration as the 
cyp1a1(-/-) mouse, which is explained by the lack of BaP detoxification by CYP1A1 (Dragin et 
al., 2008). 
 
The effects of oral BaP treatment on the cyp1a1/1a2/1b1(-/-) triple knockout mouse were recently 
determined (Dragin et al., 2008). These mice show a rescued phenotype similar to the 











tissues. These mice also exhibit reduced viability and altered metabolic pathways, especially in 
eicosanoid metabolism (Dragin et al., 2008). Collectively, the CYP1 knockout mouse models 
allow vast insight into the effects of BaP in the intact mouse. 
 
 
1.6       The Aryl Hydrocarbon Receptor (AHR) 
 
1.6.1 The AhR and AhR-Mediated Transcriptional Regulation Pathway 
 
The AhR is a receptor for PAH ligands such as BaP and is part of a transcription factor that 
regulates the transcription of several XMEs. The AhR protein consists of 805 amino acids 
(Burbach et al., 1992). It is a member of the basic helix-loop-helix-Per-ARNT-Sim (bHLH-PAS) 
family of transcription factors owing to its bHLH and PAS domains. The bHLH region is 
involved in DNA binding, while the PAS region is involved in ligand binding and dimerization 
(Ma and Lu, 2007). The AhR contains both nuclear localization (NLS) and nuclear exit signals 
(NES) in its bHLH region (Kawajiri and Fujii-Kuriyama, 2007). 
 
The schematic representation of ligand-activated AhR-mediated transcription is shown in Figure 
1.13. In its unliganded state, the AhR resides in the cytoplasm in a chaperone complex consisting 
of two units of heat shock protein 90 (HSP90, Perdew, 1988), the immunophilin XAP2 (also 
known as AhR interacting protein or AIP, Meyer et al., 1988) and the co-chaperone p23 
(Kaslauskas et al., 1999, Cox and Miller, 2004). Upon ligand binding, the AhR dissociates from 
its cytoplasmic complex and translocates into the nucleus (Pollenz and Barbour, 2000) where it 
binds to the AhR nuclear translocator (ARNT) to form a heterodimeric transcription factor 
(Whitelaw et al., 1993, Probst et al., 1993). The AhR-ARNT dimer binds to the xenobiotic 
response elements (XREs, also known as AhR responsive elements, AhREs, Whitelaw et al., 
1993, Probst et al., 1993) in the enhancer regions upstream of its target genes. The AhR binds to 
the 5’TNGC-3’ half site of the highly conserved XRE motif: 5’- TNGCGTG-3’ (where N is any 
nucleotide) (Ramos et al., 2007). 
 
Genes transcribed by ligand-activated AhR include CYP1A1, CYP1B1 and NQO1 
(Androutsopoulos et al., 2009). In this way, ligands of the AhR induce their own metabolism by 
activating AhR-mediated transcription of Phase I and II XMEs. The AhR also plays a role in the 
cellular response to oxidative stress and in determining the balance between cell cycle 



































Figure 1.13 Regulation of phase I and II XME gene transcription by ligand-activated AhR. BaP 
passively enters the cell through the hydrophobic cell membrane. Upon binding to BaP, AhR dissociates 
from XAP2, HSP90 and p23 (its chaperone complex) and translocates to the nucleus. Phosphorylation of 
residues within its NLS inhibits AhR nuclear import, but phosphorylation of the AhR carboxy terminal is 
required for heterodimer formation with the ARNT. The AhR-ARNT dimer complex binds to XRE 
sequences upstream of target genes such as CYP1A1, and activates their transcription by recruitment of 
transcription initiation factors such as Sp1, p300, p/CIP, TBP and Pol II. AhR-ARNT binding to XREs is 
inhibited by AHRR-ARNT complexes which compete for XRE binding.  
XAP2: AhR interacting protein; p23: co-chaperone; HSP90: heat-shock protein 90; AhR: aryl hydrocarbon 
receptor; ARNT: AhR nuclear translocator; AHRR: AhR repressor; NLS: nuclear localization signal; XRE: 
xenobiotic response element; CYP1A1: cytochrome P450 1A1; CYP1B1: cytochrome P450 1B1; CYP1A2: 
cytochrome P450 1A2; NQO1: NADPH quinone oxidoreductase; UGT1A6: uridine diphosphate 
glucuronosyltransferase 1A6; ALDH3A1: aldehyde dehydrogenase 3A1; Sp1: transcription factor; p300 
and p/CIP: co-activators; TBP: TATA binding protein; Pol II: RNA polymerase II. (Adapted from 
Androutsopoulos et al., 2009). 
 
 
1.6.2 Role of the AhR in Cancer 
 
Substantial evidence has shown that deregulated expression and function of the AhR may play a 
role in carcinogenesis. AhR is overexpressed in human breast, lung and pancreatic cancers 
(Schlezinger et al., 2006, Lin et al., 2003, Koliopanos et al., 2002). In mice, a constitutively 
active AhR induces tumorigenesis in the stomach and promotes hepatocarcinogenesis (Andersson 
et al., 2002, Moennikes et al., 2004), while overexpression stimulates proliferation of A549 lung 














been identified; some of these are associated with increased risk of lung and breast cancer and 
modulate CYP activity (Chen et al., 2009, Bozina et al., 2009, Kim et al., 2007, Long et al., 
2006).  
 
The role of the AhR in BaP-initiated cancer was further substantiated when it was observed that 
AhR(-/-) knockout mice are protected against BaP-induced skin tumours (Shimizu et al., 2000). 
These mice are unable to induce CYP expression through the AhR and therefore BaP cannot be 
metabolically activated to BPDE. There is evidence of cross-talk between the AhR and other 
survival pathways (Puga et al., 2009) through direct interactions between the AhR and NFKB 
(Kim et al., 2000, Tian, 2009), estrogen receptor  (Ohtake et al., 2003, Matthews and 
Gustafsson, 2006, Wormke et al., 2000), glucocorticoid receptor (Dvorak et al., 2008), 
retinoblastoma protein (Puga et al., 2000), MAPK pathways (Tan et al., 2002) and the E2F1 
transcription factor (Watabe et al., 2010). The AhR has been shown to act as both a positive and 
negative regulator of cell cycle progression, depending on cell type (Kawajiri and Fujii-
Kuriyama, 2007, Abdelrahim et al., 2003). Collectively, this evidence suggests an important role 
for the AhR in the development of cancer. 
 
1.6.3 The AhR Nuclear Translocator (ARNT) 
 
The AhR heterodimerization partner, the ARNT, is a ~90 kDa protein that is also a member of the 
bHLH-PAS family of transcription factors. The bHLH and PAS domains are necessary for DNA 
binding and protein interactions, respectively (Beischlag et al., 2008, Reisz-Porszasz et al., 1994). 
The interaction between AhR and ARNT occurs in the nucleus and requires ligand binding to the 
AhR (Whitelaw et al., 1993, Probst et al., 1993, Beischlag et al., 2008). The ARNT binds to the 
5’-GTG-3’ half site of the target gene’s XRE sequence prior to transcriptional activation (Ramos 
et al., 2007).  
 
 
ARNT(-/-) knockout mice are not viable, but mice in which ARNT has been deleted only in adult 
skin epidermis are protected against BaP-initiated skin tumours (Shi et al., 2009). These results 
suggest that the ARNT is essential for BaP-associated tumour initiation (Shi et al., 2009). Recent 
evidence suggests that ARNT activity is required more during early than late stages of tumour 
growth (Shi et al., 2010). ARNT, also known as hypoxia inducible factor (HIF) 1, also plays a 











tumour growth (Shi et al., 2010). The ARNT therefore plays a role, together with the AhR, in 
mediating the effects of BaP. 
 
1.6.4 The AhR Repressor (AHRR) 
 
The AHRR gene has been identified in humans (Watanabe et al., 2001) and its transcriptional 
activation is regulated by the ligand-activated AhR-ARNT complex. AHRR mRNA is expressed 
in adult liver, breast, lung, uterus, colon, kidney, testis, ovary, adrenal gland and bladder 
(Tsuchiya et al., 2003). The AHRR is also inducible by the PAHs TCDD and 3-
methylcholanthrene (3-MC) in cancer cell lines (Tsuchiya et al., 2003). High levels of AHRR 
mRNA are thought to be responsible for low PAH-inducibility of the CYP1 isoforms in HeLa 
cells (Tsuchiya et al., 2003). AHRR mRNA levels are down-regulated in various human cancer 
tissues, including colon, lung and breast (Zudaire et al., 2008).  
 
The AHRR has been shown to repress the ability of the AhR to activate transcription of its target 
genes by competing with the AhR for binding to the ARNT (Mimura et al., 1998, Fig. 1.13). 
Since the AHRR has no transactivation domain, the AHRR-ARNT complex blocks transcription, 
thereby forming a negative feedback loop by which the AhR is regulated (Mimura et al., 1999). 
Owing to the role of the AhR in cancer, the AHRR has been suggested as a putative tumour 
suppressor in multiple tumour types (Zudaire et al., 2008). Recent evidence suggests that the 
AHRR may repress AhR function not by competition but by protein-protein interactions (Evans et 
al., 2008). This evidence collectively suggests that the AHRR may be important in regulation of 
the AhR in cancer. 
 
1.7 Transcriptional Profiling of the Effects of BaP on Global Gene Expression 
 
1.7.1 Microarrays as Tools for the Analysis of Whole Genome Expression  
 
Microarray technology is a fast and easy way to examine the effects of various compounds on the 
expression of the approximately 37000 genes in the human genome. Microarray platforms are 
synthesized by different methods, such as printing or photolithography, depending on the 
manufacturing company. Spotted chips, often produced in-house for a laboratory’s own 
experiment, contain DNA probes that are printed onto the array surface, whereas oligonucleotide 
arrays are made by attaching oligonucleotide probes to a surface such as glass or silica. 
Affymetrix arrays use shorter 25-mer probes (www.affymetrix.com), while Agilent arrays use 











beads in place of a solid surface (www.illumina.com).  Despite different manufacturing 
procedures, all microarray platforms share a common principle and can be used in different 
applications such as gene expression profiling, comparative genomic hybridization, or detection 
of single nucleotide polymorphisms (SNPs).   
 
Through analysis of global gene expression profiling, expressed genes can be grouped according 
to their biological function and the cellular pathway to which they belong, which allows 
researchers to understand the biological context behind their expression pattern. The types of 
genes that are differentially expressed allow for compounds to be classified according to their 
therapeutic, toxicological or carcinogenic effects. Transcriptional responses to carcinogens such 
as BaP may give insights into their molecular mechanisms of carcinogenesis. BaP has been 
recognized for its carcinogenic potential for many years (IARC, 2004) but scientists are still 
uncovering the detailed molecular mechanisms behind how BaP exposure initiates cancer.  
 
1.7.2 Transcriptional Profiling of the Effects of BaP and BPDE in Human Cell Lines 
 
Since BaP may play an important role in tobacco smoking-associated cancers, scientists have 
used microarrays to carry out transcriptional profiling of the effects of BaP on global gene 
expression in various human cell lines. Microarray data has been published for the effects of BaP 
or BPDE on HepG2 (van Delft et al., 2004, Staal et al., 2006, Lee et al., 2006, Hockley et al., 
2006, 2007, 2009, Iwano et al., 2010), MCF-7 (Mahadevan et al., 2005, Hockley et al., 2006, 
2007, Kemp et al., 2006), A549 (Yoshino et al., 2007, Kometani et al., 2009), Caco-2 (de Waard 
et al., 2008), HCT116 (Hockley et al., 2008), TK6 (Akerman et al., 2004, Luo et al., 2005), HeLa 
(Yu et al., 2000), NHMEC (Gwinn et al., 2005, Keshava et al., 2005, John et al., 2008), HIOEC 
(Li et al., 2008), WI38 (Sohn et al., 2008), HME87 (Wang et al., 2003), FL (Lu et al., 2009), 
NHBE (Belitskaya-Levy et al., 2007), and NHEK (Perez et al., 2008) cell lines. The tissue origins 
of each cell line and the BaP or BPDE treatment conditions for each microarray are summarized 
in Tables 1.2 and 1.3, respectively. The differential expression of hundreds of genes in these 
microarrays suggests that BaP exposure has common and cell type-specific effects on gene 
expression patterns in human normal and cancer cell lines. To date, no microarray data is 
available on the effects of BaP on global gene expression in normal or cancer cell lines from the 
oesophagus. Microarray studies continue to uncover more about the transcriptional response to 













Table 1.2 List of published microarray data using normal and cancer cell lines treated with BaP 
 
Cell line Origin [BaP] Incubation Reference 
HepG2 Hepatocarcinoma 9mM 24h Van Delft et al., 2004 
NHMEC Normal human mammary 
epithelial cells 
4 M 12h Gwinn et al., 2005 
NHMEC Normal human mammary 
epithelial cells 
4 M 6h, 24h Keshava et al., 2005 
MCF-7 Breast carcinoma 0.404g/l 24h Mahadevan et al., 2005 
HepG2 Hepatocarcinoma 3, 10, 30 M 6h Staal et al., 2006 





0.25, 1, 2.5, 5 
M 
6h, 24h, 48h Hockley et al., 2006 
MCF-7 Breast carcinoma 5 M 24h Kemp et al., 2006 
A549 Lung adenocarcinoma 1 M 24 weeks Yoshino et al., 2007 
HIOEC Human immortalized oral 
epithelial cells 
0.1-1.2mg/l 6 months Li et al., 2008 
WI38 Foetal lung fibroblasts 10 M 72h Sohn et al., 2008 
NHEK Normal human epidermal 
keratinocytes 
2 M 24h Perez et al., 2008 
Caco-2 Human colorectal 
adenocarcinoma 
1 M 24h De Waard et al., 2008 
HCT116 Human colorectal 
carcinoma 
2.5, 5 M 6h, 24h, 48h Hockley et al., 2008 
NHMEC Normal human mammary 
epithelial cells 
4 M 24h John et al., 2008 
A549 Lung adenocarcinoma 1 M 24 weeks Kometani et al., 2009 
HepG2 Hepatocarcinoma 2.5, 3 M 6h, 24h Hockley et al., 2009 
HepG2 Hepatocarcinoma 1, 3, 10 M 24h Iwano et al., 2010 
 
Table 1.3 List of published microarray data using normal and cancer cell lines treated with BPDE 
 
Cell line Origin [BPDE] Incubation Reference 
HeLa Cervical carcinoma 0.4 M 53h Yu et al., 2000 
HME87 Human mammary epithelial 
cells 
1M 0.5h Wang et al., 2003 




4h, 24h Akerman et al., 2004 




1h Luo et al., 2005 
NHBE Normal human bronchial 
epithelial cells 






0.5, 1 M 2h, 6h, 24h Hockley et al., 2007 
HCT116 Human colorectal 
carcinoma 
0.5, 1 M 2h, 6h, 24h Hockley et al., 2008 
FL Human amnion epithelial 
cells 
0, 0.005, 0.05, 
0.5 M 
















The aim of this project is to investigate the differential effects of BaP treatment on normal and 
cancer cell lines from the oesophagus, in order to further our understanding of the molecular 




There are 3 main objectives within the aim of comparing the effects of BaP treatment between a 
normal oesophageal cell line and an oesophageal cancer cell line:  
(a) To investigate the effect of BaP treatment on induction of xenobiotic metabolizing genes and 
investigate the role of the AhR,  
(b) To investigate the effect of BaP treatment on cellular proliferation and morphology, and 
(c) To investigate the effect of BaP treatment on global gene transcription using microarray 
analysis. Within the third objective of transcriptional profiling, there are 5 sub-objectives:  
(i) To determine what genes are affected by BaP treatment in normal and cancer cells,  
(ii) To determine the fundamental difference in gene expression between normal and cancer cells, 
(iii) To investigate whether normal cells treated with BaP become like cancer cells,  
(iv) To investigate whether normal cells and cancer cells respond in the same way to BaP 
treatment, and  
(v) To determine whether oesophageal normal and cancer cells respond to BaP treatment in the 












Induction of CYP1A1 and CYP1B1 in normal and tumour oesophageal 




In this chapter, a normal oesophageal epithelial cell line and an OSCC cell line were used as a 
model to further our understanding of the molecular mechanisms of tobacco smoke-associated 
cancer initiation and promotion in the oesophagus. The effects of the major PAH in tobacco 
smoke, BaP, on the expression of xenobiotic metabolism genes in oesophageal cancer cell lines 
were investigated. Since Phase I metabolism and therefore bioactivation of BaP to BPDE is 
catalyzed by CYP1A1 and CYP1B1, gene transcription, protein levels and enzyme activity of 
CYP1A1 and CYP1B1, and nuclear translocation of AhR and its dimerization partner ARNT in 
response to BaP, were investigated.  
 
The polymorphic variants of CYP1 exhibit differential enzyme activity and may therefore 
influence the balance between metabolic activation and detoxification of BaP. The variants 
investigated in this study have been shown to be associated with increased enzyme activity 
(Hanna et al., 2000, London et al., 2000) as indicated in Table 2.1. 
 
Table 2.1 Polymorphisms of the CYP1A1 and CYP1B1 genes 
 









Effect on enzyme 
function 
CYP1A1 4889 A G I462V Increased 
inducibility and 
enzyme activity 
CYP1B1 4326 C G L432V Increased catalytic 
activity 





2.2.1 CYP1 genotypes and enzyme activity of oesophageal cell lines 
 
The genotypes for CYP1A1 (4889A>G) and CYP1B1 (4326C>G) were determined in the normal 
oesophageal epithelial cell line, EPC-2, in four OSCC cell lines derived from South African 











Japanese patients, KYSE 30, KYSE 70, KYSE 150, KYSE 180, KYSE 410, KYSE 450 and 
KYSE 520, using PCR-RFLP. The results are shown in Table 2.2 below. 
 
 
Table 2.2 Genotypes of CYP1A1 and CYP1B1 in normal oesophageal epithelial cells and 
oesophageal cancer cell lines. 
  




EPC-2 A/A G/G 
WHCO1 A/A C/G 
WHCO3 A/A C/C 
WHCO5 A/A C/C 
WHCO6 A/A C/G 
KYSE 30 A/A C/C 
KYSE 70 A/A C/G 
KYSE 150 A/G C/C 
KYSE 180 A/A G/G 
KYSE 410 A/A C/C 
KYSE 450 A/A C/C 
KYSE 520 A/A C/G 
 
 
Genotyping for the CYP1B1 4326C>G polymorphism showed that WHCO3, WHCO5, KYSE 30, 
KYSE 150, KYSE 410 and KYSE 450 were homozygous for the common allele (C/C), whereas 
WHCO1, WHCO6, KYSE 70 and KYSE 520 were heterozygous (C/G) and only EPC-2 and 
KYSE 180 were homozygous for the polymorphic allele (G/G). These results suggest that EPC-2 
and KYSE 180 should have the highest CYP1B1 enzyme activity, the heterozygous cell lines 
have intermediate CYP1B1 enzyme activity and the C/C cell lines have normal or baseline 
CYP1B1 activity. 
 
Genotyping for the CYP1A1 4889A>G polymorphism showed that all oesophageal cell lines are 
homozygous for the low activity allele (A/A), except for KYSE 150, which is heterozygous 
(A/G). These results suggest that most cell lines have low CYP1A1 activity, while KYSE 150 
















2.2.2 Induction of CYP1A1 and CYP1B1 mRNA by BaP in oesophageal cell lines 
 
CYP1A1 and CYP1B1, and to a lesser extent, CYP1A2, are involved in BaP metabolism. The 
relative levels of these CYP1 mRNAs were therefore determined in WHCO1 (OSCC) and EPC-2 
(normal) cells in response to treatment with 10M BaP. A time course was carried out to 
determine (i) the time-dependent induction of the CYP1 genes by BaP and (ii) the effect of BaP 
withdrawal on CYP1 gene expression. 
 
In WHCO1 cells, treatment with BaP resulted in a 10-fold and 44-fold induction of CYP1A1 
mRNA at 24h and 48h, respectively, compared to the DMSO control, while subsequent removal 
of BaP resulted in almost no change after 1h and a 60% reduction in mRNA levels after 6h (Fig. 
2.1). CYP1B1 mRNA induction was somewhat lower, with a significant 7-fold and 20-fold 
increase at 24h and 48h, respectively, while removal of BaP resulted in almost no change in 
mRNA levels after 1h and 75% reduction after 6h. CYP1A2 mRNA induction was even lower, 
with a 3-fold and 17-fold increase at 24h and 48h, respectively, while removal of BaP resulted in 




Figure 2.1  Induction of the CYP1 mRNAs in BaP-treated WHCO1 and EPC-2 cells. 7.5 × 105 of 
WHCO1 cells were plated in 100mm dishes and after 24 hours were treated with 10µM BaP for 24 or 48 
hours as described in Methods. Cells treated with 0.1% DMSO for 24 hours were used as a control and are 
indicated as Un (untreated). To investigate reversal after withdrawal of BaP, cells were incubated in fresh 
medium without BaP for 1 hour or 6 hours after treatment with 10µM BaP for 48 hours. CYP1A1 and 
CYP1B1 mRNA levels were detected by qRT-PCR using GAPDH as a control. The data are shown as 



















































In EPC-2 cells, there was no induction of CYP1A1 or CYP1B1 mRNA at 48h BaP treatment; in 
fact mRNA levels were significantly down-regulated (Fig. 2.3). CYP1A1 and CYP1B1 mRNA 
were not detectable at the other time points, and CYP1A2 mRNA was not detectable at all time 
points in EPC-2 cells. 
 
These results suggest that CYP1A1 and CYP1B1 mRNA are more readily inducible by BaP in 
oesophageal cancer cells compared to normal cells and return to basal levels occurs more rapidly 
in normal cells compared to cancer cells.  
 
2.2.3 Induction of CYP1A1 and CYP1B1 protein by BaP in oesophageal cell lines 
 
In order to confirm that the induction of CYP1 mRNA reflected an increase in CYP1 protein, the 
levels of cytoplasmic CYP1A1, CYP1A2 and CYP1B1 proteins in response to treatment with 
10M BaP were investigated in WHCO1 and EPC-2 cells by Western blotting.  
 
BaP treatment of WHCO1 cells resulted in a 3.2-fold and 31.5-fold induction of CYP1A1 protein 
at 24h and 48h, respectively; whereas for CYP1A2 there was a much lower increase in protein 
levels at 1.6-fold and 18.7-fold for the same time points, while CYP1B1 protein was greatly 
elevated by 5.2-fold and 26.9-fold after 24h and 48h of BaP treatment, respectively (Fig. 2.2A/B). 
One hour after removal of BaP from the medium, CYP1A1, CYP1A2 and CYP1B1 protein levels 
reduced somewhat to 14.6-, 13.4- and 13.9-fold, respectively, whereas after 6h in fresh media, 
CYP1A1 levels declined sharply to 3.74-fold, similar to the 24h induction point, and CYP1A2 
and CYP1B1 levels declined even further to 2.8- and 3.9-fold, respectively (Fig. 2.2A/B). 
Antibody cross-reactivity allowing detection of both CYP1A1 and CYP1A2 proteins shown in 
Figure 2.2A has been reported by other researchers (Lechreval et al., 1999, Galvan et al., 2005, 
Bao et al., 2002).  
 
In EPC-2 cells, lower CYP1 protein inducibility was observed. CYP1A1 was induced 3.2-fold 
and 5.6-fold at 24h and 48h, respectively, while CYP1A2 levels increased by only 1.6-fold at 
48h, and CYP1B1 levels increased slightly by 1.8-fold at 24h (Fig. 2.2C/D). After removal of 
BaP from the medium, CYP1A2 proteins returned to near basal levels, while CYP1A1 levels 
gradually declined to 4.2-fold at 1h and to near basal levels at 6h after BaP withdrawal (Fig. 
2.2C/D). CYP1B1 levels decreased to around basal levels at 48h which was maintained at 1h after 






































































































Figure 2.2 Induction of the CYP1 proteins by BaP in WHCO1 and EPC-2 cells. 1 × 106 of WHCO1 
(A) or EPC-2 (C) cells were plated in 100mm dishes and after 24 hours were treated with 10µM BaP for 24 
or 48 hours as described in Methods. Cytoplasmic extracts were separated on a 10% SDS-PAGE and 
probed for CYP1A1, CYP1A2 or CYP1B1. Cells treated with 0.1% DMSO for 24 hours were used as a 
control (Un). To investigate reversal after withdrawal of BaP, cells were incubated in fresh medium without 
BaP for 1 hour or 6 hours after treatment with 10µM BaP for 48 hours. β-tubulin was used as a loading 
control. The data represents three independent experiments. Densitometry ratios of CYP1A1, CYP1A2 and 
CYP1B1 protein levels normalized to -tubulin and relative to untreated cytoplasmic extracts are indicated 
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These results show that while basal levels of the CYP1 isoforms in WHCO1 cells were very low, 
they were highly inducible upon BaP treatment; whereas in EPC-2 cells these proteins were 
constitutively expressed at low levels but were not as inducible as in WHCO1. CYP1A2 did not 
appear to be playing a significant role in BaP metabolism in EPC-2 cells and therefore subsequent 
experiments focused on CYP1A1 and CYP1B1. 
 
2.2.4 Analysis of CYP1 expression in WHCO and KYSE cell lines 
 
From the results in Figure 2.1 and 2.2, it can be seen that CYP1 induction by BaP was highest at 
48h BaP treatment. In order to compare CYP1A1 and CYP1B1 induction by BaP at 48h between 
South African patient-derived cell lines (WHCO series) and Japanese patient-derived cell lines 
(KYSE series), CYP1A1 and CYP1B1 mRNA and protein levels were investigated in all cell 
lines by qRT-PCR and Western blotting.  
 
BaP induced CYP1A1 mRNA in all WHCO and KYSE cell lines with the exception of KYSE 
520. CYP1A1 mRNA induction was highest in WHCO6 (949-fold) whereas no induction was 
observed in the control cells, EPC-2 (0.3-fold) and KYSE 520 (0.9-fold, Fig. 2.3A). KYSE 410 
(439-fold) had the highest induction of CYP1A1 of the KYSE series, while WHCO1 CYP1A1 
induction (29-fold) was comparable to the 44-fold induction at 48h in the time course (Fig. 2.1). 
On average, CYP1A1 mRNA levels were induced by approximately 226-fold by BaP. 
 
CYP1B1 mRNA induction was much lower than that observed for CYP1A1, with the highest 
induction seen in WHCO3 (20-fold) followed by WHCO6 (14.8-fold), and again no induction 
was observed in EPC-2 (0.6-fold) and KYSE 520 (0.9-fold, Fig. 2.3B). KYSE 180 (11-fold) had 
the highest induction of the Japanese cell lines, followed by KYSE 30 (10.5-fold). On average, 
CYP1B1 mRNA levels underwent a 7-fold induction by BaP treatment. 
 
The average fold change for CYP1A1 and CYP1B1 was 330- and 11-fold, respectively, in the 
WHCO series, and a much lower 198- and 5.5-fold induction, respectively, in the KYSE series. 
These results suggest that, on average, CYP1A1 and CYP1B1 mRNA were more inducible in the 
South African OSCC cell lines than the Japanese OSCC cell lines. A correlation between 















Figure 2.3 Induction of CYP1A1 and CYP1B1 mRNA in South African and Japanese oesophageal 
cell lines. 7.5 × 105   of EPC-2, WHCO1, WHCO3, WHCO5, WHCO6, KYSE 30, KYSE 70, KYSE 150, 
KYSE 180, KYSE 410, KYSE 450 and KYSE 520 cells were plated in 100mm dishes and after 24 hours 
were treated with 10µM BaP for 48 hours as described in Methods. Cells treated with 0.1% DMSO for 24 
hours were used as a control (Un). CYP1A1 (A) and CYP1B1 (B) mRNA levels were detected by qRT-
PCR using GAPDH as a control. The data are shown as mean ± S.D. of three independent experiments. 































The changes in CYP1A1 and CYP1B1 protein levels as investigated by Western blotting showed 
that protein levels also varied among the twelve cell lines (Fig. 2.4).  
 
CYP1A1 protein induction was highest for KYSE 180 (36-fold, Fig. 2.4C) and KYSE 410 (7.5-
fold, Fig. 2.4C) and lowest for KYSE 520 (0.4-fold, Fig. 2.4C). Within the WHCO series, 
WHCO6 had the highest induction (2-fold, Fig. 2.4B), while WHCO3 had no induction (Fig. 
2.4A). CYP1A1 was induced by 2-fold in EPC-2 (Fig. 2.4A). On average, CYP1A1 protein levels 
were induced by 5-fold in response to BaP treatment. 
 
As for the mRNA levels, CYP1B1 induction was lower than CYP1A1. CYP1B1 induction was 
highest in KYSE 30 (10.5-fold, Fig. 2.4B), KYSE 180 (7-fold, Fig. 2.4C) and KYSE 410 (6-fold, 
Fig. 2.4C) and lowest in EPC-2 (0.7-fold, Fig. 2.4A), KYSE 150 (0.8-fold, Fig. 2.4B) and KYSE 
520 (0.7-fold, Fig. 2.4C). For the WHCO series, CYP1B1 induction was highest in WHCO1 (4-
fold, Fig. 2.4A) and lowest in WHCO6 (1.7-fold, Fig. 2.4B). On average, CYP1B1 protein levels 
were induced 3-fold by BaP treatment. 
 
The average induction for CYP1A1 and CYP1B1 was 1.4- and 2.6-fold, respectively, in the 
WHCO series, and 7.6- and 4-fold, respectively, in the KYSE series. These results suggest that 
there is not necessarily an association between mRNA and protein levels and that CYP1A1 and 
CYP1B1 protein levels were more inducible in Japanese OSCC cell lines than South African 
OSCC cell lines. 
 
However, CYP1A1 mRNA and protein levels were clearly related for KYSE 410, WHCO6 and 
KYSE 520, while CYP1B1 mRNA and protein levels agreed for KYSE 30, KYSE 180, KYSE 
520 and EPC-2. Similar to mRNA levels, an association between CYP1A1 or CYP1B1 protein 





























































































































































































Figure 2.4 Induction of CYP1A1 and CYP1B1 protein in South African and Japanese oesophageal 
cell lines. 7.5 × 105   of EPC-2, WHCO1, WHCO3, WHCO5 (A), WHCO6, KYSE 30, KYSE 70, KYSE 
150 (B), KYSE 180, KYSE 410, KYSE 450 and KYSE 520 (C) cells were plated in 100mm dishes and 
after 24 hours were treated with 10µM BaP for 48 hours as described in Methods. Cells treated with 0.1% 
DMSO for 24 hours were used as a control (Un). CYP1A1 and CYP1B1 protein levels were detected by 
western blotting using β-tubulin as a control. The data represents two independent experiments. 
Densitometry ratios of CYP1A1 and CYP1B1 protein levels relative to β-tubulin in total protein extracts 
from all cell lines are indicated below the western blots and graphically in (D) and (E). 
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2.2.5 Induction of AhR and ARNT mRNA, protein and nuclear translocation 
 
Since BaP is a ligand for the AhR, which together with its dimerization partner, ARNT, increases 
transcription of CYP1 genes in a feedback loop, the effect of BaP treatment and withdrawal on 
the mRNA and nuclear protein levels of the AhR and ARNT was investigated. AhR and ARNT 
mRNA levels were determined by qRT-PCR. 
 
In WHCO1 cells, AhR mRNA levels increased 4-fold after 24h BaP treatment and 8.6-fold after 
48h BaP treatment (Fig. 2.5A). After BaP withdrawal, AhR levels declined by 19% after 1h and 
by 77% after 6h. ARNT levels increased 1.5-fold and 3-fold after 24h and 48h BaP treatment, 
respectively (Fig. 2.5A) One hour after BaP withdrawal, ARNT mRNA levels further increased to 
5-fold, but declined by 81% after 6h. Basal AhR and ARNT mRNA levels were higher than in 
EPC-2 cells. 
 
In EPC-2 cells, AhR mRNA levels were significantly increased by 2.2-fold after 24h BaP 
treatment, which was maintained at 48h and after BaP withdrawal, AhR mRNA returned to basal 
levels (Fig. 2.5B). ARNT levels were significantly up-regulated by 2.4-fold after 24h BaP 
treatment, which was maintained at 48h BaP treatment and even 1h after BaP withdrawal (Fig. 
2.5B). ARNT levels declined by 40% after 6h post BaP removal. 
 
These results suggest that AhR and ARNT mRNA levels were higher in WHCO1 compared to 
EPC-2 cells. In WHCO1 cells, AhR levels follow a similar induction pattern to that of CYP1A1 
and CYP1B1, while ARNT levels continued to rise even after 1h post BaP removal. In EPC-2 
cells, AhR levels declined after 24h, reaching basal levels after BaP withdrawal, whereas ARNT 
levels reached maximum induction after 24h, which was maintained even 1h after BaP removal. 
The varied induction patterns may suggest differential roles for AhR and ARNT in normal and 








































































































Figure 2.5 Induction of AhR and ARNT in BaP-treated WHCO1 and EPC-2 cells. 7.5 × 105   of 
WHCO1 (A) or EPC-2 (B) cells were plated in 100mm dishes and after 24 hours were treated with 10µM 
BaP for 24 or 48 hours as described in Methods. Cells treated with 0.1% DMSO for 24 hours were used as 
a control (Un). To investigate reversal after withdrawal of BaP, cells were incubated in fresh medium 
without BaP for 1 hour or 6 hours after treatment with 10µM BaP for 48 hours. AhR and ARNT mRNA 
levels were detected by qRT-PCR using GAPDH as a control, using the same samples as for Figure 2.1. 
The data are shown as mean ± S.D. of three independent experiments. * indicates significant differences (p 


















In order to relate mRNA with protein levels, nuclear AhR and ARNT protein levels were 
determined by Western blotting.  
 
In nuclear extracts from WHCO1 cells, there was a 1.9-fold increase in ARNT levels at 24h and a 
1.4- and 3.3-fold increase in AhR and ARNT levels, respectively, at 48h (Fig. 2.6A). After 
removal of BaP from the medium, AhR protein levels declined to basal levels after 1h in fresh 
medium, whereas ARNT levels declined to 1.9-fold by 1h and remained unchanged after 6h in 
fresh medium (Fig. 2.6A). Cytoplasmic AhR and ARNT levels increased 1.8- and 1.7-fold, 
respectively, at 24h BaP treatment and then rapidly declined at 48h and after BaP withdrawal to 
below basal levels (Fig. 2.6B). 
 
In EPC-2 extracts, AhR and ARNT levels were not significantly altered from basal levels at all 
time points (Fig. 2.6C). Lower levels of the loading control, Lamin B1, were observed in 
untreated cells compared to BaP-treated cells (Fig. 2.6C). Cytoplasmic AhR and ARNT levels did 
not change significantly (Fig. 2.6D). Although background was subtracted during densitometry 
analysis, it appears to be higher in blots from EPC-2 extracts. Taking this into consideration, the 
results should be cautiously interpreted as showing the trend that AhR and ARNT protein levels 
are higher in WHCO1 than EPC-2 cells. 
 
These results suggest that Lamin B1 protein levels may be affected by BaP treatment in EPC-2 
cells. In addition, nuclear AhR-ARNT levels were elevated in oesophageal cancer cells in 
response to BaP exposure but were not affected in normal oesophageal epithelial cells. Increased 
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Figure 2.6 Induction of nuclear AhR and ARNT protein by BaP in WHCO1 and EPC-2 cells. 1 × 
106 of WHCO1 (A) or EPC-2 (C) cells were plated in 100mm dishes and after 24 hours were treated with 
10µM BaP for 24 or 48 hours as described in Methods. Nuclear extracts were separated on a 7% SDS-
PAGE and probed for AhR and ARNT. Cells treated with 0.1% DMSO for 24 hours were used as a control 
(Un). To investigate reversal after BaP withdrawal, cells were incubated in fresh medium without BaP for 1 
hour or 6 hours after treatment with 10µM BaP for 48 hours. Lamin B1 was used as a loading control. The 
data represent three independent experiments. Cytoplasmic AhR and ARNT levels at the same time points 
are shown in WHCO1 (B) and EPC-2 (D) cells. -tubulin was used as a loading control. Normalized 
densitometry ratios of AhR and ARNT protein levels relative to untreated cells are indicated below the 
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In order to confirm that increased nuclear AhR and ARNT protein levels was due to increased 
nuclear translocation, the rate of nuclear entry and exit of AhR and ARNT in response to BaP 
treatment and removal was investigated in WHCO1 and EPC-2 cells using immunofluorescence. 
 
In both WHCO1 and EPC-2 cells, both AhR and ARNT were visible at low levels in the 
cytoplasm in the absence of BaP (Fig. 2.7). In WHCO1 cells, AhR and ARNT showed a stronger 
signal in the nucleus after 24h BaP treatment, which was further increased after 48h treatment 
(Fig. 2.7A). In EPC-2 cells, however, AhR and ARNT accumulated in the nucleus after 24h BaP 
treatment and their levels were maintained at 48h (Fig. 2.7B). After BaP withdrawal and 6h 
growth in fresh medium, AhR and ARNT levels declined sharply in EPC-2 cells but only 
decreased slightly in WHCO1 cells (Fig. 2.7).  
 
These results suggest that AhR-ARNT nuclear entry and exit occurred more rapidly in EPC-2 
cells than in WHCO1 cells, and therefore that AhR-ARNT have prolonged duration in the nuclei 
of WHCO1 cells. These results imply that AhR-ARNT transcriptional events cease after BaP 
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Figure 2.7 Nuclear translocation and exit of AhR and ARNT in response to BaP treatment in 
WHCO1 and EPC-2 cells. 0.5 × 105 of WHCO1 (A) or EPC-2 (B) cells were seeded and after 24 hours, 
cells were exposed to 10M BaP for 24 hours, 48 hours, and 48 hours + 6 hours in fresh medium. Cells 
were incubated with anti-AhR or anti-ARNT and fluorescent-labeled secondary antibodies and visualized 
by fluorescent microscopy to determine cellular localization as described in Methods.  DAPI was used to 














  2.2.6 BaP-induced changes in cellular proliferation 
 
The above results have shown that treatment with BaP resulted in increased mRNA levels, 
protein levels and nuclear translocation of the AhR and ARNT in WHCO1 cells compared to 
EPC-2 cells. In order to determine whether the increased AhR levels and associated signaling 
events might enhance the proliferative potential of BaP-treated cells, cell proliferation was 
measured in EPC-2 and WHCO1 cells in response to 10M BaP treatment. 
 
Cell viability measured using the MTT assay showed significantly (p<0.05) increased viability in 
BaP-treated WHCO1 cells compared to untreated cells at 72h and 96h whereas BaP-treated EPC-
2 cells showed significantly (p<0.05) reduced viability after 72h compared to untreated cells (Fig. 
2.8A). 
 
To confirm the MTT results and to show that the difference in cell viability was not solely due to 
mitochondrial reductase activity, a BrdU ELISA was carried out to measure DNA synthesis in 
treated and untreated cells. These results showed no significant difference between untreated and 
BaP-treated WHCO1 cells, but indicated significantly reduced cell division in BaP-treated 
compared to untreated EPC-2 cells at 72h, 96h (p<0.001) and 120h (p<0.05) of BaP exposure 
(Fig. 2.8B). 
 
Cell proliferation was also measured over 5 days (Fig. 2.8C). BaP treatment resulted in reduced 
cell number for both WHCO1 and EPC-2 cells compared to untreated cells (Fig. 2.8C). Cell 
number was significantly reduced by BaP treatment at 96h for both WHCO1 (p<0.05) and EPC-2 
(p<0.001) and at 120h for EPC-2 cells (p<0.05, Fig. 2.8C). The increased MTT activity is 
possibly accounted for by increased metabolism in BaP-treated WHCO1 cells, despite the lower 
cell number. 
 
These results suggest that WHCO1 cells were resistant to BaP-induced reduction in cell growth 
and continued to grow almost normally in the presence of BaP, whereas EPC-2 cells were 
sensitive to BaP-associated cell growth reduction and showed lower cell viability, cell division 




































































































































Figure 2.8 Changes in cellular proliferation of WHCO1 and EPC-2 cells induced by BaP treatment. 
2 x 103 of WHCO1 and  EPC-2 cells were seeded in 96-well plates and after 24 hours were treated with 
either 0.1% DMSO (Un) or 10µM BaP (BaP) for 1, 2, 3, 4 or 5 days as described in Methods. 	 WHCO1 
cells treated with 0.1% DMSO. 
 WHCO1 cells treated with 10µM BaP.  EPC-2 cells treated with 0.1% 
DMSO. x EPC-2 cells treated with 10µM BaP. (A) Measurement of cellular proliferation using the MTT 
assay. (B) Measurement of cellular proliferation using the BrdU ELISA. (C) Growth curve of WHCO1 and 
EPC-2 cells. The data shows mean ± S.D. of three independent experiments. * indicates significant 
























2.2.7 Effects of long-term BaP treatment on EPC-2 cell morphology 
 
Previous studies have shown that prolonged BaP or BPDE treatment can lead to the 
transformation of normal cell lines (Du et al., 2006, Ouyang et al., 2007, Srivastava et al., 2007, 
Ding et al., 2009). Since transformed cells exhibit altered cell morphology, EPC-2 cells exposed 
to BaP for prolonged periods were monitored by phase contrast microscopy. 
 
Compared to untreated cells (Fig. 2.9A), after the first 48h BaP treatment, some cells displayed 
an elongated shape (Fig. 2.9B, arrows) and while some cells appeared to have recovered to a 
normal shape after one week’s growth in BaP-free media, all cells were smaller and some had 
started to lose adhesion to the plate, an indication of cell death (Fig. 2.9C, arrows). After a second 
BaP treatment, cells again exhibited an elongated shape (Fig. 2.9D, arrows) which was still 
apparent in cells after one week’s growth in BaP-free media, despite recovery of most cells to 
their original round shape (Fig. 2.9E, arrows).  
 
After a third round of BaP treatment, cells were either elongated or round with evidence of cell 
shrinkage and membrane blebbing, an indication of cells undergoing apoptosis (Fig 2.9F, arrows). 
After one week following the final BaP treatment, most cells had blebbing cell membranes and 
had rounded and lost adhesion (Fig. 2.9G, arrows). 
 
These results suggest that EPC-2 cells exposed to prolonged treatment with BaP had altered 
morphology, which was represented by the loss of integrity of their cell membranes and change in 
shape from round to elongated. This implies that BaP is toxic to the cells and links with the cell 
proliferation experiments in Figure 2.8, where BaP-treated EPC-2 cells decreased their growth 
rate over 5 days compared to untreated cells. WHCO1 cells showed no change in morphology 




























































Figure 2.9 EPC-2 cell morphology changes during prolonged BaP treatment. EPC-2 cells were 
treated with 10µM BaP for 48 hours followed by incubation in media without BaP for one week. The same 
cells were then treated again with 10µM BaP for 48h followed by incubation in media without BaP for 
another week. The same cells were treated a third time and grown for a third week. Cells were split as 
necessary during the weeks of incubation in BaP-free media. Phase contrast photographs were taken at 20x 
magnification directly before BaP treatment (A, C, E, G) after 7 days growth and directly after 48h in BaP-
containing media (B, D, F) before incubation in fresh media, as described in Methods. Photographs are 


















This study compared the response of oesophageal cancer cell lines and a normal oesophageal 
epithelial cell line to treatment with the tobacco smoke procarcinogen BaP and explored 
differences in CYP1 genotype, CYP1 mRNA and protein induction, AhR-ARNT nuclear 
translocation and cellular proliferation between WHCO1 and EPC-2 cells. This work may 
contribute to our understanding of BaP-associated oesophageal cancer promotion and 
carcinogenesis. 
 
It should be noted that a limitation of this study is the use of only one control cell line. While 
other normal human oesophageal epithelial cell lines exist, they were difficult to obtain for this 
study. The influence of telomerase immortalization on the observed results can be ruled out, since 
EPC-2 cells share the biochemical, morphological and cytogenetic properties of normal 
oesophageal epithelium (Lim et al., 2009) and have functional p53 and Rb pathways (Harada et 
al., 2003). EPC-2 cells therefore represent normal oesophageal cells and may give an indication 
as to how the normal epithelium might respond to BaP treatment.  
 
2.3.1 CYP1 polymorphisms 
 
CYP1A1 and CYP1B1 are the primary enzymes involved in the metabolic activation of BaP to its 
carcinogenic metabolite BPDE. The polymorphic variants in CYP1A1 (4889A>G) and CYP1B1 
(4326C>G) have been shown to encode enzymes with increased catalytic activity compared to the 
common alleles. Furthermore, these polymorphisms have also been associated with increased risk 
of cancer in various extra-hepatic tissues. These findings form the basis of our interest in their 
potential role in the development of OSCC as a result of BaP exposure from tobacco smoke. We 
hypothesize that the high activity alleles of CYP1A1 and CYP1B1 would metabolically activate 
BaP to BPDE at a faster rate during Phase I metabolism, and that the resulting high levels of 
BPDE would enhance the risk of developing cancer.  
 
While the CYP1A1 4889A>G polymorphic variant was only present in KYSE 150, the genotypes 
for the CYP1B1 4326C>G polymorphism were shown to vary among the WHCO, KYSE and 
EPC-2 cell lines. It was not unexpected that all four WHCO cell lines possessed the CYP1A1 
A/A genotype, given that the frequency of this polymorphism is high in African populations 
(http://www.ncbi.nlm.nih.gov/SNP), thereby suggesting that metabolic activation by CYP1A1 
may not be important in WHCO cell lines. Similarly, the CYP1B1 C/G genotype occurred in four 











highest in Asian populations (http://www.ncbi.nlm.nih.gov/SNP). The varied distribution of the 
CYP1B1 4326C>G polymorphism in these twelve cell lines suggests that the role of CYP1B1 in 
the metabolic activation of BaP may be more important than CYP1A1. Although other studies 
have linked these polymorphic sites to increased catalytic activity, CYP1A1 and CYP1B1 
enzyme activity was not directly measured. One should consider methods of measuring CYP1A1 
and CYP1B1 enzyme activity, such as the 7-ethoxyresorufin O-deethylase (EROD) assay, either 
in intact cells (Donato et al., 1993) or in microsomal extracts (Burke and Mayer, 1974). Enzyme 
activity may also be influenced by other polymorphic sites in the CYP1A1 gene, either alone or 
in combination, for example, the 3801T>C MspI polymorphism, which is also linked with 
increased enzyme inducibility and risk for lung and breast cancer (Zhou et al., 2009).  
 
Since CYP1B1 genotypes varied greatly between cell lines, it is possible that CYP1B1 may be 
playing a more important role in BaP bioactivation than CYP1A1, especially in the two high 
activity cell lines, EPC-2 and KYSE 180. The high CYP1B1 activity in EPC-2 cells suggests that 
normal cells may metabolically activate BaP more rapidly than cancer cells; however a 
generalization cannot be made since this study is limited by the use of only one normal cell line. 
CYP1B1 enzyme activity can also be assessed using the EROD assay, however not in our intact 
cell model since the assay cannot distinguish between the relative contributions made by 
CYP1A1 and CYP1B1, except for the observation that CYP1B1 is inhibited by lower 
concentrations of the CYP1 inhibitor, NF (McFadyen et al., 2004).  
 
Our hypothesis is based on the concept that increased Phase I enzyme activity would result in an 
imbalance between metabolic activation and detoxification and an accumulation of BPDE that 
eventually results in carcinogenesis. However, researchers in the field argue that in vitro 
experiments such as this one do not accurately reflect the coupling between Phase I and II 
metabolism that occurs within intact animals (Nebert et al., 2004; Nebert and Dalton, 2006). 
Indeed, in our experiments, the focus is on Phase I metabolism by the CYP1 family only. The 
total detoxification of a xenobiotic such as BaP depends on the rate of both oxidation and 
conjugation reactions. If metabolic activation by CYP1 occurs rapidly and is coupled to rapid 
conjugation, then there should be efficient detoxification and removal of the harmful products. 
However, if rapid metabolic activation by CYP1 is coupled to slow conjugation, then there is an 
accumulation of the reactive intermediate (BPDE) which then binds to DNA and forms 
mutagenic adducts that can initiate cancer. Therefore, high activity CYP1 enzymes coupled with 
low activity Phase II enzymes or null allele Phase II genes should infer increased risk to OSCC 











Although it is possible to genotype the polymorphic alleles in candidate Phase II genes and infer 
the balance between metabolic activation and detoxification within our cell line model, more 
precise conclusions can be made about BaP detoxification and coupling between Phase I and II 
metabolism through population-based case-control studies. Previous research in our laboratory 
has investigated the role of polymorphisms within several Phase I and Phase II detoxification 
genes and risk of OSCC associated with cigarette smoking and alcohol consumption (Table 1.1). 
Polymorphic phase I genes investigated include CYP2E1 (7632T>A) and CYP3A5 (6986A>G), 
while phase II genes analyzed include SULT1A1 (638G>A), GSTM1 (*0), GSTT1 (*0) and 
GSTP1 (341 C>T). 
 
Results from our laboratory have shown that in South African populations, the CYP1A1 
4889A>G and CYP1B1 4326C>G polymorphisms may play a role in the development of 
smoking-associated OSCC (Li et al, unpublished results). The CYP1A1 polymorphism together 
with smoking status was marginally associated with increased risk of OSCC in the South African 
Mixed Ancestry population. This is consistent with studies carried out in French, Japanese and 
North American populations, but not in Chinese (Bartsch et al., 2000; Abbas et al., 2004; Suzuki 
et al., 2004; Wideroff et al., 2007). In contrast, the CYP1B1 polymorphism was associated with 
reduced risk of OSCC in the Mixed Ancestry population. This finding has not been reported in 
any other studies, although no significant association was found between the CYP1B1 Val432Leu 
polymorphism and OSCC risk in a Chinese population (Wang et al., 2006). Since the CYP1B1 
4326C>G polymorphism is associated with increased risk in other cancers, these results may 
reflect differences in sample size and ethnic genetic variation. 
 
2.3.2 Induction of CYP1A1 and CYP1B1 mRNA and protein by BaP 
 
The tissue-specific expression patterns of CYP1A1 and CYP1B1 are thought to directly affect the 
balance between detoxification and metabolic activation of procarcinogens such as BaP and 
therefore influence BaP toxicity and carcinogenicity (reviewed by Nebert and Dalton, 2006, 
Shimada and Fujii-Kuriyama, 2004). From extensive research using cyp1a1(-/-), cyp1b1(-/-), 
cyp1a2(-/-) single knockout mice, cyp1a1/1a2(-/-), cyp1a2/1b1(-/-), cyp1a1/1b1(-/-) double 
knockout mice and cyp1a1/1a2/1b1(-/-) triple knockout mice, it has been demonstrated that 
CYP1A1 plays a more protective role in detoxification of BaP, whereas CYP1B1 plays a more 













Other studies using animal or cell line models have shown that expression of CYP1A1 and 
CYP1B1 mRNA and protein is induced by BaP in various normal and cancer tissue types, but 
that CYP induction varies greatly. 
 
mRNA quantification showed that BaP-induced CYP1A1 levels ranged from 1.5-fold in ACHN 
(renal carcinoma), A549 (lung adenocarinoma) and NEC14 cells (testis embryonal carcinoma, 
Iwanari et al., 2002) to 110-fold in BEP2D cells (human immortalized bronchial epithelium, 
Uppstad et al., 2010). In WHCO1 cells, CYP1A1 was induced 10-fold by BaP at 24h, which is 
similar to CYP1A1 induction in HepG2 (hepatocarcinoma, 11-fold, Iwanari et al., 2002) and rat 
liver cells (11.3-fold, Harrigan et al., 2006). In EPC-2 cells, CYP1A1 was induced 6-fold by BaP 
at 48h, which is most similar to CYP1A1 induction in HepG2 cells (7.5-fold, Wen et al., 2005). 
Different induction of CYP1A1 in HepG2 cells can be explained by different BaP concentrations, 
despite having the same duration of treatment: HepG2 cells were treated for 24h with 5M BaP 
(Iwanari et al., 2002), or with 1M BaP (Wen et al., 2005), correlating with higher CYP1A1 
mRNA induction and lower induction, respectively. 
 
BaP-induced CYP1B1 mRNA levels ranged from 1.5-fold in NEC14 cells (Iwanari et al., 2002) 
and 1.7-fold at 24h in EPC-2 cells, to 40-fold in NHMECs (normal human mammary epithelial 
cells, Keshava et al., 2009). In WHCO1 cells, CYP1B1 induction at 24h by BaP was 7-fold, 
which is similar to CYP1B1 induction in MCF-10A (human mammary epithelium, 6-fold, Chang 
et al., 2010) and NHMECs (8.7-fold, Keshava et al., 2005). In EPC-2 cells, CYP1B1 induction 
was 20-fold at 48h by BaP, which is similar to CYP1B1 induction in LS-180 (colon carcinoma, 
20-fold, Iwanari et al., 2002) and BEP2D cells (19-fold, Uppstad et al., 2010). Different fold 
induction of CYP1B1 in NHMECs resulted from different BaP treatment periods, despite 
treatment with the same BaP concentration: NHMECs were treated with 4M BaP for 12h 
(Keshava et al., 2005) or 24h (Keshava et al., 2009), which relates to lower CYP1B1 mRNA 
induction and higher induction, respectively. 
 
CYP1A1 and/or CYP1B1 mRNA induction is increased by BaP treatment in MSK-Leuk1 (oral 
leukoplakia) and KYSE 450 cells (OSCC, Hughes et al., 2008), RL95-2 (human endometrial 
epithelium, Bao et al., 2002), SCC449 cells (OSCC, Port et al., 2004) and OVCA (ovarian 
carcinoma, Leung et al., 2006). Since the fold induction was not quantified, no comparisons can 












CYP1A1 protein levels are elevated by BaP treatment of MSK-Leuk1, KYSE 450 (Hughes et al., 
2008), HOSE (human ovarian surface epithelium, Leung et al., 2006), HepG2, SCC-9 (human 
oral epithelial squamous cell carcinoma, Wen and Walle, 2005, Wen et al., 2005) and rat liver 
cells (Umannova et al., 2008), although no quantification was done. Similarly, quantification of 
increased CYP1B1 protein levels in SCC449 (Port et al., 2004), MSK-Leuk1, KYSE 450 
(Hughes et al., 2008) and SCC-9 cells (Wen and Walle, 2005) was not carried out. Interestingly, 
CYP1B1 protein was not detected in mouse liver and lung (Galvan et al., 2005) or HepG2 cells 
(Wen et al., 2005). These observations are difficult to compare to our findings of increased 
CYP1A1 and CYP1B1 protein levels by BaP treatment in WHCO1 and EPC-2 cells.  
 
Collectively, these results suggest that CYP1A1 and CYP1B1 mRNA and/or protein induction 
are cell-, tissue- and species-specific. Our data is consistent with the observations in other cell 
lines and animal models which show that BaP-induced CYP1 mRNA levels and protein levels are 
linked with each other. In addition, our data agrees with the generalization that CYP1 induction 
by BaP appears to be greater in cancer cell lines than in normal or immortalized cell lines. Higher 
levels of CYP1 mRNA and protein in cancer cells should make these cells more capable of 
metabolically activating BaP to DNA-damaging metabolites than normal cells.  
 
When comparing CYP1A1 and CYP1B1 inducibility in OSCC cell lines from different ethnic 
origins, our results showed that CYP1 induction by BaP was on average higher in South African 
OSCC cell lines than Japanese OSCC cell lines. The differential CYP1 mRNA and protein 
induction patterns could contribute to inter-population differences in BaP metabolism and 
detoxification, and therefore susceptibility to tobacco smoking-associated OSCC. 
 
mRNA and protein levels did not clearly associate with the genotypes for the CYP1A1 4889A>G 
and CYP1B1 4326C>G polymorphic sites. The absence of a simple relationship suggests that the 
link between CYP1 inducibility and genotype – inferring enzyme activity – is more complex than 
can be demonstrated here. 
 
A possible explanation for the diverse inducibility patterns of CYP1A1 and CYP1B1 is their 
regulation through epigenetic mechanisms, particularly gene or promoter methylation (Nakajima 
et al., 2003). Aberrant DNA methylation occurs frequently in cancer and while hypermethylation 
is associated with gene silencing, hypomethylation is linked to gene over-expression (Esteller, 
2007). Interestingly, CYP1B1 is hypomethylated and overexpressed in prostate cancer (Tokizane 











2009, Kang et al., 2008). CYP1B1 is also down-regulated by methylation in HepG2 cells 
(Beedanagari et al., 2010), while CYP1A1 is possibly down-regulated by methylation in HeLa 
cells (Nakajima et al., 2003). Therefore the epigenetic regulation of CYP1B1 may contribute to 
the metabolic activation and carcinogenicity of BaP.  
 
CYP1A2, primarily a hepatic enzyme, has been shown to be expressed to a limited degree in 
extra-hepatic tissues including the oesophagus (Lechevral et al., 1999). However, metabolism of 
BaP by CYP1A2 is thought to be negligible (Shimada et al., 1996; Shimada and Fujii-Kuriyama, 
2004) and instead CYP1A2 plays a more important role in the metabolic activation of other 
procarcinogens. CYP1A2 mRNA and protein were shown to be mildly inducible in WHCO1 
cells, and while CYP1A2 mRNA was not detectable in EPC-2 cells, CYP1A2 protein was 
maintained at low constitutive levels. The inability to detect CYP1A2 mRNA in EPC-2 cells is 
consistent with undetectable CYP1A2 mRNA in ACHN, A549, NEC14 and HeLa cells (Iwanari 
et al., 2002). CYP1A2 protein was not detected in SCC-9 cells (Wen and Walle, 2005), but was 
constitutively expressed in HepG2 cells (Wen et al., 2005). These results, together with our data, 
show that CYP1A2 expression may not play an important role in the metabolic activation of BaP 
in the oesophagus. 
 
2.3.3 Nuclear translocation of AhR and ARNT in response to BaP  
 
A role for the AhR has clearly been demonstrated in carcinogenesis and BaP-associated 
carcinogenesis (Dietrich and Kaina, 2010, Nebert et al., 2004, Beischlag et al., 2008, Kawajiri 
and Fujii-Kuriyama, 2007, Marlowe and Puga, 2005). The effects of BaP treatment on AhR and 
ARNT mRNA and protein levels and nuclear translocation rate may provide insight into why 
EPC-2 and WHCO1 cells have different CYP1 induction capacities when exposed to BaP. This 
work is the first to describe the effect of BaP treatment and withdrawal on the rate of AhR and 
ARNT nuclear translocation in oesophageal normal and tumour cells. 
 
Since the ligand-activated AhR, together with the ARNT, functions as a transcription factor, it 
was not surprising to see an increase in their nuclear translocation after treatment with BaP. Our 
results are consistent with the nuclear translocation of the AhR in Hepa1c1c7 cells after exposure 
to TCDD or BaP quinone (BPQ, Burczynski and Penning, 2000). After 90min treatment, nuclear 
translocation of the AhR was evident in TCDD- or BPQ-treated cells, but not in BPDE-treated 
cells (Burczynski and Penning, 2000). Since our work only assessed translocation after 24h, 











24h), and use other methods of monitoring translocation, such as tagging the AhR and ARNT 
with the green fluorescent protein (GFP) reporter. 
 
From our results, we hypothesize that the prolonged duration of the AhR in the nuclei of WHCO1 
cells may lead to sustained AhR signaling – and therefore CYP1 induction – in WHCO1 cells, 
whereas in EPC-2 cells, the rapid nuclear exit of the AhR and ARNT may lead to shorter AhR 
signaling – and therefore reduced CYP1 induction. The AhR also cross-talks with other signaling 
pathways involved in cell proliferation and apoptosis, including MAPK cascades (Puga et al., 
2009, Beischlag et al., 2008). The AhR has been shown to interact, either directly or indirectly, 
with NFB, ER, GR, Rb and E2F. Differences in AhR signaling may help explain why EPC-2 
and WHCO1 cells showed differences in CYP1 induction, AhR-ARNT nuclear translocation and 
cellular proliferation in response to BaP. 
 
The complete metabolism of BaP generates many other BaP metabolites (Fig. 1.7) which may 
serve as AhR ligands that sustain AhR activation (Spink et al., 2008). BaP ultimately initiates 
cancer through the action of its carcinogenic metabolite, BPDE, however the other metabolites 
generated may play an important role in CYP1 induction, AhR activation and nuclear 
translocation, and cell proliferation. BaP metabolites could also have different specificity for the 
AhR. There is already evidence that structurally diverse PAHs and inducers have varied effects 
on CYP1 induction potency. For example, in a range of cell lines, CYP1A1 and CYP1B1 are 
induced at higher levels by TCDD and 3-MC than by BaP, which itself has a higher induction 
potency than 6-nitroBaP (Iwanari et al., 2002). The complete effects of BaP treatment in EPC-2 
and WHCO1 cells are therefore also mediated by the formation of AhR-activating BaP 
metabolites. Although CYP1 induction is dependent on the AhR and ARNT, BaP 
biotransformation and the formation of BPDE-DNA adducts still occur in AhR(-/-) knockout 
mice (Sagredo et al., 2006). These mice still had significant basal CYP1B1 levels that were not 
affected by BaP treatment, so BaP activation was most probably attributable to basal CYP1B1 
activity (Sagredo et al., 2006).  
 
AhR and ARNT mRNA and protein levels were much higher in WHCO1 compared to EPC-2 
cells. Decreased AhR and ARNT mRNA and protein levels in EPC-2 cells appear to relate to 
lower CYP1 induction capacity, a shorter duration in the nucleus and therefore less AhR 
signaling in EPC-2 cells compared to WHCO1 cells. These results are consistent with increased 
AhR mRNA levels demonstrated in response to BaP treatment in Caco-2 colon carcinoma cells 











in mouse embryo fibroblasts (Kann et al., 2005) and the decrease in AhR mRNA and protein after 
BaP exposure in mouse aortic endothelial cells (Wang et al., 2009). In addition, previous research 
has shown that AhR mRNA levels are up-regulated 1.4-fold after exposure to 10nM TCDD in 
T24 transitional cancer cells (Ishida et al., 2010) but are down-regulated by 30% after exposure to 
5nM TCDD and by 25% after exposure to 10M -NF in HepG2 cells (Dvorak et al., 2008, 
Iwano et al., 2010). AhR mRNA levels were up-regulated 4-fold and 6-fold in MCF10AT1 and 
MCF-7 breast cancer cells, respectively, after exposure to 1nM 17--estradiol (Wong et al., 
2009). These results collectively suggest that AhR mRNA and protein levels vary in a cell-type 
and compound-specific manner.  
 
Our results showed that nuclear ARNT protein levels were induced to a greater degree in 
response to BaP treatment than AhR levels in WHCO1 cells and that ARNT mRNA levels were 
up-regulated in response to BaP treatment in both EPC-2 and WHCO1 cells. This disagrees with 
the observed down-regulation of ARNT mRNA levels by BaP treatment in Caco-2 cells (Niestroy 
et al., 2011), and there is no evidence for increased ARNT mRNA levels in response to BaP. 
However, since the ARNT has been shown to be essential for BaP-induced tumour initiation (Shi 
et al., 2009), it must still play an important role in CYP1 induction in EPC-2 and WHCO1 cells.  
 
The observed increase in nuclear AhR and ARNT levels appeared to associate with decreased 
cytoplasmic AhR and ARNT levels, although the cytoplasmic proteins appear to disappear 
completely. This does not seem to be because all the protein has entered the nucleus, since their 
nuclear levels also decline after BaP withdrawal. The decrease in protein levels is therefore 
probably attributable to cytoplasmic AhR and ARNT protein degradation by the proteasome, 
which occurs in response to ligand binding (Davarinos and Pollenz, 1999, Ma and Baldwin, 
2000) and is mediated by ROS signaling (Choi et al., 2008).  
 
The nuclear protein western blot results suggest that Lamin B1 is a poor loading control in EPC-2 
cells. In untreated cells, Lamin B1 levels are extremely low and appear to be inducible upon BaP 
treatment. However, levels are maintained even after BaP withdrawal. Lamin B1 levels appear to 
be constant in nuclear extracts from WHCO1 cells, and although not presented here, all SDS gels 
were routinely stained with Coomassie to confirm equal loading of protein extracts. These 
findings suggest that nuclear expression of Lamin B1 is affected by BaP treatment in EPC-2 cells, 
and that another loading control should be used, such as histone H3. Interestingly, Lamin B1 
mRNA is down-regulated by BPDE treatment in FL normal human amnion epithelial cells (Lu et 











Lamin B1 detected in untreated EPC-2 cells could reflect loss of the Lamin B1-containing nuclear 
membrane during the nuclear protein extraction process.  
 
2.3.4 BaP-induced changes in cellular proliferation and cell morphology 
 
The cytotoxicity of BaP suggests that BaP treatment may have a negative effect on cellular 
proliferation in our cell line model. Our results show that BaP-treated EPC-2 cells had lower 
proliferation than untreated cells, whereas WHCO1 cells were more resistant to BaP-associated 
growth reduction. The decreased cell growth in both EPC-2 and WHCO1 cells may be explained 
by BaP-induced apoptosis or cell cycle arrest. BaP treatment has indeed been shown to induce 
apoptosis through various mechanisms in several cell line models, including HepG2 (human 
hepatocarcinoma, Chen et al., 2003), Hepa1c1c7 (mouse hepatoma, Solhaug et al., 2004a), H460 
(human lung cancer, Xiao et al., 2007) and F258 cells (rat liver epithelial cells, Tekpli et al., 
2010). BaP-induced apoptosis is thought to be a result of oxidative stress signaling (Nebert et al., 
2000). The complete effects of BaP on cellular proliferation are probably more complex: BaP 
induces both pro- and anti-apoptotic signaling events in mouse hepatoma Hepa1c1c7 cells 
(Solhaug et al., 2004). The effects may therefore depend on various parameters such as cell type, 
species and BaP concentration.  
 
The analysis of cellular proliferation using three different methods – cell viability (MTT 
metabolism), DNA synthesis (BrdU incorporation) and cell number – showed a general trend that 
while BaP-treated EPC-2 cells displayed reduced growth, BaP treatment showed no effect on 
WHCO1 cell growth. This concordance between different methods was however not consistent 
with the MTT assay, which showed higher cell viability in BaP-treated WHCO1 cells after 48h. 
Increased MTT levels after 48h may simply reflect increased mitochondrial reductase enzyme 
activity, since treatment with BaP increases the activity of many metabolic enzymes. 
Alternatively, increased MTT activity may also represent increased BaP metabolism by 
mitochondrial CYP1A1, since both mitochondrial and microsomal CYP1A1 metabolize BaP 
(Dong et al., 2009). Despite the difference shown using the MTT assay, the two other methods 
confirmed the trend of decreased cellular proliferation in BaP-treated EPC-2 cells compared to 
WHCO1 cells. It should be noted that there is no evidence to suggest that BaP interacts with any 
components of the different growth media used to culture WHCO1 and EPC-2 cells (DMEM and 
KSFM, respectively) and therefore the observed differences in cellular proliferation do not reflect 












The oxidative metabolism of BaP by Phase I XMEs contributes to the production of oxidative 
stress as a result of increased ROS, for example, hydrogen peroxide and superoxide (Burdick et 
al., 2003, Miller and Ramos, 2001). Oxidative stress signaling during BaP metabolism may 
trigger apoptosis (Nebert et al., 2000, Tekpli et al., 2010), which would be reflected as decreased 
cellular proliferation in BaP-treated cells, as observed in BaP-treated EPC-2 and WHCO1 cells.  
 
The results show that prolonged treatment with BaP resulted in altered morphology in EPC-2 
cells. The most obvious effects were the formation of elongated cells and membrane blebbing. 
This observation is consistent with evidence that membrane remodeling is a primary step in BaP-
induced apoptosis in F258 rat liver epithelial cells (Tekpli et al., 2010). The small, rounded cells 
observed in Figure 2.9 are similar to the apoptotic cells identified after BaP exposure in 
Hepa1c1c7 cells (Solhaug et al., 2004a). Therefore our results suggest that prolonged BaP 
treatment causes apoptosis in most EPC-2 cells. 
 
Prolonged exposure to low concentrations of BaP or BPDE has been shown to lead to 
transformation and deregulated growth kinetics in MRC-5 SV2 human lung fibroblasts and MCF-
7 breast cancer cells (Pliskova et al., 2005, Zhu and Gooderham, 2002, Jiao et al., 2007, Jeffy et 
al., 2000). Our results show that BaP has a profound negative effect on EPC-2 cell morphology 
and membrane integrity, although the ability of BaP to transform EPC-2 cells has yet to be 
determined.  
 
BaP- or BPDE-induced transformation has recently been shown to involve other key players. For 
example, the ERK/cyclin D1 pathway and JNK and p38 MAPK activation are required for BaP-
induced transformation in human lung fibroblasts (Du et al., 2006), while NFAT3 and TNF are 
critical in BPDE-induced transformation in mouse epidermal CI41 cells (Ouyang et al., 2007). 
There is evidence that CDC25B phosphatase levels are important for BPDE-induced 
transformation (Srivastava et al., 2007) and transformation through Cyclin D1 also depends on 
the PI3K/Akt/MAPK pathway (Ding et al., 2009). Transformation of EPC-2 cells in particular, 
also requires various factors, such as the EGFR (epidermal growth factor receptor, Andl et al., 
2002), ILGFBP3 (insulin-like growth factor binding protein 3), TGFB1 (transforming growth 
factor beta, Natsuizaka et al., 2010), TLR3 (toll-like receptor 3), NFB (nuclear factor kappa B, 
Lim et al., 2009), or various combinations of expressed oncogenes (Kim et al., 2006). This 















BaP, a PAH procarcinogen present in tobacco smoke, binds to and activates the AhR, which 
dissociates from its cytoplasmic chaperone complex and enters the nucleus together with the 
ARNT. Here the AhR-ARNT transcription factor binds to xenobiotic response elements (XREs) 
in the promoter regions of its target genes, such as CYP1A1, CYP1A2, CYP1B1 and some phase 
II detoxification genes, thereby activating their transcription (Nebert and Dalton, 2006, 
Androutsopolous et al., 2009, Whitlock, 1999, Barouki et al., 2007). CYP1A1 and CYP1B1 
enzymes are primarily responsible for the Phase I metabolism of BaP to its activated metabolites 
including BPDE. BaP therefore stimulates its own metabolism in a feedback loop. 
 
Figure 2.10 represents the response to BaP in WHCO1 and EPC-2 cells based on the findings 
presented in this chapter. In normal (EPC-2) cells, there are lower levels of AhR and ARNT 
proteins which transcribe fewer CYP1A1 and CYP1B1 mRNA transcripts, resulting in lower 
amounts of enzyme to metabolize BaP. Rapid nuclear exit of AhR and ARNT reduces the 
duration of AhR signaling. BaP and its metabolites accumulate and cells reduce growth in 
response to BaP toxicity and possibly enhanced ROS production and apoptosis (Fig. 2.10A). In 
cancer (WHCO1) cells, however, there are higher levels of AhR and ARNT which transcribe 
more CYP1A1 and CYP1B1 transcripts, and therefore increased enzyme levels enhance BaP 
metabolic activation to BPDE. Increased levels of BaP metabolites may also serve as AhR 
ligands that can sustain AhR activation (Spink et al., 2008). The higher levels of AhR and ARNT 
and their prolonged duration in the nucleus may result in a constitutively active or sustained AhR 
signaling cascade which may predispose WHCO1 cells to AhR-mediated abnormal cell 
proliferation in the presence and even after the removal of BaP, which may contribute to cancer 
progression (Fig. 2.10B).  
 
Our proposed model of the molecular events occurring in response to BaP in EPC-2 and WHCO1 
cells, however, does not take into consideration the expression of all possible genes involved in 
this response. In order to further our understanding of the effects of BaP on gene expression 
patterns in normal and transformed oesophageal cells, a DNA microarray is an obvious next step 












































Figure 2.10 Summary of the molecular response to BaP treatment in normal and transformed 
oesophageal epithelial cells. (A) In normal (EPC-2) cells, there are lower levels of AhR and ARNT, which, 
in response to BaP treatment, translocate more rapidly into and out of the nucleus, resulting in the 
transcription of lower amounts of CYP1A1 and CYP1B1 mRNA and protein, which metabolize BaP less 
efficiently and cellular proliferation is reduced due to the accumulation of toxic BaP metabolites and 
possibly from increased apoptosis. (B) In transformed (WHCO1) cells, there are higher levels of AhR and 
ARNT, which, in response to BaP treatment, transcribe greater amounts of CYP1A1 and CYP1B1 mRNA 
and protein, which metabolically activate BaP more efficiently, resulting in a higher production of ROS. 
Prolonged duration of AhR-ARNT in the nucleus may lead to sustained AhR activation and AhR signaling, 
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Transcriptional profiling of normal and tumour oesophageal epithelial 





Transcriptional profiling by microarray analysis is frequently used to analyze the toxic, 
therapeutic or carcinogenic effects of various compounds on whole-genome expression in cell 
lines and tissues. BaP has been recognized for its carcinogenic potential for many years (IARC, 
2004) but the detailed molecular mechanisms are still unsolved. Microarray studies have shown 
the effects of BaP treatment on global gene expression in various cell lines, including MCF-7 
(breast carcinoma), HepG2 (hepatocarcinoma), A549 (lung adenocarcinoma), WI38 (foetal lung 
fibroblasts) and NHMEC (normal human mammary epithelial cells). This chapter investigates the 
effect of BaP on global gene expression in a normal oesophageal epithelial cell line (EPC-2) and 
an oesophageal cancer cell line (WHCO1), since no prior studies have focused on oesophageal 





RNA from WHCO1 and EPC-2 cells treated with 0.1% DMSO or 10M BaP were amplified, 
labeled and hybridized to the Illumina WG6 v3 Expression BeadChip. Gene expression data was 
analyzed using Illumina’s BeadStudio/GenomeStudio software and with the assistance of Dr Otu 
from the Department of Bioengineering, Istanbul Bilgi University, Istanbul, Turkey and 
Department of Medicine, BIDMC Genomics Centre, Harvard Medical School, Boston, USA, and 
Dr Nicki Tiffin from the South African National Bioinformatics Institute (SANBI) at the 
University of the Western Cape. Lists of differentially expressed genes were analyzed using 
Ingenuity Pathways Analysis (IPA) and GOstat. 
 
 
3.2.1 Microarray sample selection and clustering analysis 
 
Data were analyzed and the gene expression fold change was calculated. In order to determine the 
concordance between biological replicates, untreated and BaP-treated samples from both 
WHCO1 and EPC-2 microarrays were clustered according to the similarity of genes expressed 
(Fig. 3.1A-B). From the dendrograms it was clear that sample “BaP1” from the WHCO1 groupset 











in the incorrect groups (Fig. 3.1A). These samples were subsequently removed as outliers before 
further analysis, generating a final combined cluster (Fig. 3.1C). 
 
Differentially expressed genes were clustered together, generating heat maps (Fig. 3.2) that 
indicate the variation of gene expression fold change between 0.6 and 3-fold up- (red) or down- 
(green) regulation across the samples in each groupset. Despite the low fold change within one 
sample, overall fold change for Un or BaP groups were greater than 2-fold in all genes. In the 
WHCO1 heat map, there were a larger number of up-regulated than down-regulated genes (Fig. 









Figure 3.1 Sample clustering dendrograms. Triplicate samples of 0.1% DMSO- or 10M BaP-
treated cRNAs from WHCO1 and EPC-2 cells were clustered by similarity of expressed genes as described 
in Methods. Original clustering of EPC-2 (A) and WHCO1 (B) samples shows that triplicates do not all 
cluster together. Outlier samples were removed to generate a final combined dendrogram (C) showing the 
replicates used for subsequent analysis. Un denotes cells treated with 0.1% DMSO; BaP denotes cells 
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Figure 3.2 Differential gene expression heat maps. Heat maps depict signal intensity and clustering 
of differentially expressed genes in (A) EPC-2 and (B) WHCO1 cells. Green indicates down-regulated 
genes; red indicates up-regulated genes. Colour intensity indicates fold change as shown in the legend 
below the heat maps. B denotes BaP-treated samples; U denotes 0.1% DMSO-treated samples.  
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3.2.2 Differentially expressed genes in response to BaP treatment 
 
BaP treatment resulted in differential expression of several hundred genes in both EPC-2 and 
WHCO1 cells (Fig. 3.3). Gene expression fold change was calculated for each gene by dividing 
“BaP” average signal values by “Un” average signal values. In addition, each treatment group 
was compared to every other treatment group, generating a total of 6 comparisons: EPC-2 BaP vs 
EPC-2 Un, WHCO1 BaP vs WHCO1 Un, WHCO1 BaP vs EPC-2 Un, WHCO1 Un vs EPC-2 
BaP, WHCO1 Un vs EPC-2 Un and WHCO1 BaP vs EPC-2 BaP. The number of differentially 
expressed genes varied widely between comparisons (Fig. 3.3), from 183 genes up-regulated in 
BaP-treated WHCO1 cells compared to untreated cells, to 2900 genes up-regulated in BaP-treated 
EPC-2 cells compared to untreated WHCO1 cells. The top 50 genes up- or down-regulated in 
each comparison (except for WHCO1 BaP vs EPC-2 Un, which is not relevant in this study) are 


















Figure 3.3 Number of up- and down-regulated genes in each dataset comparison. All possible 
comparisons made between EPC-2 and WHCO1 treatment groups generate twelve lists of up-regulated () 
and down-regulated () genes differentially expressed by at least two-fold in each comparison. Un indicates 




















3.2.3 Validation of Microarray Data by qRT-PCR 
 
Genes were selected from the lists of differentially expressed genes to confirm the validity of 
microarray gene expression fold changes by qRT-PCR. Genes were selected from the EPC-2 and 
WHCO1 gene lists, respectively, and fold change comparisons were made between qRT-PCR and 
microarray gene expression (Fig. 3.4). 
 
In general, microarray fold change and qRT-PCR fold change followed the same trend. Gene 
expression was often exaggerated by the microarray data, for example, for MMP9, GPX3, 
P53AIP1 and ITGB7 (Fig 3.4A). The only gene whose expression was not consistent between 
microarray and qRT-PCR is UGT2B7 (Fig 3.4B). The common gene, ITGB7, was up-regulated 
in WHCO1 cells (Fig. 3.4B) but down-regulated in EPC-2 cells (Fig 3.4A). The general 
concordance between gene expression fold changes suggests that the microarray gene expression 
data are reproducible by qRT-PCR. 
 
 
3.2.4 Genes and biological pathways affected by BaP treatment 
 
The first objective was to determine which genes are differentially expressed in response to BaP 
treatment in normal and tumour oesophageal cell lines. BaP induced the up-regulation of 521 and 
183 genes and the down-regulation of 1056 and 289 genes in EPC-2 and WHCO1 cells 
respectively. The functional relevance of differentially expressed genes was analyzed by 
determining the biological functions, canonical pathways and gene ontology (GO) terms 
(molecular function, biological process or cellular component) that were affected during the 
response to BaP treatment. Gene ontology was investigated using IPA and GOstat. The top genes 






































































































































A)     EPC-2 
B)             WHCO1 
 
Figure 3.4 Validation of microarray fold change by qRT-PCR on selected genes. Selected genes 
with altered expression in response to BaP exposure in EPC-2 (A) and WHCO1 (B) cells were analyzed by 
qRT-PCR as described in Methods. Fold change shown was normalized to GAPDH mRNA levels and 
relative to 0.1% DMSO-treated replicates. Results shown are mean + standard deviation from triplicate 
samples per biological replicate. CCNB2: cyclin B2; CDKN3: cyclin-dependent kinase inhibitor 3; 
IL13RA2: interleukin 13 receptor alpha 2; POLM: DNA polymerase mu; SULF1: sulfatase 1; ADAM23: 
ADAM metallopeptidase domain 23; CCNA1: cyclin A1; TFPI2: tissue factor pathway inhibitor 2; MT1G: 
metallothionein 1G; GSTM1: glutathione S-transferase M1; MMP9: matrix metallopeptidase 9; IFITM1: 
interferon induced transmembrane protein 1; GPX3: glutathione peroxidase 3; P53AIP1: p53-regulated 
apoptosis-inducing protein 1; ITGB7: integrin beta 7; AHRR: aryl hydrocarbon receptor repressor; 
CYP1A1: cytochrome P450 1A1; CYP1B1: cytochrome P450 1B1; SERPINB2: serpin peptidase inhibitor 
B2; ETV5: ets variant gene 5; ALDH3A1: aldehyde dehydrogenase 3A1; TIPARP: TCDD-inducible 
poly(ADP-ribose) polymerase; UGT2B7: UDP glucuronosyltransferase 2B7; KISS1: KiSS-1 metastasis 
suppressor; SERPINA3: serpin peptidase inhibitor A3; DEFB1: defensin beta 1; HIST1H2BH: histone 














In EPC-2 cells, the most important biological functions as determined by IPA altered in response 
to BaP treatment were Cancer, Cellular Growth and Proliferation, and Cellular Movement (Fig. 
3.5A). The most significant IPA canonical pathways affected include Acute Phase Response 
Signaling and Graft-vs-Host Disease Signaling, but most pathways showed more down-regulated 
than up-regulated genes (Fig. 3.5B). This agrees with the larger number of down-regulated genes 
than up-regulated genes in the heat map (Fig 3.2A). 
 
In WHCO1 cells, the important IPA biological functions were Cell-to-Cell Signaling and 
Interaction, Cell Death, Inflammatory Response and Cellular Growth and Proliferation (Fig. 
3.6A). Most canonical pathways contained more up-regulated than down-regulated genes, and the 
most important pathways include Xenobiotic Metabolism Signaling and Aryl Hydrocarbon 
Receptor Signaling (Fig. 3.6B). The higher number of up-regulated than down-regulated genes in 
these canonical pathways also agrees with the WHCO1 heat map (Fig. 3.2B).  
 
In both cell lines, BaP frequently altered diverse metabolic pathways, such as Arachidonic Acid 
Metabolism, Taurine and Hypotaurine Metabolism (Fig 3.5B), Retinol Metabolism, Xenobiotic 
Metabolism (Fig 3.6B) and LXR/RXR Activation, which is involved in the regulation of lipid 
metabolism (Fig 3.5B, 3.6B). These findings suggest that metabolic pathways were altered in 
response to BaP in both cell lines, but that detoxification pathways were affected more 
significantly in WHCO1 cells. A large number of xenobiotic metabolism genes were 
differentially expressed in WHCO1 cells in response to BaP exposure. These include the up-
regulation of CYP1A1, CYP1B1, UGT1A6, UGT1A10, UGT2B7 and ALDH3A1 and the down-
regulation of GSTA4 and SULT1C3. The altered xenobiotic metabolism agrees with GOrilla 
(Gene Ontology enRIchment anaLysis and visuaLizAtion tool) analysis indicating the most 






















































Figure 3.5 Functions and Pathways affected by BaP treatment in EPC-2 cells. Biological functions 
(A) and canonical pathways (B) were generated from the list of differentially expressed genes in EPC-2 
cells by IPA. In (A) –log(p-value) indicates significance of biological function. In (B) green indicates 
down-regulated; red indicates up-regulated. Number above bar indicates number of genes within the 
pathway. Bar represents percentage of genes within pathway that are up- or down-regulated. Orange line 





















































Figure 3.6 Functions and Pathways affected by BaP treatment in WHCO1 cells. Biological functions 
(A) and canonical pathways (B) were generated from the list of differentially expressed genes in WHCO1 
cells by IPA. In (A) –log(p-value) indicates significance of biological function. In (B) green indicates 
down-regulated; red indicates up-regulated. Number above bar indicates number of genes within the 
pathway. Bar represents percentage of genes within pathway that are up- or down-regulated. Orange line 
graph indicates significance of canonical pathway [-log(p-value)] according to secondary scale. 
WHCO1 
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In WHCO1 cells, the Inflammatory Response function was significantly altered by BaP treatment 
(Fig. 3.6A). BaP induced the expression of several pro-inflammatory cytokines in these cells, 
such as IL6, IL1B, IL11, IL1F9 and other molecules involved in pro-inflammation such as 
CXCL1, PTGS2, LIF and CXCL10, and anti-inflammatory molecules such as IL10RA. The up-
regulation of genes involved in inflammation in WHCO1 cells, such as the IL6 gene interaction 
network (Fig. 3.7B) occurred in contrast to the down-regulation of inflammatory genes in EPC-2 
cells, for example the TNF gene interaction network (Fig. 3.7A). These findings highlight the 
difference in inflammatory response between normal and cancer cells. This is important since 
both tobacco smoking and BaP metabolism are associated with increased inflammation which is 
linked to cancer risk. 
 
In EPC-2 cells, a large number of cell cycle-related genes were differentially expressed. These 
include the up-regulation of CCNB1, CCNB2, CCNA1, CDC25C, CDC20, CDC2, CDCA2, 
CDCA3 and CDKN3, and the down-regulation of CDKN1A and CDKN2A. Interestingly, the 
most significantly over-represented GO terms in BaP-treated EPC-2 cells were Cell Cycle, M 
Phase, Mitosis and Cell Division (Fig. 3.8). Significantly over-represented GO terms are shown 
in Figure 3.8A. The most significant biological processes, shown in red in Figure 3.8B, include 
Cell Division and M Phase of Mitotic Cell Cycle. However, the up-regulation of cell cycle genes 
and cell cycle processes did not result in increased cellular proliferation when EPC-2 cells were 
treated with BaP (Fig. 2.8). This suggests that increased cellular proliferation was suppressed or 
overridden by another mechanism. Indeed, when examining further canonical pathways below the 
top ten (Fig. 3.5B) IPA analysis showed that pathways involved in DNA damage checkpoints and 
cell cycle checkpoint regulation were up-regulated (Fig. 3.9). These results suggest that DNA 
damage from BaP metabolism caused cell cycle checkpoints that inhibit proliferation, despite an 


















Figure 3.7 Differential response of inflammatory genes in BaP-treated EPC-2 and WHCO1 cells. 
Significant gene interaction networks were generated by IPA from lists of differentially expressed genes in 
BaP-treated EPC-2 (A) and WHCO1 (B) cells. TNF and interacting genes are mostly down-regulated in 
EPC-2 cells (A), while IL6 and its interacting genes are mostly up-regulated in WHCO1 cells (B). Solid 
lines indicate direct interactions; dotted lines indicate indirect interactions. In EPC-2: TNF: tumour necrosis 
factor, AKR1B10: aldo-keto reductase 1B10, HMGN: high mobility group nucleosomal binding domain, 
KMO: kynurenine 3-monooxygenase, DHRS3: dehydrogenase/reductase SDR family, TNFRSF21: tumour 
necrosis factor receptor superfamily 21, SPSB1: splA/ryanodine receptor domain and SOCS box containing 
1, TYMP: TIMP metallopeptidase inhibitor, PDZD2: PDZ domain-containing 2, PLA2G7: phospholipase 
A2 group 7, AQP3: aquaporin 3, CTSF: cathepsin F, SLC43A2: solute carrier 43A2, ADAMTS7: ADAM 
metallopeptidase with thrombospondin motif 7, TGFBP2: transforming growth factor binding protein 2, 
DLEU1: deleted in lymphocytic leukemia 1, NOV: nephroblastoma overexpressed, IGFBP4: insulin-like 
growth factor binding protein 4, ALOX15B: arachidonate 15-lipoxygenase type B, SVIL: supervillin, 
FOXE1: forkhead box E1, MTHFD2L: methylenetetrahydrofolate dehydrogenase 2-like, KIF20A: kinesin 
family member 20A, SLC7A6: solute carrier 7A6, IGFBP6: insulin-like growth factor binding protein 6, 
ICAM: intercellular adhesion molecule, SULF2: sulfatase 2, ST3GAL2: ST3 beta-galactoside alpha-2,3-
sialyltransferase 2, ST3GAL3: ST3 beta-galactoside alpha-2,3-sialyltransferase 3, ARS: aryl sulfatase. In 
WHCO1: MYEF2: myelin expression factor 2, TNFSF12: tumour necrosis factor superfamily 12, CXCL1: 
chemokine (C-X-C motif) ligand 1, MMP1: matrix metallopeptidase 1, SERPINA3: serpin peptidase 
inhibitor A3, GSTA4: glutathione S-transferase A4, IL1: interleukin 1, IL6: interleukin 6, LIF: leukaemia 
inhibitory factor, CXCL10: chemokine (C-X-C motif) ligand 10, ANPEP: alanyl aminopeptidase, HPGD: 
hydroxyprostaglandin dehydrogenase 15-(NAD), SPHAR: S-phase response, CRLF1: cytokine receptor-
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Figure 3.8 Significant over-representation of Cell Cycle gene ontology in response to BaP treatment 
in EPC-2 cells. Lists of differentially expressed genes in BaP-treated EPC-2 cells were entered into GOstat 
(A) and GOrilla (B). GOstat results show percentage of genes that are significantly over-represented in a 
GO term out of the entire list of genes in the same GO term. GOrilla results graphically show the most 
significant biological process GO terms from GOstat. Legend shows p-value significance of GO term. 
Adapted from GOrilla results. 
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Figure 3.9 Up-regulation of cell cycle checkpoint pathways in EPC-2 cells in response to BaP. 
Differentially expressed genes in BaP-treated compared to untreated EPC-2 cells were entered into IPA to 
determine significant canonical pathways. Most pathways show down-regulated genes, but the genes 
involved in cell cycle checkpoint pathways were mostly up-regulated. Green indicates down-regulated; red 
indicates up-regulated. Number above bar indicates number of genes within the pathway. Bar represents 
percentage of genes within pathway that are up- or down-regulated. Orange dots indicate significance of 
canonical pathway [-log(p-value)] according to secondary scale. Adapted from IPA results. 
 
 
3.2.5 Fundamental differences in gene expression between EPC-2 and WHCO1 cells 
 
The differentially expressed genes between WHCO1 and EPC-2 cells in the absence of BaP 
treatment were determined in order to assess the baseline transcriptional differences between 
normal and cancer cells (WHCO1 Un vs EPC-2 Un). The genes with the highest and lowest fold 
changes were not known to be directly involved in cancer or cancer-related pathways. Further 
analysis therefore shifted to which canonical pathways and biological processes were altered in 
untreated WHCO1 cells compared to untreated EPC-2 cells (reference cell line). 
 
Interestingly, biological functions (Fig. 3.10A) and biological processes (Fig. 3.11) both showed 
significant representation of the Cell Cycle, Cellular Growth and Proliferation, DNA Replication, 
Recombination and Repair and Mitotic Phase of the Cell Cycle. The top canonical pathways in 
WHCO1 compared to EPC-2 cells were p53 Signaling, Molecular Mechanisms of Cancer, VEGF 
Signaling and Role of BRCA1 in DNA Damage Response (Fig. 3.10B). In Figure 3.11, the 
significant GO biological processes were grouped together into four representative groups, since 


































Figure 3.10 Baseline transcriptional differences in untreated WHCO1 cells compared to untreated 
EPC-2 cells. Differentially expressed genes in the WHCO1 Un vs EPC-2 Un comparison were analyzed 
using IPA and GOstat. Significant biological functions (A) and canonical pathways (B) shown are 




















Figure  3.11 Biological processes significantly over-represented in untreated WHCO1 cells compared to untreated EPC-2 cells. Differentially expressed 
genes in the WHCO1 Un vs EPC-2 Un comparison were entered into GOrilla to visualize significant GO terms involved in biological processes. The most 
significant biological processes were grouped together into four representative groups to aid visualization. Legend indicates p-value significance of GO term. 
Taken from GOrilla results. 
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3.2.6 The role of BaP exposure in transformation: do BaP-treated EPC-2 cells have 
similar gene expression profiling to untreated WHCO1 cells? 
 
Previous publications have shown that normal cells treated with either BaP or BPDE can undergo 
transformation into cancer cells. Phase contrast photographs in Figure 2.9 showed that prolonged 
treatment of EPC-2 cells with BaP resulted in morphological changes associated with apoptosis. 
BaP-treated EPC-2 cells were compared with untreated WHCO1 cells to determine whether BaP 
treatment causes EPC-2 cells to become like cancer cells.  
 
The top biological functions analyzed by IPA were Cancer, Genetic Disorder, Cell Death, Cell 
Cycle, Cellular Growth and Proliferation, and DNA Replication, Recombination and Repair (Fig. 
3.12A). GOstat analysis showed an over-representation of cell cycle GO terms, including Mitotic 
Cell Cycle (39% of all mitotic cell cycle genes over-represented), M phase (39.9%), Cell 
Proliferation (29.7%) and Cell Cycle (31.3%). Cell cycle genes such as cell division cycle genes 
(CDC2 [CDK1], CDC66, CDC7, CDC20, CDC25C) cell division cycle-associated or –like genes 
(CDCA1, CDCA3, CDCA5, CDCA7, CDCA8, CDC45L, CDCA7L), cyclins (CCNB1, CCNB2, 
CCNA1, CCNA2, CCNE2, CCNF), cyclin-dependent kinases (CDK1, CDK2, CDK3, CDK4, 
CDKL1) and their inhibitors (CDKN2A, CDKN2D, CDKN3), were down-regulated in BaP-
treated EPC-2 cells compared to untreated WHCO1 cells. 
 
Canonical pathway analysis showed aberrant expression of pathways known to be involved in 
cancer, including p53 signaling, ERK/MAPK signaling, Wnt/-catenin signaling, Breast and 
Ovarian Cancer signaling and AhR signaling (Fig. 3.12B). Genes involved in the DNA damage 
response were up-regulated (Fig. 3.12B, Fig. 3.13). The down-regulated expression of genes 
involved in the cell cycle and up-regulation of genes involved in the repair of DNA damage 
suggests that BaP-treated EPC-2 cells do not become like WHCO1 cells because EPC-2 cells 
























































Figure 3.12 Biological functions and canonical pathways altered in BaP-treated EPC-2 cells 
compared to untreated WHCO1 cells. Differential expression gene lists of WHCO1 Un vs EPC-2 BaP were 
entered into IPA to determine significant biological functions (A) and canonical pathways (B) in this 
comparison. Significance is indicated by –log(p-value). Green indicates down-regulated; red indicates up-
regulated. Number above bar indicates number of genes within the pathway. Bar represents percentage of 
genes within pathway that are up- or down-regulated. The top canonical pathway is represented graphically 



















Figure 3.13 Up-regulation of the DNA Damage Response pathway in BaP-treated EPC-2 cells. The 
most significant canonical pathway was the role of BRCA1 in the DNA damage response. In response to 
DNA damage, such as exposure to BaP or ionizing radiation, nuclear BRCA1 (breast cancer 1) associates 
with several other molecules to allow for DNA repair (with repair genes MLH1, MSH2, MSH6, BLM, 
MRE11, CHK2, Rad51 and RFC), cell cycle arrest at cell cycle checkpoints (involving FANCD2, PLK1, 
OCT1, GADD45) and progression through the cell cycle (E2F). Red shaded genes are up-regulated; green 
shaded genes are down-regulated. Arrow indicates direction of pathway; circle indicates biological result. 











3.2.7 Similarities and differences between the transcriptional responses of EPC-2 and 
WHCO1 cells to treatment with BaP 
 
BaP-treated EPC-2 and WHCO1 datasets were compared to determine which genes were 
commonly and uniquely expressed after BaP exposure, and therefore whether EPC-2 and 
WHCO1 cells respond in the same way to BaP treatment (Fig. 3.14). There were more commonly 
down-regulated genes between WHCO1 and EPC-2 cells (45, Fig. 3.14B) than commonly up-
regulated genes (19, Fig. 3.14A). The lists of commonly up- and down-regulated genes are 



























Figure 3.14 Common genes up- or down-regulated in response to BaP exposure. Venn diagrams show 
number of genes commonly and uniquely up-regulated (A) or down-regulated (B) by BaP exposure in 
WHCO1 (left) and EPC-2 (right) cells. I: Genes uniquely expressed by BaP exposure in WHCO1 cells; II: 
Genes uniquely expressed by BaP exposure in EPC-2 cells; III: Genes commonly expressed by BaP 
exposure in both WHCO1 and EPC-2 cells. Total numbers of up- or down-regulated genes are indicated at 





















Commonly up-regulated genes of interest include EREG (epiregulin), FOSL1 (FOS-like antigen 
1) and IL10RA (interleukin 10 receptor alpha), although many of the genes up-regulated were 
hypothetical protein loci, open reading frames and cloned sequences (Appendix A). The most up-
regulated genes were ANPEP (alanyl membrane aminopeptidase, 10.05-fold) for WHCO1 and 
HS.389988 (cDNA clone, 9.02-fold) for EPC-2. 
 
Commonly down-regulated genes of interest include TGFB2 (transforming growth factor beta 2), 
SULT1C3 (sulfotransferase 1C3) and ITGB8 (integrin beta 8), while, similar to the commonly 
up-regulated genes, many of the genes were hypothetical protein loci and cDNA clones 
(Appendix A). The most down-regulated genes were HS.537735 (cDNA clone, -8.99-fold) and 
DHRS2 (-8.28-fold) for WHCO1 and KRT4 (keratin 4, -61.76-fold) and H19 (non-coding 
maternally expressed transcript, -45.94-fold) for EPC-2. Although genes in common between 
BaP-treated WHCO1 and EPC-2 cells varied widely in function, many are involved in metabolic 
pathways. 
 
IPA analysis showed that important biological functions in the transcriptional response to BaP in 
WHCO1 and EPC-2 cells were Cancer, Cell Cycle, Cell Death, Cellular Growth and 
Proliferation, and DNA Replication Recombination and Repair (Fig. 3.15A). Important canonical 
pathways were Role of BRCA1 in DNA Damage Response, Role of CHK Proteins in Cell Cycle 
Checkpoint Control, and p53 Signaling (Fig. 3.15B). The up-regulation of 40-50% of genes in 
DNA damage pathways (Role of BRCA1 in DNA damage response and Role of CHK proteins in 
























































Figure 3.15 Functions and Pathways affected in the common transcriptional response to BaP 
treatment in EPC-2 and WHCO1 cells. Biological functions (A) and canonical pathways (B) were 
generated in IPA from the list of differentially expressed genes in BaP-treated WHCO1 cells compared to 
BaP-treated EPC-2 cells. In (A) –log(p-value) indicates significance of biological function. In (B) green 
indicates down-regulated; red indicates up-regulated. Number above bar indicates number of genes within 
the pathway. Bar represents percentage of genes within pathway that are up- or down-regulated. Orange 











3.2.8 Meta-analysis: common differentially expressed genes affected by BaP treatment 
in normal and transformed cell lines 
 
The final objective was to determine whether normal and cancer cells from the oesophagus 
respond to BaP treatment in the same way as cells from other tissues. Genes differentially 
expressed in response to BaP in WHCO1 and EPC-2 cells were compared to gene lists from 
published microarray data from other BaP-treated cell lines (Table 1.2) in a meta-analysis as 
described in Methods.  
 
The genes most commonly affected in response to BaP were CYP1A1 (shared by 5 cell lines), 
CYP1B1, NQO1, TIPARP, MMP1, AKR1C2 and CTGF (Table 3.1). The expression of several 
metabolism genes suggests common mechanisms of BaP metabolism by the cells from the breast, 
oesophagus and liver. BaP-treated EPC-2 cells had more genes in common with mammary 
epithelial cells (NHMECs, 5 genes in common) than with normal cell lines derived from lung 
fibroblasts (WI38), skin keratinocytes (NHEK) or oral epithelial cells (HIOEC, Table 3.1). BaP-
treated WHCO1 cells had more genes in common with liver carcinoma cells (HepG2, 5 genes in 
common) than breast carcinoma (MCF-7), colorectal carcinoma (HCT116; Caco-2) or lung 
adenocarcinoma cells (A549, Table 3.1).  
 
The cell lines sharing the most common genes were NHMEC and WHCO1 cells, commonly 
expressing 7 genes (MMP1, CYP1A1, CYP1B1, SERPINB2, IL1B, CA9 and TIPARP, Table 
3.1). Six genes were shared by NHMEC and MCF-7 (CYP1A1, CYP1B1, AKR1C2, PPARG, 
NQO1 and TIPARP), NHMEC and HepG2 (CYP1A1, CYP1B1, SERPINB2, AKR1C2, CTGF 
and NQO1) and MCF-7 and HepG2 (CYP1A1, CYP1B1, AKR1C2, AKR1C3, OKL38 and 
NQO1, Table 3.1). These findings suggest a small common transcriptional response to BaP 
exposure between cell lines derived from the breast, oesophagus and liver. However, since gene 
expression was more divergent than common between the normal and transformed cell lines, the 











Table 3.1 Meta-analysis: Common genes with altered expression in response to BaP exposure 
: up-regulation; : down-regulation; MMP1: matrix metalloprotease 1; CYP1A1: cytochrome P450 1A1; CYP1B1: cytochrome P450 1B1; ID1: inhibitor of DNA 
binding 1; SERPINB2: serine peptidase inhibitor B2; AKR1C2: aldo-keto reductase C2; IL1B: interleukin 1 beta; FN1: fibronectin 1; RRAD: Ras-related 
associated with diabetes; PPARG: peroxisome proliferators-activated receptor gamma; OKL38: pregnancy-induced growth inhibitor; CTGF: connective tissue 
growth factor; AKR1C3: aldo-keto reductase 1C3; S100A8: S100 calcium binding protein A8; CXCL10: chemokine (C-X-C motif) ligand 10; CA9: carbonic 
anhydrase 9; SPP1: secreted phosphoprotein 1; NQO1: NADPH quinone oxidoreductase; TIPARP: TCDD-inducible poly(ADP)-ribose polymerase  
 
       Normal                 Cancer 
 
 
Cell Line and Tissue Origin 
EPC-2 WI38 NHMEC NHEK HIOEC WHCO1 HepG2 MCF-7 HCT116 Caco-2 A549 Genes 
 Oesophagus Lung Breast Skin Mouth Oesophagus Liver Breast Colon Colon Lung 
MMP1                   
CYP1A1                  
CYP1B1                  
ID1                    
SERPINB2                    
AKR1C2                   
IL1B            
FN1            
RRAD            
PPARG            
OKL38                    
CTGF                   
AKR1C3                    
S100A8                    
CXCL10                    
CA9                    
SPP1                    
NQO1                   













Characterizing the complex transcriptional responses of normal and transformed oesophageal 




3.3.1 Microarray data analysis 
 
The method used for data analysis may influence the final differential gene expression pattern and 
interpretation of the results. Methods of data pre-processing such as filtering, background 
subtraction, truncating signal values and trimmed mean scaling lead to the exclusion of some 
signal values, and therefore some gene expression information may be lost. We omitted 
background subtraction in our analysis as it should not greatly affect the outcome (de Waard et 
al., 2008, C. Waterfall, Illumina UK, personal communication). Gene expression fold change was 
frequently exaggerated by the microarray differential expression analysis, generating more than 
2000-fold regulation of many genes (Appendix A). Since fold change was reproducible by qRT-
PCR but shown to be overestimated in some genes, fold change by microarray analysis should be 
considered an indication but not a direct measurement of gene expression. 
 
 
3.3.2 Differential gene expression in response to BaP exposure 
 
Transcriptional profiling of BaP-treated EPC-2 and WHCO1 cells showed differential expression 
of many interesting genes (objective i). The expression of many xenobiotic metabolism genes in 
WHCO1 cells in response to BaP was not unexpected. The up-regulation of several UDP-
glucuronosyltransferases (UGT1A1, UGT1A6, UGT1A10, UGT2B7) suggests that 
glucuronidation is an important BaP Phase II detoxification mechanism, which agrees with 
previous studies (Zheng et al., 2002, Miller and Ramos, 2001). In contrast, GSTA4 (WHCO1), 
GSTM1, GSTM2 (EPC-2) and SULT1C3 (WHCO1 and EPC-2) were down-regulated; 
suggesting that formation of sulfate and glutathione conjugates are not the preferred methods of 
BaP phase II detoxification. 
 
CYP1A1 and CYP1B1 were greatly up-regulated in WHCO1 cells in response to BaP but were 
not differentially changed in EPC-2 cells. These findings agree with the known role of CYP1A1 
and CYP1B1 in Phase I metabolism of BaP, and in our results, the up-regulation of these genes 











frequently induced in BaP microarray analyses in other cell lines (NHMEC, Gwinn et al., 2005, 
Keshava et al., 2005, John et al., 2008, HepG2, Staal et al., 2006, van Delft et al., 2004, Hockley 
et al., 2006, 2007, 2009, MCF-7, Mahadevan et al., 2005, Hockley et al., 2006, 2007, Kemp et 
al., 2006, Caco-2, de Waard et al., 2008). The absence of CYP1A1 and CYP1B1 induction in 
EPC-2 microarray data agrees with the results in Figure 2.3 (CYP1 induction in twelve cell lines). 
The absence of xenobiotic metabolism pathways in the EPC-2 microarray data suggests that 
metabolic activation and detoxification of BaP are not the major response in BaP-treated EPC-2 
cells. CYP1A2 was not differentially expressed in either WHCO1 or EPC-2 cells, thereby 
confirming its insignificant role in BaP metabolism. 
 
In EPC-2 cells, the major response to BaP treatment was the expression of genes involved in cell 
cycle regulation and up-regulation of the DNA damage response (Fig. 3.8-9). Negative regulation 
of the cell cycle was evident as BaP-treated EPC-2 cells had decreased cellular proliferation 
compared to untreated cells (Fig. 2.8). Reduced cellular proliferation is believed to be a result of 
cell cycle arrest to allow repair of BPDE-damaged DNA. One of the consequences of the DNA 
damage response is the induction of programmed cell death or apoptosis in cells where damaged 
DNA cannot be repaired. This would protect cells against transformation from genotoxicity and 
mutations. In BaP-treated EPC-2 cells, however, no increase in pro-apoptotic pathways or up-
regulated expression of apoptotic genes was observed. In contrast, caspase 14 (apoptosis-related 
cysteine peptidase) was down-regulated 16-fold in BaP-treated EPC-2 cells. However, changes in 
EPC-2 cell morphology during prolonged BaP treatment showed an increase in the number of 
apoptotic cells (Fig. 2.9), suggesting that while apoptosis was not induced after 48h BaP 
treatment in the microarray, apoptosis was induced in some cells only after successive treatments 
with BaP. 
  
The inflammatory response was significantly altered in response to BaP treatment in WHCO1 
cells. Both pro-inflammatory genes and xenobiotic metabolism genes were up-regulated. The 
increase in the inflammatory response is probably due to the increased production of ROS during 
phase I metabolism of BaP, which increases oxidative stress signaling. Oxidative stress and 
chronic inflammation are known to be associated with cancer, and oxidative stress signaling in 
response to BaP has been reported in MCF-7 and HepG2 cells (Hockley et al., 2006). Our 
microarray results agree with the model that increased BaP metabolism in WHCO1 cells results 












Some alcohol metabolizing genes (ADH7, ALDH3A1, ALDH1L2, ALDH3B2) were expressed 
in response to BaP treatment in WHCO1 and EPC-2 cells. The observed induction of ALDH3A1 
is consistent with the fact that it is a target gene for the ligand-activated AhR (Androutsopoulos et 
al., 2009). The regulation of alcohol metabolizing genes by BaP may be important in mediating 
the synergistic effects of tobacco smoking and alcohol consumption on the risk of developing 
OSCC. In other words, BaP exposure during tobacco smoking may regulate expression of alcohol 
metabolizing genes that activate ethanol to the carcinogenic acetaldehyde, thereby enhancing 
DNA damage and OSCC risk. 
 
Interestingly, the AHRR is up-regulated 3.27-fold in BaP-treated WHCO1 cells, suggesting that 
AhR signaling should be negatively regulated in this response. However, AhR signaling was not 
entirely down-regulated (Fig. 3.6B), which suggests that the AHRR is not fully repressing AhR 
activity in WHCO1 cells. Future work should therefore further investigate the role of the AHRR 
protein and its function. 
 
Lamin B1 (LMNB1) was up-regulated 2.68-fold in BaP-treated EPC-2 cells but was not affected 
in WHCO1 cells. This result is consistent with the increase in Lamin B1 nuclear protein levels in 
BaP-treated EPC-2 cells compared to untreated cells (Fig. 2.6) and the evidence that BPDE 
induces Lamin B1 mRNA in normal human amnion epithelial cells and foetal lung fibroblasts (Lu 
et al., 2009, Dreij et al., 2010). These findings further support the need for alternative nuclear 
protein loading controls. 
 
Integrin beta 7 (ITGB7), a target gene for the ligand-activated AhR (Monteiro et al., 2008), was 
up-regulated in WHCO1 cells but down-regulated in EPC-2 cells in response to BaP treatment 
(Fig. 3.4). Integrins are cellular adhesion molecules that are involved in cell fate control between 
growth, differentiation and apoptosis. Up-regulation of ITGB7 in response to BaP was observed 
in macrophages (Sparfel et al., 2010). However, down-regulation of other integrins (ITGB6, 
ITGB8, ITGAV) was observed in BaP-treated WHCO1 and/or EPC-2 cells. In epidermal 
keratinocytes, down-regulation of integrins is associated with differentiation (Tennenbaum et al., 
1996), suggesting that differentiation may be part of the cellular response to BaP in EPC-2 cells. 
 
Several histone genes (HIST1H2BH, HIST1H2BC, HIST1H2BF, HIST1H2AM, HIST1H3G) 
were differentially regulated in BaP-treated WHCO1 and EPC-2 cells. Down-regulation of other 











nucleosome and chromatin assembly by BaP was observed in MCF-7 and HepG2 cells (Hockley 
et al., 2006). Histone gene suppression is believed to be important for cell cycle arrest following 
DNA damage to allow for DNA repair (Hockley et al., 2007). Consistent with this, the DNA 
damage response and DNA repair pathways were significantly altered in response to BaP in 
WHCO1 and EPC-2 cells. 
 
The role of BaP in carcinogenesis is not limited to changes in gene expression profiles and 
cellular responses to AhR activation. BaP has also been shown to disrupt DNA methylation 
(Sadikovic and Rodenhiser, 2006) and recruit DNA methyltransferases to silence target genes, 
such as RAR2 (Ye and Xu, 2010). In addition, natural DNA methylation inhibitors like tea 
polyphenols and soy isoflavones are able to reverse BaP-associated gene methylation (Manna et 
al., 2009, Fang et al., 2003) and DNA damage (Baumeister et al., 2009). Genes known to be 
silenced by methylation in OSCC (Ishii et al., 2007, Roth et al., 2006) were also down-regulated 
in BaP-treated WHCO1 and EPC-2 cells, including MGMT (O-6 methylguanine 
methyltransferase), SFRP1 (secreted frizzled-related protein), DAPK3 (death-associated protein 
kinase 3) and p16INK4a/p14ARF, although COX2 (cyclooxygenase 2), CLDN3 (claudin 3) and 
MT1G (metallothionein 1G) were up-regulated. These findings implicate a role for BaP in gene 
silencing by methylation in WHCO1 and EPC-2 cells, which opens up a new avenue for future 
work. 
 
IPA analysis showed that p53 signaling was significantly affected with around 35% of total p53 
signaling genes affected in three of the comparisons: BaP-treated normal cells compared to 
cancer cells, the common transcriptional response to BaP and the baseline differences in gene 
expression between normal and cancer cells (WHCO1 Un vs EPC-2 BaP, WHCO1 BaP vs EPC-2 
BaP and WHCO1 Un vs EPC-2 Un). Since cell cycle regulatory and DNA repair pathways were 
frequently altered in response to BaP and in untreated cancer cells, the role and function of p53 in 
the cellular response to BaP should be explored further. 
 
Transcriptional profiling of untreated WHCO1 compared to untreated EPC-2 cells allowed for the 
examination of fundamental differences in gene expression in the absence of the BaP response 
(objective ii). Cell cycle regulatory genes and cell cycle processes were up-regulated in untreated 
WHCO1 compared to EPC-2 cells (Fig. 3.10-11), suggesting increased proliferation occurs in the 
absence of BaP. This agrees with our results showing increased cellular proliferation in WHCO1 











processes in untreated WHCO1 compared to untreated EPC-2 cells is also in agreement with the 
established fact that enhanced proliferative potential is a hallmark of cancer (Hanahan and 


















Figure 3.16 Common genes shared between untreated EPC-2 and WHCO1 cells and known OSCC 
biomarkers. Genes known to be over-expressed or down-regulated in OSCC (Kashyap et al., 2009, 2010) 
were found to be expressed in WHCO1 and EPC-2 cells in the absence of BaP. Over-expressed genes: 
SPP1: secreted phosphoprotein 1, MMP11: matrix metalloproteinase 11 (stromelysin 3), TACSTD1: 
tumour associated calcium signal inducer 1, HAS3: hyaluronic acid synthase 3, EMP1: epithelial 
membrane protein 1, MMP13: matrix metalloproteinase 13 (collagenase), MMP1: matrix metalloproteinase 
1, COL5A1: collagen type 5 alpha 1, MMP12: matrix metalloproteinase 12, TIMP2: TIMP 
metallopeptidase inhibitor 2, ANXA9: annexin A9, ADAMTSL4: ADAMTS-like 4. Down-regulated 
genes: PLAU: urokinase plasminogen activator, SPARC: secreted protein acidic cysteine rich osteonectin, 
IL1: interleukin 1 beta, PDPN: podoplanin, MMP9: matrix metalloproteinase 9 (gelatinase B), CTHRC1: 
collagen triple helix repeat containing 1, POSTN: periostin, TNFRSF12A: tumour necrosis factor receptor 
superfamily 12A, CDH11: cadherin 11, PTHLH: parathyroid hormone-like hormone, STC2: stanniocalcin 
2, BAMBI: BMP and activin membrane-bound inhibitor homolog, TNC: tenascin C, THBS1: 
thrombospondin 1, CTSK: cathepsin K, BGN: biglycan, LOX: lysyl oxidase, MMP10: matrix 
metalloproteinase 10 (stromelysin 2), FN1: fibronectin 1, CTGF: connective tissue growth factor, 
SERPINB2: serpin peptidase inhibitor B2, SERPINB13: serpin peptidase inhibitor B13, LCN2: lipocalin 2, 
CTSD: cathepsin D, IGFBP7: insulin-like growth factor binding protein 7, PLEC1: plectin 1 intermediate 
filament binding protein. 
 
 
Kashyap and colleagues have recently shown that several genes are over-expressed or down-
regulated in patients with OSCC (Kashyap et al., 2009, 2010). These OSCC genes or biomarkers 
were compared to the genes expressed in untreated EPC-2 and WHCO1 cells. In the absence of 
BaP, untreated EPC-2 and WHCO1 cells share the expression of 26 and 13 genes, respectively, 
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the matrix metalloproteinases (MMP). MMPs play an important role in the breakdown of 
extracellular matrix (ECM) proteins during primary steps in the invasion, migration and tissue 
remodeling associated with cancer progression. EPC-2 and WHCO1 cells express MMP1, 9, 10, 
11, 12 and 13 (Fig. 3.16), suggesting that these cells are more active in ECM degradation. 
 
When examining the role of BaP in carcinogenesis in normal cells, we hypothesized that BaP 
treatment causes normal cells to become like cancer cells (objective iii). There was significant 
aberrant regulation of known cancer-related pathways (AhR, p53, ERK/MAPK and Wnt/-
catenin) in BaP-treated EPC-2 cells compared to untreated WHCO1 cells (Fig. 3.12). 
ERK/MAPK and Wnt/-catenin pathways are signal transduction cascades that are important in 
cell growth, differentiation and proliferation, and therefore deregulated gene expression in these 
pathways may play a role in carcinogenesis. Together with the dynamic expression of genes 
known to be over-expressed in OSCC, these results suggest that BaP treatment has the potential 
to lead to cancer initiation in EPC-2 cells. However, EPC-2 cells protect against genotoxicity and 
possible oncogenic mutations by regulating the DNA damage r sponse and conducting cell cycle 
checkpoints (Fig. 3.12). The balance between BaP-induced transformation and prevention of 
carcinogenesis is therefore mediated by the interplay between pro-cancer pathways and anti-
cancer cell cycle regulation and DNA repair. However, no studies to date have shown that a 
single treatment with BaP can induce cellular transformation. Therefore our results suggest that 
while events preceding cancer initiation occur in BaP-treated EPC-2 cells, complete 
carcinogenesis does not occur. It is likely that consecutive BaP treatments, which more closely 
mimic chronic tobacco smoking although do not take into account the presence of other tobacco 
smoke carcinogens, will be more effective at initiating cancer.  
 
 
3.3.3 Comparison to other BaP microarrays 
 
Published BaP microarray data have shown that the transcriptional responses to BaP are complex 
and dependent on various factors such as length of BaP treatment, BaP concentration and cell 
type (Hockley et al., 2006, 2007, objective v). The treatment conditions used in our experiment 
were 10M BaP treatment for 48h, but conditions in other BaP microarrays varied from 6h-72h 
and even 6 months treatment with BaP of concentrations varying from 0.25M to 9mM. 
However, while specific gene expression profiles may vary in a time- and concentration-












Most published microarray studies have shown that the transcriptional response to BaP involved 
xenobiotic metabolism, cell cycle regulation, DNA damage repair, apoptosis, cell proliferation, 
oxidative stress signaling and nucleosome assembly (Hockley et al., 2006, 2007, 2008, 2009, de 
Waard et al., 2008, Perez et al., 2008, Keshava et al., 2005, van Delft et al., 2004, Mahadevan et 
al., 2005, Sohn et al., 2008, Gwinn et al., 2005, John et al., 2008). Our results are consistent with 
these findings, except there is no obvious effect on apoptotic signaling processes in our cell lines. 
The down-regulation of apoptosis-related genes and the absence of apoptosis in response to BaP 
has been reported in HepG2 and WI38 cells (Staal et al., 2006, Sohn et al., 2008), and apoptotic 
signaling genes were not up-regulated in the absence of p53 in HCT116 cells (Hockley et al., 
2008). Collectively, these results suggest that the regulation of apoptosis is complex and depends 
on other factors such as p53 status and cell type. 
 
Common genes were found to be differentially expressed by BaP in multiple cell types by meta-
analysis of our results and other BaP microarrays. Xenobiotic metabolism genes (CYP1A1, 
CYP1B1, NQO1, AKR1C2, AKR1C3) were the most commonly shared, followed by genes 
involved in cell cycle or growth regulation (IL1, RRAD, PPARG, OKL38, CTGF), adhesion 
and invasion (FN1, SPP1, MMP1, CA9), inflammation (FN1, S100A8, CXCL10), DNA damage-
induced repair (TIPARP) and apoptosis (S100A8, SERPINB2). Aldo-keto reductases (AKRs) 
represent another mechanism of BaP metabolic activation and a source of oxidative stress. BaP-
diols are converted by AKRs to BPQ ortho-quinones which greatly amplify ROS while 
participating in useless redox cycles (Burczynski and Penning, 2000). BPQs also form DNA 
adducts and cause oxidative DNA damage (Burczynski and Penning, 2000). The elevated 
expression of AKRs suggests that an increase in the metabolic activation of BaP to BPQ and 
generation of ROS is a common pathway activated during BaP exposure. S100A8 (S100 calcium 
binding protein A8) is a pro-inflammatory gene that together with its dimerization partner, 
S100A9, is down-regulated in OSCC (Zhang et al., 2004). S100A9 is a p53 target and S100A8 
and 9 have been shown to play a role in inhibition of cell growth and induction of apoptosis (Li et 
al., 2009). TIPARP (TCDD-inducible poly(ADP-ribose) polymerase) is a member of the PARP 
family of enzymes that are induced in response to DNA strand breakage and participate in DNA 
repair pathways (Ma et al., 2001). The expression of TIPARP is therefore a cellular defense 
mechanism against DNA damage. The common expression of these genes (Table 3.1) suggests 
that, despite different treatment conditions and cell types, there are universal transcriptional 












Consistent with one of the major responses to BaP in multiple cell types, the common 
transcriptional response to BaP in WHCO1 and EPC-2 cells was an increase in the DNA damage 
response and DNA repair pathways (objective iv). This suggests that, regardless of cell type or 
CYP1 induction capacity, exposure to BaP results in increased levels of BPDE and BPQ that 
effectively bind and damage DNA. 
 
The transcriptional response to BaP has both similar and distinguishable gene expression patterns 
to other PAHs. This may reflect their different properties and mechanisms of action. BaP is 
readily metabolized and exhibits genotoxic effects due to DNA binding (de Waard et al., 2008). 
Benzo[e]pyrene (BeP), the non-carcinogenic isomer of BaP, allows for determination of toxic 
compared to genotoxic effects (Hockley et al., 2006). TCDD, which is not readily biodegradable, 
activates the AhR but does not bind DNA (de Waard et al., 2008, Hockley et al., 2007). BPDE, 
the carcinogenic metabolite of BaP, causes DNA damage but does not activate the AhR (Hockley 
et al., 2007). Despite mediating different gene expression profiles, these PAHs also share 
overlapping gene expression patterns that will be important when considering the combined role 





Transcriptional profiling of BaP-treated EPC-2 and WHCO1 cells has shown that the response to 
BaP exposure is complex and, despite a small common response, is generally divergent between 
normal and transformed oesophageal epithelial cells.  
 
Normal cells (EPC-2) differentially express cell cycle regulation genes and up-regulate DNA 
damage response pathways in response to BaP (Fig. 3.17). Cell proliferation is slowed, most 
likely to allow for repair of BPDE-damaged DNA. EPC-2 cells therefore try to protect themselves 
against BaP-induced genomic instability and transformation. While expression of apoptotic genes 
and pathways was not evident after 48h BaP treatment, apoptotic cells were prevalent after 
prolonged exposure to BaP, suggesting that a single treatment is not sufficient to induce apoptosis 
in these cells. 
 
EPC-2 cells treated with BaP become somewhat like cancer cells due to their aberrant regulation 
of cancer-related signaling pathways and expression of genes known to be over-expressed in 











cycle checkpoints and DNA damage repair. This suggests that BaP has the potential to initiate 
transformation of EPC-2 cells, but since BPDE-damaged DNA is repaired, a single treatment 
does not initiate transformation. 
 
Cancer cells (WHCO1) increase expression of genes involved in xenobiotic metabolism and the 
oxidative stress response (Fig. 3.17). The increased expression of xenobiotic metabolism genes 
allows for the increased production of ROS and other DNA damaging metabolites during BaP 
metabolism, which enhance oxidative stress signaling. Sustained AhR signaling may lead to 
cancer maintenance or progression. 
 
The common transcriptional response of WHCO1 and EPC-2 cells to BaP treatment involves the 
DNA damage response and DNA repair pathways. This suggests that the DNA damage caused by 
the carcinogenic metabolite of BaP, BPDE, is significant. 
 
Genes involved in xenobiotic metabolism, cell cycle regulation, adhesion, invasion, 
inflammation, DNA repair and apoptosis are commonly expressed in response to BaP in multiple 
cell lines, from normal breast and breast carcinoma, hepatocarcinoma, normal and transformed 
oesophageal epithelium, colon carcinoma, oral epithelium, normal lung and lung 
adenocarcinoma, and epidermal keratinocytes. 
 
Our results agree with the major conclusions drawn from microarrays in other cell lines treated 
with BaP. However, transcriptional profiling does not take into account the role of gene products 
in the cellular response to BaP. It is therefore important to look at the proteomic response to BaP 









































Figure 3.17 Summary of the transcriptional response to BaP in WHCO1 and EPC-2 cells. BaP 
treatment results in increased expression of genes involved in xenobiotic metabolism, AhR signaling and 
the inflammatory/oxidative stress response in WHCO1 cells and cell cycle regulation and the DNA damage 
response in EPC-2 cells. In the absence of BaP, WHCO1 cells have enhanced cell proliferation and mitosis 
compared to EPC-2 cells. The common transcriptional response to BaP treatment in WHCO1 and EPC-2 
cells is the DNA damage response and DNA repair pathways. Treatment with BaP causes EPC-2 cells to 
differentially express genes involved in the DNA damage response, cell cycle regulation and cancer-related 










Xenobiotic metabolism, AhR 
signaling, Inflammatory response
























n DNA damage response, Cell cycle regulation, 














This study investigated the cellular and transcriptional responses to BaP in a normal oesophageal 
epithelial cell line (EPC-2) and an OSCC cell line (WHCO1) in order to characterize and gain 
insight into the mechanisms of carcinogenesis of BaP and its role in tobacco smoking-associated 
OSCC.  
 
BaP is metabolically activated to its carcinogenic metabolite, BPDE, by the Phase I XMEs, 
CYP1A1 and CYP1B1. CYP1 transcription is activated by the AhR-ARNT transcription factor 
dimer when BaP binds the AhR. The project’s first objective was to determine the effect of BaP 
on the expression of XMEs and the AhR in WHCO1 and EPC-2 cells. The results showed that 
WHCO1 cells were more efficient at CYP1 induction and subsequent BaP bioactivation than 
EPC-2 cells. CYP1A1 and CYP1B1 activities were sustained at higher levels after the removal of 
BaP in WHCO1 than EPC-2 cells. AhR and ARNT entered and exited the nucleus more rapidly 
after BaP treatment and withdrawal, respectively, in EPC-2 than WHCO1 cells. CYP1A1 and 
CYP1B1 induction in the panel of South African WHCO cell lines were more efficient at BaP 
activation than the Japanese KYSE cell lines.  
 
The project’s second objective was to investigate the effects of BaP on cellular proliferation and 
morphology in WHCO1 and EPC-2 cells. Treatment with BaP had no effect on WHCO1 cell 
proliferation but severely reduced EPC-2 cell growth. WHCO1 cells were therefore more 
resistant to BaP-induced reduction in cell growth than EPC-2 cells. Reduction in EPC-2 growth 
was linked to an increase in apoptotic cells following prolonged BaP treatment.  
 
The project’s third objective was to explore global gene expression profiles in response to BaP in 
WHCO1 and EPC-2 cells. Within this investigation, the five sub-objectives were to determine (i) 
which genes and pathways were affected by BaP in WHCO1 and EPC-2 cells, (ii) differences in 
gene expression profiles in the absence of BaP, (iii) whether BaP-treated EPC-2 cells have a 
similar gene expression profile to untreated WHCO1 cells, (iv) whether there was a common 
transcriptional response to BaP in both cell lines, and (v) which genes were expressed in common 
with other BaP-treated cell lines from published microarrays. Transcriptional profiling showed 
differential gene expression responses to BaP. WHCO1 cells showed increased expression of 
xenobiotic metabolism and inflammatory genes, while EPC-2 cells showed increased expression 











fundamental differences in gene expression included cell cycle and proliferation genes (sub-
objective ii). BaP-treated EPC-2 cells have the potential to become like WHCO1 cells owing to 
their expression of genes known to be over-expressed in OSCC, but cells are protected against 
transformation by up-regulation of DNA damage repair pathways (sub-objective iii). The 
common transcriptional response to BaP in WHCO1 and EPC-2 cells was DNA damage repair 
(sub-objective iv), while common gene expression induced by BaP but independent of cell type, 
length of treatment or BaP concentration included genes involved in xenobiotic metabolism, cell 
cycle regulation, inflammation, adhesion, invasion and apoptosis (sub-objective v). 
 
From these results we hypothesize that sustained CYP1 induction in WHCO1 cells increases BaP 
metabolic activation and subsequent production of ROS, resulting in oxidative stress signaling 
and the expression of inflammatory genes. Sustained nuclear AhR signaling may contribute to 
cancer maintenance or progression in WHCO1 cells. The differences in CYP1 induction capacity 
between the Japanese and South African cell lines may contribute to inter-population differences 
in susceptibility to BaP-associated OSCC. In EPC-2 cells, lower CYP1 and Phase II XME 
induction capacity may result in less efficient BaP detoxification and subsequent accumulation of 
DNA-damaging metabolites, such as BPDE and BPQ, which cause reduced cell proliferation to 
allow for DNA damage repair.  
 
This work examined the transcriptional response to BaP in oesophageal cells and compared 
global gene expression in normal and transformed oesophageal epithelial cells to other cell lines 
from published microarray data. This work also demonstrates how AhR/ARNT nuclear 
translocation and prolonged duration in the nucleus (shown by immunofluorescence) corresponds 
to increased AhR signaling (shown by microarray analysis) in WHCO1 cells compared to EPC-2 
cells. Sustained AhR signaling may play an important role in BaP-associated OSCC. Gene 
expression profiling demonstrated that a major response to BaP exposure was up-regulation of 
DNA repair genes, indicating that BaP is metabolically activated to its DNA-damaging 
carcinogenic metabolites more rapidly than it is detoxified. 
 
This research provides an indication of the role of BaP-associated gene expression profiles in the 
initiation and maintenance of OSCC, and can contribute to further research characterizing the role 
of whole tobacco smoke in oesophageal carcinogenesis. Transcriptional profiling also aids the 
identification of new molecular targets (such as AhR signaling and the oxidative stress response) 

















All chemicals were analytical grade, purchased from Merck (Darmstadt, Germany) while all other 
reagents were purchased from the specified manufacturers. BaP powder and DMSO were 
purchased from Sigma-Aldrich (Steinholm, Germany). Primary antibodies against CYP1A1, 
CYP1A2, CYP1B1, AhR, ARNT, Lamin B1 and -tubulin, were obtained from Santa Cruz 
Biotechnology (La Jolla, CA, USA), secondary antibodies (goat anti-rabbit IgG-HRP conjugate 
and goat anti-mouse IgG-HRP conjugate) from Bio-Rad (Hercules, CA, USA) and fluorescent 
secondary antibodies (goat anti-mouse IgG fluorescein conjugate and goat anti-rabbit IgG Texas 
Red conjugate) from Calbiochem (San Diego, CA, USA). Other reagents used are described in 
Appendix C. 
 
5.2 Cell Culture and Benzo[a]pyrene Treatment  
 
The oesophageal squamous cell carcinoma cell lines, WHCO1, WHCO3, WHCO5 and WHCO6, 
derived from surgical biopsies from South African OSCC patients were obtained from Prof. 
Thornley, University of the Witwatersrand, South Africa (Veale and Thornley, 1984); while the 
KYSE series of cell lines, KYSE 30, KYSE 70, KYSE 150, KYSE 180, KYSE 410, KYSE 450 
and KYSE 520, were obtained from Prof. Yutaka Shimada, Kyoto University, Japan (Shimada et 
al., 1992). The WHCO and KYSE series of cell lines were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% foetal calf serum (FCS), 100U/ml penicillin and 100g/ml 
streptomycin, in a humidified atmosphere of 5% CO2 at 37°C. The telomerase-immortalized 
normal oesophageal epithelial cell line, EPC-2, was obtained from Harada et al., (2003) and 
cultured in Keratinocyte Serum Free Medium (KSFM, Gibco, Invitrogen, Carlsbad, CA, USA) 
containing 100U/ml penicillin and 100g/ml streptomycin and supplemented with 50g/ml 
bovine pituitary extract (BPE, Invitrogen, Carlsbad, CA, USA) and 1ng/ml epidermal growth 
factor (EGF, Invitrogen, Carlsbad, CA, USA). 
  
Cells were trypsinized using Trypsin-EDTA, neutralized (using DMEM for WHCO and KYSE 
cell lines and Sodium Trypsin Inhibitor for the EPC-2 cell line) and pelleted by centrifugation at 
1000 x g for 5 min at 4°C. Cells were seeded at 3 x 105 cells per 100mm dish. Twenty-four hours 











of BaP dissolved in DMSO (of final concentration 0.1%) to the medium, while untreated cells 
were treated with 0.1% DMSO and grown for a further 24 hours. The time points investigated are 
indicated in the relevant figure legends. 
 
For cell growth assays, cells were seeded at 1-2 x 104 cells/well in 12-well plates and incubated 
for 24h. Cells were treated with either 0.1% DMSO (Un) or 10M BaP (BaP) in medium in 
triplicate wells and incubated for 5 days. At days 1, 3, 4 and 5, cells were trypsinized, neutralized, 
stained with 0.4% trypan blue and counted using the Countess Automated Cell Counter 
(Invitrogen, Carlsbad, CA, USA).  
 
The effects of long-term BaP exposure on cell morphology were examined by phase contrast 
microscopy at 100x and 40x magnification were taken before and after each BaP treatment using 
an Olympus SC30 camera calibrated for our Olympus CKX41 microscope (Center Valley, PA, 
USA), and were compared to phase contrast images of untreated EPC-2 cells and untreated 
WHCO1 cells. 
 
5.3 Genomic DNA Isolation and Quantification 
 
Genomic DNA was extracted from cultured cells using the method of Strauss (1998). Cells were 
harvested by trypsinisation and pelleted by centrifugation at 1000 x g for 5 min at 4°C. Cells were 
washed twice with 5ml ice-cold PBS pH 7.4 and centrifuged for 5 min at 500 x g. The cells were 
resuspended in 5ml digestion buffer (100mM NaCl, 10mM Tris-HCl pH 8, 25mM EDTA, 0.5% 
SDS, 0.1mg/ml proteinase K) and incubated overnight at 50°C. An equal volume of 
phenol:chloroform:isoamylalcohol (25:24:1) was added. The sample was mixed by vortexing, 
centrifuged for 10 min at 1700 x g and the top aqueous layer transferred to a new tube. This 
process was repeated until no precipitate accumulated at the interphase. The aqueous phase was 
transferred to a clean microfuge tube and the DNA precipitated by the addition of one half 
volume of 7.5M ammonium acetate and two volumes of cold 100% ethanol. DNA was pelleted 
by centrifugation at 1700 x g for 2 min. The supernatant was discarded, the DNA pellet was 
washed twice with 70% ethanol, air-dried and resuspended in 100µl TE buffer (10mM Tris-HCl, 
1mM EDTA pH 7.5). 
 
DNA was quantified by absorbance at 260 and 280nm using a Nanodrop 2000 spectrophotometer 











260/280 ratio of between 1.8 and 2. DNA integrity was determined by agarose gel 
electrophoresis. 
 
5.4  Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-
RFLP) Analysis 
 
Primers used to genotype the CYP1 genes in the twelve cell lines were adapted from Landi et al. 
(2005) and Dandara et al. (2004). Each PCR reaction contained 100ng genomic DNA, 1 x PCR 
buffer (Green GoTaq Flexi Buffer, Promega, Madison, WI, USA), 2mM MgCl2 (for CYP1A1) or 
1.2mM MgCl2 (for CYP1B1), 0.2mM dNTP mix (Promega, Madison, WI, USA), 1pmol forward 
primer, 1pmol reverse primer and 1U Kapa Taq DNA polymerase (Kapa Biosystems, Woburn, 
MA, USA) in a final reaction volume of 50l. PCR reactions were carried out according to the 
conditions described in Table 5.1. The primer pairs used are described in Table 5.2. Reactions 
were carried out using an Applied Biosystems Veriti 96 well thermal cycler (Carlsbad, CA, 
USA). 
 
Table 5.1 PCR cycling conditions for amplification of CYP1 genes 
 
35 cycles Gene Initial 
denaturation Denaturation Annealing Extension 
Final extension 







95°C 30 sec 60°C 30 sec 
 







Table 5.2 Primer pairs used for PCR amplification of CYP1 genes 
 
 
To check for the specificity of the PCR products, 10l of each PCR product were electrophoresed 
on a 1% agarose gel containing 0.5g/l ethidium bromide in 1 x TBE buffer at 60V for 40 min. 
Bands were visualised using a UV transilluminator (UVP BioSpectrumTM 500 Imaging System, 
Upland, CA, USA) and VisionWorks LS Image Acquisition and Analysis Software (Version 6.8). 
 
After PCR amplification of the desired product, 10µl of PCR product was digested overnight at 
37°C with the appropriate restriction endonuclease: 5 units of BsrD I (Fermentas, Hanover, MD, 
USA) for CYP1A1 and 5 units of Eco57 I (Fermentas, Hanover, MD, USA) for CYP1B1, in 1 x 
Gene Forward Primer Reverse Primer 
CYP1A1 5’-CTG TCT CCC TCT GGT 
TAC AGG AAG C-3’ 
5’-TTC CAC CCG TTG CAG CAG 
GAT AGC C-3’ 
CYP1B1 5’-TAT GAA GCC ATG CGC 
TTC TC-3’ 












Buffer (specific for each restriction enzyme, Fermentas, Hanover, MD, USA) in a final reaction 
volume of 20l. 10µl of undigested PCR product and 10µl of digested PCR product were loaded 
onto 2% agarose gels containing 0.5µg/µl ethidium bromide and electrophoresed at 60V for 80 
min. The bands were visualised under UV light and CYP1 genotypes for each cell line were 
determined by restriction enzyme fragments generated according to Table 5.3 below. 
 
Table 5.3 CYP1 polymorphic sites, alleles and restriction fragments used for PCR-RFLP 


















CYP1A1 4889 A G 204 G A 149, 55 
CYP1B1 4326 C G 270 C G 165, 105 
* relative to transcription start site 
 
 
5.5  RNA Isolation and Quantification 
 
Cells were washed twice with ice cold 1 x PBS, after which 1ml of the TRIzol lysis reagent 
(Invitrogen, Carlsbad, CA, USA) was added to each dish. Cells were aspirated and transferred to 
an eppendorf tube. After 5 min at room temperature, 200l chloroform was added and each 
sample was mixed vigorously. After 3 min at room temperature, samples were centrifuged at 
12000 x g for 15 min at 4°C. The top aqueous layer was transferred to a new tube and an equal 
volume of isopropanol was added. After 10 min at room temperature, samples were centrifuged at 
12000 x g for 10 min at 4°C and the supernatant was discarded. Pellets were washed twice by the 
addition of 500l 75% ethanol, vortexing and centrifugation at 7500 x g for 5 min at 4°C. 
Samples were left to dry at room temperature, dissolved in 25l DEPC-treated water and stored at 
-80°C. The absorbance of the samples was measured at 260nm and 280nm using a Nanodrop 
2000 Spectrophotometer (Thermo Scientific, Waltham, MA, USA). RNA purity was determined 
by a 260/280 ratio of greater than 2 and the RNA integrity was determined by running RNA 
samples on a 1.5% agarose gel containing 2% formaldehyde in MOPS buffer (0.2M MOPS, 
0.05M Na Acetate, 0.01M EDTA). Intact RNA was monitored by a 28S:18S ratio of 2:1. 
 
5.6  Quantitative Real-Time PCR (qRT-PCR) 
 














5.6.1 Reverse Transcription of mRNA 
 
Five micrograms of RNA was mixed with 1µl oligo dT 20 (Promega, Madison, WI, USA), 10mM 
dNTP mix (Promega, Madison, WI, USA) and DEPC-treated water to a final volume of 13µl. 
Samples were briefly centrifuged, heated at 65°C for 5 min, left on ice for 2 min and then briefly 
centrifuged again. To each was added 4µl of 5 x First Strand Buffer (Invitrogen, Carlsbad, CA, 
USA), 1µl 0.1M DTT, 1µl RNasin RNase inhibitor (Promega, Madison, WI, USA) and 1µl 
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Samples were mixed, 
incubated at 50°C for 60 min, followed by enzyme inactivation by heating at 70°C for 15 min. 
30µl DEPC-treated water was mixed into each sample and stored at -20°C. 
 
5.6.2  qRT-PCR 
 
qRT-PCR for CYP1A1, CYP1B1, AhR, ARNT and the house-keeping gene GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) was performed using 200ng cDNA, 1µl forward 
primer, 1µl reverse primer, 12.5µl KAPA SYBR FAST qPCR master mix (Kapa Biosystems, 
Woburn, MA, USA) and DEPC-treated water to a final volume of 25µl. For CYP1A2, qRT-PCR 
was carried out using 300ng cDNA was mixed with 1µl forward primer, 1µl reverse primer (both 
primers final concentration 10M), 12.5µl KAPA SYBR FAST qPCR master mix, 2.5µl DMSO 
and DEPC-treated water to a final volume of 25µl.  
 
qRT-PCR was carried out according to the PCR cycling conditions described in Table 5.4 below, 
using a Roche LightCycler 480 II (Roche, Mannheim, Germany), with 45 cycles of denaturation, 
annealing and extension for CYP1A1, CYP1A2, CYP1B1 and GAPDH, and 40 cycles for AhR 
and ARNT. Both C(t) values and melting curve analysis were calculated using the LightCycler 
480 software (Version 1.5.0.39). Duplicate samples were analysed at each time point. The 
primers used for qRT-PCR are listed in Table 5.5. The data were analysed using the comparative 
critical threshold [C(t)] method where fold change was calculated as 2-C(t). The level of gene 
expressed was normalised to GAPDH, the internal control, and was expressed as fold induction 


















Table 5.4 qRT-PCR cycling conditions for mRNA amplification of CYP1, AhR and ARNT 
genes 
 































Table 5.5 Primers used for qRT-PCR analysis of gene expression 
 
Gene Forward primer Reverse primer Product 
size (bp) 
CYP1A1 5’-GAG CTG GGT TTG 
ACA CAG TCA-3’ 
5'-  CCC ATA GCT TCT              
GGT CAT GGT -3'                            
317 
CYP1A2 5`-CTT TGA CAA GAA                            
CAG TGT CCG -3'                          
5'-AGT GTC CAG CTC                        
CTT CTG GAT-3'                            
226 
CYP1B1 5`-GAT TTG GAC AAC                            
GTA CCG GCC -3'                          
5'-ACC CAT ACA AGG                        
CAG ACG G -3'                              
174
GAPDH 5`-GCC TGC TTC ACC                            
ACC TTC -3'                                   
5'-GGC TCT CCA GAA                        
CAT CC -3'                                    
192
AhR 5’-GTC GTC TAA GGT 
GTC TGC TGGA-3’ 
5’-CGC AAA CAA AGC 
CAA CTG AGG TG-3’ 
137 
ARNT 5’-CTG TCA TCC TGA 
AGA CCA GCAG-3’ 
5’-CTG GTT CTC ATC 




5.7  Cytoplasmic, Nuclear and Total Protein Isolation and Quantification 
 
Nuclear and cytoplasmic protein fractions were isolated from from WHCO1 and EPC-2 cells 
using the ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas, Hanover, MD, 
USA). Briefly, after the removal of growth medium, cell layers were rinsed with PBS and 
collected in PBS using a cell scraper. Cells were pelleted by centrifugation at 250 x g for 5 min 
and the supernatant was discarded. Ten volumes of Cell Lysis Buffer containing protease 
inhibitors and 0.1M DTT was added to one volume of packed cells. Cells were lysed by vortexing 
for 10 min, left on ice for 10 min and vortexed again. The cytoplasmic fraction was separated 
from nuclei by centrifugation at 500 x g for 7 min at 4°C. The supernatant containing the 
cytoplasmic fraction was cleared by centrifugation at 20 000 x g for 15 min at 4°C, transferred to 
a new tube and stored at -70°C. The nuclear pellet was washed twice by the addition of 500l 
Nuclei Washing Buffer containing protease inhibitors and 0.1M DTT, vortexing, incubation on 











(150l) containing protease inhibitors and 0.1M DTT was added to the nuclei pellet and clumps 
were broken up by pipetting. One tenth the volume of Nuclei Lysis Reagent was added to the 
nuclear suspension. Samples were briefly vortexed and then shaken for 15 min at 4°C at 900rpm. 
Samples were cleared by centrifugation at 20 000 x g for 5 min at 4°C, and the supernatant 
containing the nuclear protein extract was transferred to a new tube and stored at -70°C.  
 
For the isolation of total protein, cells were washed three times with ice-cold PBS and harvested 
in 150µl RIPA buffer (150mM NaCl, 1% Triton X-100, 1% Na deoxycholate, 0.1% SDS, 10mM 
Tris pH 7.4), containing 5µl PMSF (Roche, Mannheim, Germany) and 100µl 10 x PI (Proteinase 
Inhibitor) using a cell scraper. The sample was transferred to an eppendorf tube, and sonicated 
(Model CML-4, Misonix XL-2000 Series, Newtown, CT, USA) for 20 sec to fragment the DNA 
to reduce viscosity. After incubation on ice for 30 min, samples were centrifuged at 13000 x g for 
20 min at 4°C, the supernatant containing total protein, transferred to a clean tube and stored at -
80°C. 
 
Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay kit, 
according to the manufacturer’s instructions (Thermo Scientific, Pierce, Rockford, IL, USA). 
Briefly, samples were diluted 1:10 in dH20 in a 96-well plate followed by the addition of 200µl of 
mixed A and B solutions in a ratio of 50:1 followed by incubation at 37°C for 1 hour. Absorbance 
was measured at 595nm using a Multiskan FC plate reader (Thermo Scientific) and sample 
concentrations were determined from absorbance values using BSA to construct a standard curve. 
 
5.8  Western Blotting 
 
Twenty to sixty micrograms of protein were mixed with 0.1M DTT, 5 x loading buffer (250mM 
Tris-HCl pH 6.8, 40% v/v glycerol, 5% p/v SDS, 0.005% p/v bromophenol blue, 10% -
mercaptoethanol) and RIPA buffer (150mM NaCl, 1% Triton X-100, 1% Na-deoxycholate, 0.1% 
SDS, 10mM Tris pH 7.4) in a final volume of 30µl. In order to solubilise the proteins, samples 
were heated at 99°C for 5-10 min, cooled on ice and centrifuged briefly.  
 
SDS-polyacrylamide gels were prepared (4% acrylamide/bisacrylamide, 0.125M Tris pH 6.8 
containing 1% SDS, 0.5 % APS and 0.1% TEMED for stacking gels; and 0.375M Tris pH 8.8 
containing 1% SDS, 0.5% APS and 0.05% TEMED for separating gels). 10% polyacrylamide 
gels were prepared for cytoplasmic and total protein samples, while 7% polyacrylamide gels were 











Prestained Protein Ladder, Fermentas, Hanover, MD, USA) were loaded and electrophoresed in 
running buffer (0.25M Tris, 0.250mM glycine, 0.1% SDS) at 100V for approximately 1 hour or 
until marker bands were adequately separated. Proteins were transferred onto nitrocellulose 
membranes (Amersham Hybond-ECL, GE Healthcare, Buckinghamshire, UK) in transfer buffer 
(25mM Tris, 192mM glycine, 20% methanol) at 100V for 1.5 hours. Gels were stained using 
coomassie blue staining solution (50% methanol, 10% glacial acetic acid, 0.25% coomassie blue). 
Nitrocellulose membranes were rinsed three times in TBS (50mM Tris pH7.5, 150mM NaCl) 
containing 0.1% Tween-20 (TBST) and blocked in 7% non-fat milk in TBST for 1 hour with 
shaking at room temperature to reduce non-specific binding. Primary antibodies against CYP1A1, 
CYP1A2, CYP1B1, AhR, ARNT, -tubulin and Lamin B1 were diluted 1:1000 in blocking 
solution. Membranes were incubated with the indicated primary antibody at 4°C overnight with 
shaking. Membranes were washed twice for 10 min in TBST and then twice for 10 min in 5% 
non-fat milk blocking solution. Horseradish peroxidase-conjugated secondary antibodies were 
diluted 1:1000 in 5% blocking solution. Membranes were incubated with secondary antibody for 
1 hour at room temperature with shaking. 
 
Protein bands were detected using the Lumiglo Reserve chemiluminescent substrate system 
detection kit (KPL, Gaithersburg, MD, USA) and the UVP BioSpectrum chemiluminescent 
detection system (BioSpectrumTM 500 Imaging System, Upland, CA, USA) with VisionWorks LS 
Image Acquisition and Analysis Software (Version 6.8). Membranes were stripped of primary 
and secondary antibodies by washing with 1M glycine pH 2.5 for 10 min with shaking, after 
which 1ml Tris pH 7.5 was added and membranes were washed three times for 10 min in TBST. 
Membranes were incubated with blocking solution for 1 hour before being re-probed with a 
different primary antibody.  
 
5.9  Immunofluorescence 
 
0.5 x 105 cells were seeded onto sterilized coverslips in 2ml medium and grown for 24h in 6-well 
plates. Cells were then grown in fresh medium or BaP as described in the figure legend. After 
each time point, cells were washed with ice-cold PBS, fixed with methanol at -20°C for 5 min, 
washed with ice-cold PBS and then fixed with 4% paraformaldehyde at room temperature for 5 
min. Cells were again washed with ice-cold PBS then incubated for 1h in blocking solution (1% 
BSA in PBS) at room temperature. Cells were incubated with 1:100 dilution of primary antibody 
against AhR or ARNT (Santa Cruz Biotechnology, La Jolla, CA, USA) in blocking buffer 











Red- or fluorescein-conjugated secondary antibody (Calbiochem) in blocking buffer for 45 min 
followed by incubation with 1:200 dilution of DAPI nuclear stain (4’, 6-diamidino-2-phenylinole 
dihydrochloride, Merck) for 15 min at room temperature. Coverslips were mounted onto slides 
using Mowiol reagent (Calbiochem) and analysed using a fluorescent microscope (Zeiss, 
Germany). 
 
5.10  MTT Assay 
 
Cell viability was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay (MTT, Sigma-Aldrich, Steinholm, Germany). Cells were seeded at 
2000 cells per well in 90µl complete medium with or without BaP. Cells were grown for 1, 2, 3, 4 
or 5 days. At each time point, 10µl MTT solution (5mg/ml in PBS) was added to give a final 
concentration of 0.5mg/ml. Cells were incubated a further 4 hours, after which 200µl of the 
solubilisation reagent (10% SDS in 0.01M HCl) was added. Cells were incubated at 37°C 
overnight and a Multiskan FC plate reader (Thermo Scientific) microtiter plate reader was used to 
measure the absorbance at 595nm. Average background absorbance from the medium-only 
controls was subtracted from Untreated and BaP values.  
 
5.11  Bromodeoxyuridine Incorporation Colorimetric ELISA  
 
The Cell Proliferation ELISA kit, BrdU (colorimetric) (Roche, Mannheim, Germany) was used 
according to the manufacturer’s instructions. Cells were seeded at 2000 cells per well in 96-well 
plates and grown in their respective media overnight and treated with BaP as described in the 
figure legend. For the last 6h of DMSO or BaP treatment, 10l BrdU labelling solution (final 
concentration 10M in growth medium) was added to each well and plates were re-incubated at 
37°C. Labelling media were removed and 200l FixDenat solution was added to each well, 
followed by 30 min incubation at room temperature. FixDenat solution was removed and 100l 
anti-BrdU-horseradish peroxidase (POD) working solution (1:100 dilution in antibody dilution 
solution) was added to each well, followed by 90 min incubation at room temperature. Antibody 
solution was removed and wells were washed three times with PBS (washing solution). Finally, 
100l/well substrate solution (TMB, tetramethyl-benzidine) was added and plates were incubated 
at room temperature for 20 min until colour development occured. The ELISA was stopped by 
the addition of 25l/well 1M H2SO4 and 1 min shaking. Plates were read at 450nm with a 
reference wavelength of 650nm, using the Multiskan FC plate reader (Thermo Scientific, 
Waltham, MA, USA). In addition to the DMSO control, a Blank (without cells) and a 











plate and anti-BrdU to cells, respectively. Blank values were subtracted from Untreated and BaP 
values for each time point.  
 
5.12 Statistical Analyses of Molecular Data 
 
The statistical analyses of the molecular data were done using the student’s t-test. A difference 
was considered significant if p ≤ 0.05 and highly significant if p ≤ 0.001. 
 
5.13 cDNA Microarray Analysis 
 
5.13.1  Microarray RNA Quality Control: Agilent 2100 Bioanalyzer 
 
RNA samples were quantified as described in 5.2.5 and taken on dry ice to the Department of 
Medical and Molecular Genetics at King’s College London where RNA integrity was determined 
using the Agilent 2100 BioAnalyzer (Agilent Technologies, Waldbronn, Germany) and the RNA 
6000 Nano Kit according to the manufacturer’s protocol. Briefly, 1l RNA 6000 Nano dye 
concentrate was added to 65l filtered gel matrix. The solution was vortexed, centrifuged at 13 
000 x g for 10 min at room temperature and 9l gel-dye was pipetted into three wells of the RNA 
6000 Nano chip. Gel was spread through action of the syringe plunger for 30 sec. RNA 6000 
Nano marker (5l) was added to twelve sample wells and one ladder well. Samples were heat 
denatured at 70°C for 2 min, briefly centrifuged and 1l of each sample was added to the sample 
wells, while 1l prepared ladder was added to the ladder well. The chip was vortexed for 1 min at 
2400 rpm, after which it was run in the Agilent 2100 bioanalyzer. Electrodes were 
decontaminated before set-up with 350l RNase ZAP for 1 min and 350l RNase-free water for 
10 sec. The bioanalyzer electrophoretically separates RNA fragments based on their size and 
generates an accurate RNA concentration and an image of 28S, 18S and 5S RNA bands. The 
bioanalyzer also generates the RNA integrity number (RIN), which indicates the quality of the 
RNA. An RIN  7.8 qualifies the RNA for use in a microarray, although RIN between 8.4-9.0 is 
ideal. All WHCO1 and EPC-2 RNA samples were deemed high-enough quality to continue with 
the microarray experiment. 
 
5.13.2  RNA Amplification & Biotin Labelling 
 
RNA samples were amplified and labeled with biotin using the Illumina TotalPrep RNA 
Amplification Kit (Ambion, Austin, TX, USA). Briefly, RNA was reverse transcribed to 
synthesize first strand cDNA, after which second strand cDNA was synthesized with the 











purified and yield analyzed spectrophotometrically. The protocol is as follows: RNA (500ng) 
from each sample was prepared with nuclease-free water to 11l total volume. Reverse 
transcriptase master mix (1l T7 oligo(dT) primer, 2l 10x first strand buffer, 4l dNTP mix, 1l 
RNase inhibitor and 1l ArrayScript reverse transcriptase per reaction) was added to each sample 
to bring the volume to 20l. Samples were incubated at 42°C for 2h and then briefly centrifuged 
and placed on ice. Second strand master mix (63l nuclease-free water, 10l second strand buffer, 
4l dNTP mix, 2l DNA polymerase and 1l RNase H per reaction) was added to each sample to 
bring the volume to 100l. Samples were incubated at 16°C for 2h then placed on ice. cDNA 
binding buffer (250l) was added to each sample and the mixture was passed through a cDNA 
filter cartridge (Ambion, Austin, TX, USA) by centrifugation at 10 000 x g for 1 min. The flow-
through was discarded and 500l wash buffer containing 100% ethanol was added to each 
cartridge. Samples were centrifuged at 10 000 x g for 1 min and flow-through was discarded. 
Filter cartridges were transferred to cDNA elution tubes. Preheated nuclease-free water (50-55°C, 
10l) was added to the filter cartridges; samples were incubated at room temperature for 2 min 
then centrifuged for 1.5 min at 10 000 x g. A second aliquot of 9l nuclease-free water was added 
and samples were centrifuged again, leaving eluted double-stranded cDNA in the tube. An in 
vitro transcription (IVT) master mix was prepared at room temperature (2.5l T7 10x reaction 
buffer, 2.5l T7 enzyme mix and 2.5l biotin-NTP mix) and 7.5l was mixed with each cDNA 
sample. Tubes were incubated at 37°C for 14h in a hybridization oven to maintain constant 
temperature. Reactions were stopped by the addition of 75l nuclease-free water, bringing the 
final volume to 100l. cRNA binding buffer (350l) was added to each sample, followed by 
250l 100% ethanol and mixing by pipetting. Samples were immediately placed onto cRNA filter 
cartridges (Ambion, Austin, TX, USA) and centrifuged at 10 000 x g for 1 min. Flow-through 
was discarded and 650l wash buffer was added to each cartridge. Samples were centrifuged at 
10 000 x g for 1 min and flow-through was discarded. cRNA was eluted by the addition of 100l 
preheated nuclease-free water (50-60°C) and centrifugation for 1.5 min at 10 000 x g. Purified 
cRNA was concentrated by precipitation by the addition of one tenth volume of 5M NH4OAc and 
2.5 volumes of 100% ethanol and left at -20°C for 30 min. Samples were microcentrifuged at top 
speed at room temperature for 15 min. Supernatants were discarded and pellets were washed with 
500l 70% cold ethanol by centrifugation. Pellets were air-dried and resuspended in 50l RNase-















5.13.3 Illumina Whole-Genome Gene Expression Direct Hybridization Assay 
 
cRNA samples (1.5g) were resuspended in RNase-free water to a final volume of 10l, after 
which 20l of Hybridization Buffer (HYB) was added to each cRNA sample. The Hyb chamber 
gaskets were inserted into the BeadChip Hyb chamber and 200l Humidity Control Buffer (HCB) 
was loaded into each of the humidifying buffer reservoirs. BeadChips (Illumina WG6-v3 Gene 
Expression BeadChips, Illumina, San Diego, CA, USA) were placed into the chamber inserts. 
Samples were heated at 65°C for 5 min and then loaded onto the BeadChips. The sealed Hyb 
chamber containing the BeadChips was then incubated overnight at 58°C on a rocking platform. 
BeadChips were submerged in E1BC Wash Solution and their coverseals were removed, after 
which both chips were inserted into a submerged slide rack. The slide rack was then transferred 
into a Hybex waterbath containing preheated High-Temp Wash Buffer (55°C) and chips were 
incubated at 55°C for 10 min. The slide rack was transferred into 250ml E1BC Wash buffer, 
agitated and shaken on an orbital shaker for 5 min at the highest possible speed at room 
temperature. The slide rack was transferred into 250ml 100% ethanol, agitated and shaken on an 
orbital shaker for 10 min at room temperature. The rack was transferred into 250ml fresh Wash 
E1BC solution, agitated and shaken on an orbital shaker for 2 min at room temperature. Block E1 
buffer (8ml) was added to two wash trays; BeadChips were placed into the trays and blocked for 
10 min at medium speed on a rocker. For detection, 4ml Block E1 buffer containing 4l 
streptavidin-Cy3 (from 1mg/ml in RNase-free water stock solution) was added to two fresh wash 
trays. BeadChips were placed face-up into the wash trays, which were covered and rocked at 
medium speed for 10 min. BeadChips were transferred back to the slide rack submerged in 250ml 
Wash E1BC solution, agitated then shaken on an orbital shaker for 5 min at room temperature. 
The rack of BeadChips was centrifuged at 25°C for 4 min. Dry BeadChips were stored in a dark 
box until scanned with the Illumina BeadArray Reader. Signal intensities were recorded as iDAT 
files (image data) for each chip. 
 
5.13.4 Microarray Data Analysis  
 
iDAT files were converted into data tables by Illumina BeadStudio version 3 Gene Expression 
Module software (www.illumina.com). The upgraded version of BeadStudio, GenomeStudio, 
which has an equivalent Gene Expression Analysis tool, was used towards the end of the project. 
BeadStudio analysis was carried out with the assistance of Dr Peter Green from the Genomics 
Laboratory at the Department of Medical and Molecular Genetics at King’s College London. 











Istanbul Bilgi University, Istanbul, Turkey and Department of Medicine, BIDMC Genomics 
Centre, Harvard Medical School, Boston, USA. Further analysis was conducted in collaboration 
with Dr Nicki Tiffin at the South African Bioinformatics Institute (SANBI) at the University of 
the Western Cape. 
 
Samples were classified into two groupsets (WHCO1 and EPC-2) and two groups within those 
groupsets (BaP and Un, the reference group). This allowed the generation of data manifest tables 
containing probe and gene lists and their associated signal intensities. For each gene, there are up 
to 30 probe replicates, which enhance the sensitivity of measuring mRNA abundance and 
therefore differential gene expression. Clusters (dendrograms) were generated in BeadStudio 
using the Correlation method to determine which samples are most similar based on the 
expression levels of genes within them. Absolute correlation, Manhattan and Euclidian methods 
were also used for comparison. Outliers were determined from the clusters and were removed 
before further analysis. 
 
A differential expression analysis was run with the following parameters: average normalization, 
no background subtraction, Benjamini and Hochberg false discovery rate calculation and the 
Mann-Whitney method of calculating false discovery rate. Normalization is a method of 
minimizing the effects of variation from non-biological factors by adjusting signal values. The 
Control Summary Report (hybridization control, negative control, low stringency control, gene 
intensity control of housekeeping vs all genes, biotin and high stringency control, background and 
labeling control) indicated that the performance of the built-in controls was satisfactory for both 
WHCO1 and EPC-2 microarrays. 
 
Information within gene lists includes an average signal value for each gene and its probes, and a 
detection p-value which describes whether the signal is detected significantly above background. 
Detection p-value is calculated from negative probes in the chip that measure non-specific 
hybridization. In addition, BeadStudio generated a Diff Score for each gene, which is a 
transformation of the significance p-value based on the difference in average signal in Un (the 
reference group) vs BaP. The p-value is calculated from the Diff Score by the equation: p = 
10'(DiffScore*sgn(µcond-µ ref)/10). A p-value of 0.05 corresponds to a Diff Score of ± 13. 
However, since outliers were removed from both groupsets, no statistical analysis could be 












For the combined analysis of both groupsets, data were filtered for detection p-value <0.05, 
which corresponds to a 5% false positive rate. Following advice from Dr Christy Waterfall at 
Illumina UK, no background subtraction was carried out, since this resulted in negative signal 
values for some genes. Any remaining negative signal values were truncated to 1. Average signal 
values were then filtered using 2% trimmed mean scaling in order to set the target average 
intensity of both chips to 500. This method removes highest and lowest 2% expressed genes. 
Genes with expression level below 40 in all 9 samples were then eliminated and all 6 possible 
comparisons were carried out (Un vs BaP and WHCO1 vs EPC-2). Fold change was calculated 
by averaging BaP and Un values within each cell line and dividing average BaP by average Un. 
Using the Illumina BeadChip, the minimum statistically significant detectable fold-change is 
1.35-fold for single replicates. We chose 2-fold as a cut-off since this is widely used. Lastly, 
genes were again eliminated if signal was not detected in all samples where the gene was 
supposedly up- or down-regulated. Comparative analysis using Venn diagrams was used to show 
genes that are up- or down-regulated by BaP both commonly and uniquely in WHCO1 and EPC-
2 cells. 
 
5.13.5  Quantitative Real-Time PCR (qRT-PCR) on Selected Genes for Validation of 
Microarray Results 
 
In order to confirm that the fold change of differentially expressed genes observed in the WHCO1 
and EPC-2 microarrays were reproducible results, qRT-PCR was carried out on selected genes. 
These genes are listed in Tables 5.7 and 5.8. The primers for CYP1A1, CYP1B1 and GAPDH 
and their cycling conditions are described in Table 5.6 and 5.4, respectively. The primers for 
AHRR, UGT2B7, KISS1, ETV5, SERPINB2, SERPINA3, DEFB1, HIST1H2BH, ALDH3A1 
and TIPARP were purchased from SA Biosciences (Frederick, MD, USA). Primers were 
designed using proprietary algorithms and therefore sequences are not available. The primer 
sequences for GSTM1, MMP9, IFITM1, CCNB2, CDKN3, POLM, IL13RA2, SULF1, 
ADAM23, CCNA1, TFPI2, MT1G, GPX3, P53AIP1 and ITGB7 were obtained from Origene 
(www.origene.com) and primers were synthesized at the Department of Molecular and Cell 
Biology at the University of Cape Town. qRT-PCR was carried out using 2l cDNA, 12,5l of 
either KAPA Biosystems Universal qPCR Master Mix (Kapa Biosystems, Woburn, MA, USA) or 
SA Biosciences RT2 Master Mix (for the primers bought from SA Biosciences), 1l forward 
primer, 1l reverse primer (both primers final concentration of 10M) or 1l primer mix (for SA 
Biosciences primers) and dH2O to a final volume of 25l. qRT-PCR cycling conditions for either 











melting temperatures and amplified product sizes are listed in Table 5.7, while Table 5.8 lists 
available information for the SA Biosciences primers. 
 
 















Fold change was determined using the 2-Ct method described in the SA Biosciences RT2 qPCR 
Primer Assay protocol. Threshold cycle (Ct) values were determined for each gene of interest 
(GOI) and the housekeeping gene GAPDH using the Bio-Rad MiniOpticon software (Hercules, 
CA, USA). The difference between Ct values (Ct) was calculated for control (Un) and 
experimental (BaP) conditions by subtracting Ct (GAPDH) from Ct (GOI). The difference in Ct 
values for the GOI (Ct) was calculated by subtracting Ct (Un) from Ct (BaP). Fold change 
in gene expression was calculated as 2-Ct and compared to microarray fold change.  
 
 
Table 5.7 Primers used for qRT-PCR analysis of gene expression for validation of 












5`-GCC TGC TTC ACC 
ACC TTC-3’                                                      
5'-GGC TCT CCA GAA 




5’-GAG CTG GGT TTG 
ACA CAG TCA-3’ 
5'-  CCC ATA GCT TCT 







5`-GAT TTG GAC AAC 
GTA CCG GCC -3' 
5'-ACC CAT ACA AGG 







5’-GAG ACA GCA TGG 
CCA A-3’ 








5’-GAA CTC CCT GAA 
AAG CTA AAG C-3’ 
5’-GTT GGG CTC AAA 
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5’-GGC TTC ATA GCA 
TTC GCC TAC TC-3’ 
5’-AGA TGT TCA GGC 







5’-CAA CCA GAG CAG 
CAC AAG TAG C-3’ 
5’-GGA GCC AAC TTT 







5’-ATG GAG GGA CTC 
CTG ACA TAG C-3’ 
5’-TCT CCC AAG TCC 







5’-GTG GAG TGA TAA 
ACA ATG CTG GG-3’ 
5’-TGG GTA GGT GTT 







5’-TGT GAG GAG GTG 
GAG AGA GTT C-3’ 
5’-TCG GAG GTC ATC 







5’-GGT CCA AGT GTA 
GAA CCA GGA TC-3’ 
5’-GAC AGA CTT GCC 







5’-CTT TGG AGG TGT 
CTG TTC TCG C-3’ 
5’-GGA TTC CAA GGT 







5’-GCA CAC TCA AGT 
CAG ACC TGC A-3’ 
5’-ATC ACA TCT GTG 







5’-TAC TGG CTG TGG 
AGG GAA TGA C-3’ 
5’-CGG ATT CTA CTG 







5’-AGA GTG CAA ATG 
CAC CTC CTG C-3’ 
5’-TTG TAC TTG GGA 







5’-TAC GGA GCC CTC 
ACC ATT GAT G-3’ 
5’-CAG ACC GAA TGG 







5’-AGA CCA GAA CCT 
CTC GGT GAT G-3’ 
5’-ACC ACG GTG AGA 




5’-ATC GAG GAC AGT 
GCA ACC ACG T-3’ 
5’-TCA GCT CCT CTG 




Table 5.8 SA Biosciences primers information for qRT-PCR analysis of gene expression 
for validation of microarray fold change 
 








SERPINA3 NM_001085.4 1396 85 140 
KISS1 NM_002256.3 210 79 71 
DEFB1 NM_005218.3 162 83 171 
ETV5 NM_004454.2 1640 85 157 
HIST1H2BH NM_003524.2 87 83 113 
SERPINB2 NM_002575.2 1375 77 106 
UGT2B7 NM_001074.2 1543 83 121 
AHRR NM_020731.3 4956 84 109 
ALDH3A1 NM_000691 705 85 166 
TIPARP NM_015508 1827 80 159 
* The reference position is contained within the sequence of the amplicon relative to the start of 
the RefSeq sequence 
 
 
5.13.6  Ontology and Functional Analysis using Ingenuity Pathways Analysis Software 
 
Since many gene ontology (GO) programs are routinely used with Affymetrix microarrays, our 











uploaded for functional analysis. Following primary analysis in BeadStudio and pre-processing, 
lists of differentially expressed genes from the WHCO1 and EPC-2 chips were uploaded into 
Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). The software 
generated several graphical outputs used to represent gene interactions and biological functions 
and pathways affected by BaP treatment in the gene lists. These outputs, described below, are: 
gene interaction networks, biological functions, canonical pathways and cellular flow diagrams. 
IPA also generated its own significance p-value associated with each network, function or 
pathway which further highlighted the notable results.  
 
In addition to IPA, gene ontology was analyzed using GOstat (Beissbarth and Speed, 2004, 
http://gostat.wehi.edu.au/) and GOrilla (Gene Ontology enRIchment anaLysis and visuaLizAtion 
tool, Eden et al., 2009, http://cbl-gorilla.cs.technion.ac.il/) which determine which Gene Ontology 
terms (cellular location, molecular function or biological process) are significantly over-
represented in each gene list compared to the entire genome. 
 
5.13.7  Meta-Analysis of Microarray Data 
 
Data generated from the WHCO1 and EPC-2 microarrays were compared to previously published 
results from other BaP-treated cell lines, as shown in Table 1.2. Cell line origins and full names 
are also indicated in Table 1.2. Gene lists were entered into an Excel spreadsheet and manually 
compared for selection of common genes. Where a specific cell line had more than one 
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Appendix A: Microarray Gene Lists 
 
Table A1: Genes up-regulated by treatment with BaP in EPC-2 cells (top 50) 
* indicates selection for investigation of fold change by qRT-PCR 
Gene Symbol Gene Name Fold Change 
SAMD5 Sterile alpha motif domain containing 5 23.85 
C7ORF57 Chromosome 7 open reading frame 57 23.65 
ZIC2 Zic family member 2 (odd-paired homolog, Drosophila) 18.91 
ADRA1B Adrenergic, alpha-1B-, receptor 18.09 
HS.581429 DB225675 TRACH3 cDNA clone TRACH3017643 5 16.68 
MEOX2 Mesenchyme homeobox 2 15.67 
HS.8038 
UI-E-EJ0-ahj-d-03-0-UI.r2 UI-E-EJ0 cDNA clone UI-E-EJ0-ahj-d-03-0-UI 
5 14.3 
OBSCN Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 13.84 
PLD5 Phospholipase D family, member 5 12.72 
HS.463420 
UI-E-CK1-aga-k-24-0-UI.s1 UI-E-CK1 cDNA clone UI-E-CK1-aga-k-24-
0-UI 3 11.71 
EML1 Echinoderm microtubule associated protein like 1 11.05 
SUSD3 Sushi domain containing 3 10.04 
RHOF Ras homolog gene family, member F (in filopodia) 9.84 
LRRC38 Predicted: Leucine rich repeat containing 38 9.59 
PDLIM3 PDZ and LIM domain 3 9.16 
ESM1 Endothelial cell-specific molecule 1 9.05 
HS.389988 K-EST0184252 L9SNU354 cDNA clone L9SNU354-11-G07 5 9.02 
IL13RA2* Interleukin 13 receptor, alpha 2 8.98 
SULF1* Sulfatase 1 8.74 
LOC730456 Predicted: Hypothetical protein LOC730456 8.05 
ANPEP 
Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 7.94 
ACBD7 Predicted: Acyl-Coenzyme A binding domain containing 7 7.86 
LOC649396 Predicted: Hypothetical LOC649396 7.67 
MESP1 Mesoderm posterior 1 homolog (mouse) 7.65 
CLDN3 Claudin 3 7.55 
ADAM23* ADAM metallopeptidase domain 23 7.54 
GOLT1A Golgi transport 1 homolog A (S. cerevisiae) 7.15 
KIAA1244 KIAA1244 6.86 
XK X-linked Kx blood group (McLeod syndrome) (XK) 6.49 
C14ORF72 Predicted: Chromosome 14 open reading frame 72 6.49 
SRPX2 Sushi-repeat-containing protein, X-linked 2 6.46 
SLC47A1 Solute carrier family 47, member 1 6.45 
LOC284757 Hypothetical protein LOC284757 6.24 
LOC402377 
Predicted: Similar to UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 4 6.13 
SNORD25 Small nucleolar RNA, C/D box 25, non-coding RNA. 6.09 
CD160 CD160 molecule 6 
FOXL1 Forkhead box L1 5.92 
LOC652697 Predicted: Hypothetical protein LOC652697 5.88 
SLCO1B3 Solute carrier organic anion transporter family, member 1B3 5.8 
GLDN Gliomedin 5.74 














Table A2: Genes down-regulated by treatment with BaP in EPC-2 cells (top 50) 
* indicates selection for investigation of fold change by qRT-PCR 
 
Gene Symbol Gene Name Fold Change 
A2ML1 Alpha-2-macroglobulin-like 1 -201.21 
FAM131A Family with sequence similarity 131, member A -122.95 
S100A8 S100 calcium binding protein A8 -114.96 
KRT13 Keratin 13 -109.5 
LOC653506 Predicted: Similar to meteorin, glial cell differentiation regulator-like -100.38 
PTPN20A Protein tyrosine phosphatase, non-receptor type 20A -90.86 
SLURP1 Secreted LY6/PLAUR domain containing 1 -86.2 
SPRR1A Small proline-rich protein 1A -83.5 
SPRR3 Small proline-rich protein 3 -81.98 
CTHRC1 Collagen triple helix repeat containing 1 -80.77 
SPRR2D Small proline-rich protein 2D -75.65 
HS.311428 cDNA FLJ14199 fis, clone NT2RP3002713 -74.21 
ESPN Espin -73.75 
C1ORF51 Chromosome 1 open reading frame 51 -69.9 
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) -69.27 
CRABP2 Cellular retinoic acid binding protein 2 -69.16 
SPRR2A Small proline-rich protein 2A -65.29 
KRT4 Keratin 4 -61.76 
CALML3 Calmodulin-like 3 -60.02 
SPRR2E Small proline-rich protein 2E -57.27 
SBSN Suprabasin -57.22 
S100A12 S100 calcium binding protein A12 -56.72 
GPX3* Glutathione peroxidase 3 (plasma) -55.88 
P53AIP1* p53-regulated apoptosis-inducing protein 1 -54.54 
C10ORF99 Chromosome 10 open reading frame 99 -53.41 
SPRR2C Small proline-rich protein 2C (pseudogene) -53.22 
C4ORF26 Chromosome 4 open reading frame 26 -50.89 
NMU Neuromedin U -48.56 
MFAP5 Microfibrillar associated protein 5 -47.18 
H19 H19, imprinted maternally expressed transcript (non-protein coding) -45.94 
ACTG2 Actin, gamma 2, smooth muscle, enteric -45.88 
5 
LOC728070 Predicted: Similar to chromosome 16 open reading frame 54 5.64 
GLRB Glycine receptor, beta 5.59 
HS.493947 cDNA FLJ41455 fis, clone BRSTN2012284 5.51 
HS.314414 Clone IMAGE:5743779 5.47 
APOLD1 Apolipoprotein L domain containing 1 5.36 
FLJ40288 Hypothetical protein FLJ40288 5.35 
ZDHHC23 Zinc finger, DHHC-type containing 23 5.33 
LOC653981 Predicted: Similar to olfactory receptor, family 2, subfamily T, member 34 5.28 











APOE Apolipoprotein E -44.56 
PRODH 
Proline dehydrogenase (oxidase) 1, nuclear gene encoding mitochondrial 
protein -42.7 
KMO Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) -40.93 
LOC648585 Predicted: Similar to p53-regulated apoptosis-inducing protein 1 -40.23 
ESPNL Espin-like -39.53 
S100A9 S100 calcium binding protein A9 (calgranulin B) -38.52 
SPRR2F Small proline-rich protein 2F -38.35 
FLJ10916 Hypothetical protein FLJ10916 -38 
GGTLC2 Gamma-glutamyltransferase light chain 2 -36.9 
SPRR1B Small proline-rich protein 1B (cornifin) -36.86 
GBP2 Guanylate binding protein 2, interferon-inducible -35.59 
CFB Complement factor B -35.5 
UBA7 Ubiquitin-like modifier activating enzyme 7 -34.58 
MMP9* 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase) -34.47 
MYL9 Myosin, light chain 9, regulatory -33.38 
RRAD Ras-related associated with diabetes -33.34 
RPTN Predicted: Repetin -33.04 
IGFL2 IGF-like family member 2 -32.57 
PI3 Peptidase inhibitor 3, skin-derived (SKALP) -31.56 
 
 
Table A3: Genes up-regulated by treatment with BaP in WHCO1 cells (top 50) 
* indicates selection for investigation of fold change by qRT-PCR 
 
Gene Symbol Gene Name Fold Change 
TLR4 Toll-like receptor 4 29.02 
HIST1H2BI Histone cluster 1, H2bi 19 
CYP1A1* Cytochrome P450, family 1, subfamily A, polypeptide 1 16.63 
HS.150022 Human lacrimal gland, unamplified: oj cDNA clone oj52h05 5 15.62 
HS.144129 EST386809 MAGE resequences, MAGN Homo sapiens cDNA 15.05 
C20ORF160 Chromosome 20 open reading frame 160 13.95 
CTTNBP2 Cortactin binding protein 2 10.53 
HS.545554 xd52h03.x1 NCI_CGAP_Ov23 cDNA clone IMAGE:2597429 3 10.23 
ANPEP 
Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 10.05 
HR Hairless homolog (mouse) 9.78 
LOC653276 Predicted: Hypothetical LOC653276 8.56 
C14ORF162 Chromosome 14 open reading frame 162 8.05 
STRA6 Stimulated by retinoic acid gene 6 homolog (mouse) 7.57 
NRCAM Neuronal cell adhesion molecule 7.4 
LOC554223 Predicted: Hypothetical LOC554223, transcript variant 4, misc RNA. 7.32 
TREM2 Triggering receptor expressed on myeloid cells 2 6.63 
HS.539591 wa38a03.x1 NCI_CGAP_Kid11 cDNA clone IMAGE:2300332 3 6.52 
HS.568832 603078567F1 NIH_MGC_119 cDNA clone IMAGE:5170193 5 6.32 
POSTN Periostin, osteoblast specific factor 6.31 
C2ORF27 Chromosome 2 open reading frame 27 6.16 











KRT34 Keratin 34 5.67 
HS.23681 
BX111083 Soares_fetal_heart_NbHH19W cDNA clone 
IMAGp998G09825 5.59 
TNFSF12 Tumor necrosis factor (ligand) superfamily, member 12 5.16 
FABP6 Fatty acid binding protein 6, ileal 5.13 
HS.543172 ym03e05.s1 Soares infant brain 1NIB cDNA clone IMAGE:46630 3 5.04 
IL24 Interleukin 24 4.97 
HS.563175 
UI-H-BI3-ako-c-02-0-UI.s1 NCI_CGAP_Sub5 cDNA clone 
IMAGE:2734850 3 4.88 
IL1F9 Interleukin 1 family, member 9 4.63 
HS.541726 
UI-CF-DU1-adj-b-02-0-UI.s1 UI-CF-DU1 cDNA clone UI-CF-DU1-adj-b-
02-0-UI 3 4.6 
TMEM200B Transmembrane protein 200B 4.46 
LOC652656 
Predicted: Similar to ATP-binding cassette, sub-family G (WHITE), 
member 1 4.26 
SERPINB2* Serpin peptidase inhibitor, clade B (ovalbumin), member 2 4.2 
LHB Luteinizing hormone beta polypeptide 3.97 
HS.582788 RST44785 Athersys RAGE Library cDNA 3.92 
HS.560163 qp49h09.x1 NCI_CGAP_Co8 cDNA clone IMAGE:1926401 3 3.85 
PPP1R9B Protein phosphatase 1, regulatory (inhibitor) subunit 9B 3.8 
MB Myoglobin 3.75 
MYEF2 Myelin expression factor 2 3.65 
HS.145250 
BX095239 Soares_testis_NHT Homo sapiens cDNA clone 
IMAGp998E214456 3.59 
LOC441632 Predicted: Similar to ribosomal protein L13a 3.52 
MCOLN2 Mucolipin 2 3.5 
HS.535592 
UI-H-BI2-aie-e-08-0-UI.s1 NCI_CGAP_Sub4 Homo sapiens cDNA clone 
IMAGE:2729174 3 3.5 
CYP1B1* Cytochrome P450, family 1, subfamily B, polypeptide 1 3.5 
HS.578068 DB337475 TESTI2 Homo sapiens cDNA clone TESTI2022141 3 3.44 
PDGFRB Platelet-derived growth factor receptor, beta polypeptide 3.43 
HS.437037 
UI-H-BI3-ajx-g-10-0-UI.s1 NCI_CGAP_Sub5 Homo sapiens cDNA clone 
IMAGE:2733499 3 3.43 
LOC728811 Predicted: Similar to UDP glycosyltransferase 2 family, polypeptide B17 3.4 
GREM1 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 3.36 
CD74 
Homo sapiens CD74 molecule, major histocompatibility complex, class II 
invariant chain 3.33 
 
 
Table A4: Genes down-regulated by treatment with BaP in WHCO1 cells (top 50) 
* indicates selection for investigation of fold change by qRT-PCR 
 
Gene Symbol Gene Name Fold Change 
LOC645434 Predicted: hCG1786283 -26.22 
USP31 Ubiquitin specific peptidase 31 -19.36 
HS.563928 
UI-CF-DU1-aah-j-04-18-UI.s18 UI-CF-DU1 cDNA clone UI-CF-DU1-
aah-j-04-18-UI 3 -16.24 
C1ORF167 Predicted: Chromosome 1 open reading frame 167 -15.9 
HS.338140 
AGENCOURT_10185031 NIH_MGC_107 cDNA clone 
IMAGE:6569320 5 -15.76 
VAX2 Ventral anterior homeobox 2 -15.63 












UI-H-BI1-adl-g-11-0-UI.s1 NCI_CGAP_Sub3 cDNA clone 
IMAGE:2717373 3 -9.62 
HS.537735 xk13b01.x1 NCI_CGAP_Co20 cDNA clone IMAGE:2666569 3 -8.99 
DHRS2 Dehydrogenase/reductase (SDR family) member 2 -8.28 
HS.46693 
BX096334 Soares_multiple_sclerosis_2NbHMSP cDNA clone 
IMAGp998J15617 -8.09 
LOXHD1 Lipoxygenase homology domains 1 -8.01 
HS.553145 RST11549 Athersys RAGE Library cDNA -7.94 
LOC124220 Similar to common salivary protein 1 -7.92 
ZFP57 Predicted: Zinc finger protein 57 homolog (mouse) -7.6 
ZNF717 Predicted: Zinc finger protein 717 -7.32 
HS.580929 DB259922 UTERU2 cDNA clone UTERU2017075 5 -7.31 
HS.209882 wh39c03.x1 NCI_CGAP_Kid11 cDNA clone IMAGE:2383108 3 -7.26 
HS.582641 DB336782 TESTI2 cDNA clone TESTI2010942 3 -7.14 
LOC643403 Predicted: Hypothetical protein LOC643403 -7.1 
SPRR2G Small proline-rich protein 2G -7.04 
CA9 Carbonic anhydrase IX -6.92 
LOC284757 Hypothetical protein LOC284757 -6.9 
HS.306690 
BX090584 Soares fetal liver spleen 1NFLS cDNA clone 
IMAGp998G06117 ; IMAGE:122909 -6.38 
HS.382845 602387320F1 NIH_MGC_93 cDNA clone IMAGE:4516253 5 -6.26 
HS.490243 Full length insert cDNA clone YB64E03 -6.04 
HS.151207 BX094762 Soares_testis_NHT cDNA clone IMAGp998B084412 -5.97 
TMEM121 Transmembrane protein 121 -5.63 
ATP13A4 ATPase type 13A4 -5.6 
CRCT1 Cysteine-rich C-terminal 1 -5.58 
LOC286076 Hypothetical protein LOC286076 -5.49 
OR7G2 Olfactory receptor, family 7, subfamily G, member 2 -5.29 
SERPINA3* 
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 3 -5.21 
LOC732157 Predicted: Hypothetical protein LOC732157 -5.13 
ZNF516 Predicted: Zinc finger protein 516 -5.06 
HS.563390 K-EST0153644 L7N800102 cDNA clone L7N800102-2-A04 5 -5.04 
CIT Citron (rho-interacting, serine/threonine kinase 21) -5.01 
HS.277205 602506953F1 NIH_MGC_79 cDNA clone IMAGE:4604245 5 -5 
TGFB2 Transforming growth factor, beta 2 -4.99 
PLCXD2 Phosphatidylinositol-specific phospholipase C, X domain containing 2 -4.94 
HS.570118 
UI-CF-EC1-abz-d-17-0-UI.s1 UI-CF-EC1 cDNA clone UI-CF-EC1-abz-
d-17-0-UI 3 -4.89 
HS.546710 cDNA FLJ26122 fis, clone SYN00634 -4.88 
ALDH1L2 Predited: Aldehyde dehydrogenase 1 family, member L2 -4.86 
HS.128328 AGENCOURT_7590873 NIH_MGC_72 cDNA clone IMAGE:6065319 5 -4.81 
HS.441813 
UI-H-CO0-asl-e-02-0-UI.s1 NCI_CGAP_Sub9 cDNA clone 
IMAGE:5859147 3 -4.75 
KRT4 Keratin 4 -4.47 
C6ORF91 Chromosome 6 open reading frame 91 -4.46 
DEFB1* Defensin, beta 1 -4.45 
TMOD2 Tropomodulin 2 (neuronal) -4.44 












Table A5: Genes up-regulated by treatment with BaP in EPC-2 cells compared to 
untreated WHCO1 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
EEF1A2 Eukaryotic translation elongation factor 1 alpha 2 3447.3 
KRT13 Keratin 13 2588.09 
LOC653506 Predicted: Similar to meteorin, glial cell differentiation regulator-like 1905.7 
KRT81 Keratin 81 1708.89 
GAL Galanin prepropeptide 1280.9 
SOX2 SRY (sex determining region Y)-box 2 1148.56 
FGD3 FYVE, RhoGEF and PH domain containing 3 792.49 
MOSC1 MOCO sulphurase C-terminal domain containing 1 772.53 
THY1 Thy-1 cell surface antigen 766.09 
PRSS3 Protease, serine, 3 (mesotrypsin) 726.12 
ECHDC3 Enoyl Coenzyme A hydratase domain containing 3 678.04 
CRISPLD2 Cysteine-rich secretory protein LCCL domain containing 2 638.97 
MUC20 Mucin 20, cell surface associated 572.98 
PPARG Peroxisome proliferator-activated receptor gamma 542.79 
HSPB8 Heat shock 22kDa protein 8 466.64 
GSTT1 Glutathione S-transferase theta 1 464.4 
CLDN11 Claudin 11 (oligodendrocyte transmembran  protein) 442.21 
GPX3 Glutathione peroxidase 3 (plasma) 428.71 
RBP1 Retinol binding protein 1, cellular 427.15 
MYO5C Myosin VC 423.65 
NKD2 Naked cuticle homolog 2 (Drosophila) 401.62 
RASEF RAS and EF-hand domain containing 395.79 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 387.43 
NDN Necdin homolog (mouse) 349.18 
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 338.5 
ANXA9 Annexin A9 333.93 
MSLN Mesothelin 319.81 
LOC200810 Similar to beta-1,4-mannosyltransferase; beta-1,4 mannosyltransferase 287.18 
C9ORF58 Chromosome 9 open reading frame 58 245.82 
NMU Neuromedin U 237.81 
SUSD2 Sushi domain containing 2 224.9 
LIMCH1 LIM and calponin homology domains 1 222.01 
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 221.56 
HRASLS3 HRAS-like suppressor 3 219.14 
MOSC2 MOCO sulphurase C-terminal domain containing 2 217.06 
KLHDC9 Kelch domain containing 9 211.36 
FAM71E1 Family with sequence similarity 71, member E1 211.3 
ZNF695 Zinc finger protein 695 209.52 
SEMA4D 
Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 4D 204.82 
S100P S100 calcium binding protein P 201.14 
SOX21 SRY (sex determining region Y)-box 21 193.24 
HOXD10 Homeobox D10 182.04 
KRT7 Keratin 7 176.84 











FAM131A Family with sequence similarity 131, member A 173.29 
S100A4 S100 calcium binding protein A4 173.13 
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 172.57 
LOC652644 Predicted: Similar to tumor protein p53 inducible protein 5 171.58 
FER1L4  fer-1-like 4 (C. elegans) 167.01 
CEACAM6 
Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific 
cross reacting antigen) 164.92 
 
 
Table A6: Genes down-regulated by treatment with BaP in EPC-2 cells compared to 
untreated WHCO1 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
KRT14 Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) -23507.8 
CNTNAP2 Contactin associated protein-like 2 -1426.75 
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 -1011.76 
C5ORF13 Chromosome 5 open reading frame 13 -592.2 
C3ORF14 Chromosome 3 open reading frame 14 -435.17 
HS.254632 RST7893 Athersys RAGE Library cDNA -426.84 
NRCAM Neuronal cell adhesion molecule -371.78 
SCG5 Secretogranin V (7B2 protein) -349.91 
GPR68 G protein-coupled receptor 68 -341.9 
WNT5A Wingless-type MMTV integration site family, member 5A -337.92 
TSPAN7 Tetraspanin 7 -291.87 
TMEM16D Transmembrane protein 16D -284.11 
TFCP2 Transcription factor CP2 -272.59 
MSC Musculin (activated B-cell factor-1) -266.36 
VIM Vimentin -265.54 
G0S2 G0/G1switch 2 -250.59 
ANPEP 
Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) -240.27 
TSHZ2 Teashirt zinc finger homeobox 2 -203.62 
HNT Neurotrimin -201.97 
HLA-A29.1 Major histocompatibility complex class I HLA-A29.1  -187.44 
TNF Tumor necrosis factor (TNF superfamily, member 2) -179.16 
HS3ST2 Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 -173.89 
PLD5 Phospholipase D family, member 5 -163.54 
MEX3B Mex-3 homolog B (C. elegans) -154.93 
XG Xg blood group -151.15 
FCRLA Fc receptor-like A -150.79 
SFRP1 Secreted frizzled-related protein 1 -138.89 
D4S234E DNA segment on chromosome 4 (unique) 234 expressed sequence -134.62 
HS.100261 cDNA FLJ26539 fis, clone KDN09310 -134.37 
GSTM2 Glutathione S-transferase M2 (muscle) -121.97 
CLCA2 Chloride channel, calcium activated, family member 2 -115.32 
TAGLN3 Transgelin 3 -114.96 
AOX1 Aldehyde oxidase 1 -112.11 
ACP5 Acid phosphatase 5, tartrate resistant -109.1 











ANO4 Anoctamin 4 -99.04 
HR Hairless homolog (mouse) -95.39 
GLT8D2 Glycosyltransferase 8 domain containing 2 -92.99 
HS.144479 AGENCOURT_13979145 NIH_MGC_179 cDNA clone IMAGE:30367627 5 -88.09 
HS.128708 602505656F1 NIH_MGC_77 cDNA clone IMAGE:4619364 5 -82.49 
ERV3 Endogenous retroviral sequence 3 (includes zinc finger protein H-plk/HPF9) -79.38 
ZNF215 Zinc finger protein 215 -78.57 
C7ORF10 Chromosome 7 open reading frame 10 -77.69 
SPOCK1 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 -77.28 
ANKRD29 Ankyrin repeat domain 29 -75.57 
LRRC38 Predicted: Leucine rich repeat containing 38 -71.77 
PLCL4 Predicted: Phospholipase C-like 4 -71.21 
PDCD1LG2 Programmed cell death 1 ligand 2 -70.76 
FN1 Fibronectin 1 -70.18 
DNER Delta/notch-like EGF repeat containing -69.78 
 
 
Table A7: Genes up-regulated in untreated WHCO1 cells c mpared to untreated 
EPC-2 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
GAL Galanin prepropeptide 1298.76 
NDN Necdin homolog (mouse) 1097.85 
FGD3 FYVE, RhoGEF and PH domain containing 3 729.7 
HOXA9 Homeobox A9 708.05 
ECHDC3 Enoyl Coenzyme A hydratase domain containing 3 687.49 
LIM LIM and calponin homology domains 1 551.38 
SEMA4D Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 4D 
521.72 
GSTT1 Glutathione S-transferase theta 1 470.87 
RBP1 Retinol binding protein 1, cellular 433.1 
NKD2 Naked cuticle homolog 2 (Drosophila) 407.22 
RASEF RAS and EF-hand domain containing 401.31 
KRT81 Keratin 81 373.75 
NLRP2 NLR family, pyrin domain containing 2 295.71 
SOX21 SRY (sex determining region Y)-box 21 284.13 
EEE1A2 Eukaryotic translation elongation factor 1 alpha 2 272.86 
MUC20 Mucin 20, cell surface associated 262.39 
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 253.23 
CRISPLD2 Cysteine-rich secretory protein LCCL domain containing 2 233.84 
GOLT1A Golgi transport 1 homolog A (S. cerevisiae) 229.74 
HS.579631 AGENCOURT_10229596 NIH_MGC_141 cDNA clone IMAGE:6563923 5 221.92 
ZNF695 Zinc finger protein 695 212.44 
GLB1L2 Galactosidase, beta 1-like 2 211.06 
PRSS3 Protease, serine, 3 (mesotrypsin) 207.63 
SUSD3 Sushi domain containing 3 189.98 
HOXD10 Homeobox D10 184.58 
MSLN Mesothelin 177.95 
HSPB8 Heat shock 22kDa protein 8 170.64 
CEACAM6 Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross 
reacting antigen) 
167.22 
HRASLS3 HRAS-like suppressor 3 162.9 
PPARG Peroxisome proliferator-activated receptor gamma 148.04 











DNAH2 Dynein, axonemal, heavy chain 2. 136.29 
MPP2 Membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) 134.42 
HS.545589 Small nuclear RNA U6atac, partial sequence 132.82 
HS.384594 Full length insert cDNA clone ZD67H01 127.83 
NUF2 NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) 125.89 
KRT7 Keratin 7 125.14 
TSPYL5 TSPY-like 5 123.68 
B3GNTL1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 122.29 
NES Nestin 115.64 
ACBD7 Predicted: Acyl-Coenzyme A binding domain containing 7 112.18 
C17ORF60 Chromosome 17 open reading frame 60 112.04 
MMP13 Matrix metallopeptidase 13 (collagenase 3) 111.8 
SLITRK5 SLIT and NTRK-like family, member 5 111.7 
XK X-linked Kx blood group (McLeod syndrome) 110.36 
HS.436189 17000532640995 GRN_ES cDNA 5 107.78 
PCDH20 Protocadherin 20 101.78 
DDN Dendrin 101.28 
SLC27A2 Solute carrier family 27 (fatty acid transporter), member 2 101.11 
SUSD2 Sushi domain containing 2 100.81 
 
 
Table A8: Genes down-regulated in untreated WHCO1 cells compared to untreated 
EPC-2 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
KRT14 Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) -22199.5 
CNTNAP2 Contactin associated protein-like 2 -1740.76 
CALML3 Calmodulin-like 3 -1549.04 
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 -1085.18 
WNT5A Wingless-type MMTV integration site family, member 5A -857.03 
C5ORF13 Chromosome 5 open reading frame 13 -810.4 
TNF Tumor necrosis factor (TNF superfamily, member 2) -657.34 
G0S2 G0/G1switch 2 -489.8 
SPRR2D Small proline-rich protein 2D -441.4 
HLA-A29.1 Homo sapiens major histocompatibility complex class I HLA-A29.1 -438.7 
LOC729252 Predicted: Similar to Keratin, type I cytoskeletal 14 (Cytokeratin-14) 
(CK-14) (Keratin-14) (K14) 
-413.82 
HS3ST2 Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 -388.83 
SCG5 Secretogranin V (7B2 protein) -382.54 
GPR68 G protein-coupled receptor 68 -369.63 
C30RF14 Chromosome 3 open reading frame 14 -369.11 
MSC Musculin (activated B-cell factor-1) -357.97 
ACP5 Acid phosphatase 5, tartrate resistant -354.79 
TMEM16D Transmembrane protein 16D -351.81 
GSTM2 Glutathione S-transferase M2 (muscle) -341.54 
HNT Neurotrimin -316.99 
TFCP2 Transcription factor CP2 -307.84 
GLT8D2 Glycosyltransferase 8 domain containing 2 -298.1 
LOC400578 Predicted: Similar to Keratin, type I cytoskeletal 14 (Cytokeratin-14) 
(CK-14) (Keratin-14) (K14) 
-282.09 
S100A8 S100 calcium binding protein A8 -279.96 
D4S234E DNA segment on chromosome 4 (unique) 234 expressed sequence -272.89 
IGFL1 IGF-like family member 1 -272.27 
XG Xg blood group -243.12 
MEX3B Mex-3 homolog B (C. elegans) -239.81 
HS.100261 cDNA FLJ26539 fis, clone KDN09310 -238.94 
DAPL1 Death associated protein-like 1 -232.07 











HS.311428 cDNA FLJ14199 fis, clone NT2RP3002713 -221.78 
KRT6B Keratin 6B -202.08 
VIM Vimentin -194.1 
SFRP1 Secreted frizzled-related protein 1 -189.69 
STON2 Stonin 2 -186.22 
C10ORF99 Chromosome 10 open reading frame 99 -180.63 
TSPAN7 Tetraspanin 7 -164.58 
HS.254632 RST7893 Athersys RAGE Library cDNA -162.05 
C7ORF10 Chromosome 7 open reading frame 10 -161.4 
CRYAB Crystallin, alpha B -152.37 
SERPINB3 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 -150.41 
TSHZ2 Teashirt zinc finger homeobox 2 -148.72 
CHSY3 Chondroitin sulfate synthase 3 -148.21 
SAA1 Serum amyloid A1 -136.57 
KCTD14 Potassium channel tetramerisation domain containing 14 -135.1 
PTPN20A Protein tyrosine phosphatase, non-receptor type 20A -132.42 
FCRLA Fc receptor-like A -130.79 
CLCA2 Chloride channel, calcium activated, family member 2 -129.28 









































Table A9: Genes up-regulated by BaP in BaP-treated WHCO1 cells compared to 
BaP-treated EPC-2 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
EEF1A2 Eukaryotic translation elongation factor 1 alpha 2 4010.87 
KRT13 Keratin 13 2396.84 
LOC653506 Predicted: Similar to meteorin, glial cell differentiation regulator-like 1714.88 
KRT81 Keratin 81 1447.09 
GAL Galanin prepropeptide 1134 
CRISPLD2 Cysteine-rich secretory protein LCCL domain containing 2 914.69 
PRSS3 Protease, serine, 3 (mesotrypsin) 852.64 
THY1 Thy-1 cell surface antigen 814.88 
MOSC1 MOCO sulphurase C-terminal domain containing 1 795.36 
NKD2 Naked cuticle homolog 2 (Drosophila) 736.53 
SOX2 SRY (sex determining region Y)-box 2 686.86 
PPARG Peroxisome proliferator-activated receptor gamma 630.76 
GPX3 Glutathione peroxidase 3 (plasma) 599.03 
FGD3 FYVE, RhoGEF and PH domain containing 3 580.23 
MUC20 Mucin 20, cell surface associated 544.56 
ECHDC3 Enoyl Coenzyme A hydratase domain containing 3 527.3 
GSTT1 Glutathione S-transferase theta 1 523.37 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 473.79 
HSPB8 Heat shock 22kDa protein 8 465.95 
MYO5C Myosin VC 429.24 
RASEF RAS and EF-hand domain containing 409.54 
NDN Necdin homolog (mouse) 368.3 
MSLN Mesothelin 312.49 
ANXA9 Annexin A9 301.01 
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 296.68 
RBP1 Retinol binding protein 1, cellular 291.33 
CLDN11 Claudin 11 (oligodendrocyte transmembrane protein) 289.66 
METTL7B Methyltransferase like 7B 284.96 
LOC200810 Similar to beta-1,4-mannosyltransferase; beta-1,4 mannosyltransferase 272.36 
KLHDC9 Kelch domain containing 9 270.76 
FAM71E1 Family with sequence similarity 71, member E1 265.56 
C9ORF58 Chromosome 9 open reading frame 58 265.54 
MOSC2 MOCO sulphurase C-terminal domain containing 2 250.1 
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 246.99 
UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 246.33 
HRASLS3 HRAS-like suppressor 3 246.04 
HOXD10 Homeobox D10 235.17 
NMU Neuromedin U 213.44 
FER1L4 Fer-1-like 4 (C. elegans) 199.37 
FAM131A Family with sequence similarity 131, member A 194.82 
LIMCH1 LIM and calponin homology domains 1 190.96 
ZNF695 Zinc finger protein 695 185.34 
EMILIN2 Elastin microfibril interfacer 2 185.05 













Table A10: Genes down-regulated by BaP in BaP-treated WHCO1 cells compared to 
BaP-treated EPC-2 cells (top 50) 
 
Gene Symbol Gene Name Fold Change 
KRT14 Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) -6101.44 
CNTNAP2 Contactin associated protein-like 2 -1248.32 
GPR68 G protein-coupled receptor 68 -852.93 
C5ORF13 Chromosome 5 open reading frame 13 -596.74 
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 -585.43 
CHES1 Checkpoint suppressor 1 -496.43 
SFRP1 Secreted frizzled-related protein 1 -484.11 
G0S2 G0/G1switch 2 -389.61 
WNT5A Wingless-type MMTV integration site family, member 5A -340.51 
TMEM16D Transmembrane protein 16D -335.02 
SCG5 Secretogranin V (7B2 protein) -301.39 
TSPAN7 Tetraspanin 7 -294.11 
VIM Vimentin -293.6 
CAMP Cathelicidin antimicrobial peptide -286.54 
HNT Neurotrimin -255.62 
C3ORF14 Chromosome 3 open reading frame 14 -253.83 
TAGLN3 Transgelin 3 -242.31 
TSHZ2 Teashirt zinc finger homeobox 2 -205.18 
HS.553145 RST11549 Athersys RAGE Library cDNA -200.24 
HLA-A29.1 Homo sapiens major histocompatibility complex class I HLA-A29.1 -197.84 
TFCP2 Transcription factor CP2 -183.55 
CLCA2 Chloride channel, calcium activated, family member 2 -181.87 
HS.100261 cDNA FLJ26539 fis, clone KDN09310 -172.28 
HS.254632 RST7893 Athersys RAGE Library cDNA -167.51 
PLD5 Phospholipase D family, member 5 -164.79 
PGCP Plasma glutamate carboxypeptidase -157.86 
MEX3B Mex-3 homolog B (C. elegans) -156.12 
C21ORF63 Chromosome 21 open reading frame 63 -155.46 
XG Xg blood group -152.31 
ZNF717 Predicted: Zinc finger protein 717 -152.23 
SLIT3 Slit homolog 3 (Drosophila) -150.98 
AOX1 Aldehyde oxidase 1 -149.39 
ERV3 Endogenous retroviral sequence 3 (includes zinc finger protein H-plk/HPF9) -142.61 
CPS1 Carbamoyl-phosphate synthetase 1, mitochondrial -142.5 
cytoplasmic domain, (semaphorin) 4D 
HOXA9 Homeobox A9 179.32 
C17ORF60 Chromosome 17 open reading frame 60 178.52 
CEACAM6 
Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross 
reacting antigen) 170.24 
DGKG Diacylglycerol kinase, gamma 90kDa 169.97 
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 167.26 











C7ORF10 Chromosome 7 open reading frame 10 -125.04 
MRGPRX3  MAS-related GPR, member X3 -124.96 
IGFL1 IGF-like family member 1 -119.62 
MYBPHL Myosin binding protein H-like -118.96 
HS3ST2 Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 -118.28 
PNLIPRP3 Pancreatic lipase-related protein 3 -108.83 
CHSY3 Chondroitin sulfate synthase 3 -107.8 
COL22A1 Collagen, type XXII, alpha 1 -107.37 
KCTD14 Potassium channel tetramerisation domain containing 14 -103.84 
LRRC38 Predicted: Leucine rich repeat containing 38 -95.22 
FN1 Fibronectin 1 -90.32 
FLJ14213 Protor-2 -89.22 
ALDH1L2 Predicted: Aldehyde dehydrogenase 1 family, member L2 -84.98 
STON2 Stonin 2 -84.37 
HS.128708 602505656F1 NIH_MGC_77 cDNA clone IMAGE:4619364 5 -83.13 
PRICKLE2 Prickle homolog 2 (Drosophila) -82.96 
 
Table A.11 Genes commonly up-regulated by BaP exposure in WHCO1 and EPC-2 














HS.568832 603078567F1 NIH_MGC_119 Homo sapiens cDNA clone IMAGE:5170193 5 6.32 2.11 
GLT1D1 Glycosyltransferase 1 domain containing 1 2.43 3.76 
LOC730456 Predicted: Hypothetical protein LOC730456 2.74 8.05 
HS.517692 
UI-E-EJ1-ajw-b-16-0-UI.r1 UI-E-EJ1 Homo sapiens cDNA clone UI-E-EJ1-
ajw-b-16-0-UI 5 2.06 2.41 
HS.389988 K-EST0184252 L9SNU354 Homo sapiens cDNA clone L9SNU354-11-G07 5 2.78 9.02 
TMEM200B Transmembrane protein 200B 4.46 3.78 
ANPEP 
Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 10.05 7.94 
NIPSNAP3B Nipsnap homolog 3B (C. elegans) 2.26 3.08 
HS.127934 
UI-H-BI1-afm-f-03-0-UI.s1 NCI_CGAP_Sub3 Homo sapiens cDNA clone 
IMAGE:2722324 3 2.35 2.95 
C8ORF13 Chromosome 8 open reading frame 13 2.12 2.01 
SPRY4 Sprouty homolog 4 (Drosophila) 2.22 2.56 
C14ORF162 Chromosome 14 open reading frame 162 8.05 3.31 
NRCAM Neuronal cell adhesion molecule 7.4 3.41 
C1QTNF8 C1q and tumor necrosis factor related protein 8 2.14 4.13 
EREG Epiregulin 2.36 3.2 
IL10RA Interleukin 10 receptor, alpha 3.2 2.15 
LOC647488 Predicted: Hypothetical protein LOC647488 3.16 2.59 
HS.552160 
xd91c02.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone 
IMAGE:2604962 3 2.57 2.23 
















Table A.12 Genes commonly down-regulated from Fig. 3.14B by BaP exposure in 














CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) -3.08 -7.69 
RNF39 Ring finger protein 39 -2.2 -2.35 
SPRR2G Small proline-rich protein 2G -7.04 -13.24 
SPINK4 Serine peptidase inhibitor, Kazal type 4 -3.34 -13.91 
GRIN3B Glutamate receptor, ionotropic, N-methyl-D-aspartate 3B -3.39 -4.57 
HS.582641 DB336782 TESTI2 Homo sapiens cDNA clone TESTI2010942 3 -7.14 -2.15 
H19 H19, imprinted maternally expressed transcript (non-protein coding) -2.23 -45.94 
TGFB2 Transforming growth factor, beta 2 -4.99 -4.7 
HS.537735 xk13b01.x1 NCI_CGAP_Co20 Homo sapiens cDNA clone IMAGE:2666569 3 -8.99 -2.94 
HS.441213 
UI-E-CK0-aao-f-09-0-UI.r1 UI-E-CK0 Homo sapiens cDNA clone UI-E-CK0-
aao-f-09-0-UI 5 -2.29 -2.59 
HS.542990 
UI-H-BI1-afq-a-03-0-UI.s1 NCI_CGAP_Sub3 Homo sapiens cDNA clone 
IMAGE:2722468 3 -4.28 -19.87 
ITGB8 Integrin, beta 8 -3 -2.67 
HS.46693 
BX096334 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone 
IMAGp998J15617 -8.09 -2.02 
HS.544253 Clone HED10 Cri-du-chat region mRNA -3.24 -2.92 
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 -5.21 -14.21 
LOC124220 Similar to common salivary protein 1 -7.92 -2.1 
KRT3 Keratin 3 -2.34 -4.22 
KRT4 Keratin 4 -4.47 -61.76 
SULT1C3 Sulfotransferase family, cytosolic, 1C, member 3 -2.1 -9.92 
LOC440438 Predicted: Similar to spergen-3 -2.41 -2.88 
CIB2 Calcium and integrin binding family member 2 -3.13 -2.39 
S100A1 S100 calcium binding protein A1 -3.47 -2.19 
HS.209882 wh39c03.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2383108 3 -7.26 -2.33 
HS.382845 602387320F1 NIH_MGC_93 Homo sapiens cDNA clone IMAGE:4516253 5 -6.26 -3.09 
CAPNS2 Calpain, small subunit 2 -2.32 -8.08 
LOC643841 Predicted: Hypothetical protein LOC643841 -2.85 -4.9 
LOC653855 
Predicted: Similar to rho guanine nucleotide exchange factor 5 isoform 1, 
transcript variant 2 -2.43 -2.47 
PLXNB3 Plexin B3 -3.01 -2.09 
CHST2 Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 -4.32 -2.15 
FRMPD3 Predicted: FERM and PDZ domain containing 3 -3.66 -4.39 
HS.537109 cDNA FLJ42489 fis, clone BRACE2032538 -2.76 -2.13 
HS.93739 
BX098660 Soares placenta Nb2HP Homo sapiens cDNA clone 
IMAGp998L03214 -2.08 -7.22 
COL5A2 Collagen, type V, alpha 2 -2.14 -7.57 
LOC644347 Predicted: Hypothetical protein LOC644347 -2.65 -2.85 
FLJ37078 Hypothetical protein FLJ37078 -2.19 -4.39 
HS.570118 
UI-CF-EC1-abz-d-17-0-UI.s1 UI-CF-EC1 Homo sapiens cDNA clone UI-CF-
EC1-abz-d-17-0-UI 3 -4.89 -15.71 
SH2D3C SH2 domain containing 3C -2.47 -4.04 
DHRS2 Dehydrogenase/reductase (SDR family) member 2 -8.28 -2.54 











CPE Carboxypeptidase E -3.57 -4.29 
CA9 Carbonic anhydrase IX -6.92 -14.87 
LOC648149 Predicted: Hypothetical protein LOC648149 -2.21 -3.04 
LOC402573 Hypothetical LOC402573 -2.37 -2.2 
FBXL7 F-box and leucine-rich repeat protein 7 -2.37 -3.01 


















Appendix B: Solutions 
 
 
B.1 Genomic DNA Isolation 
Digestion buffer 
 5M NaCl 2ml 
 0.5M Tris-HCl pH 8 2ml 
 0.5M EDTA 5ml 
10% SDS 5ml 
0.1mg/ml proteinase K 
Add distilled water to 100ml, store at room temperature. The proteinase K is labile and therefore must be 
added fresh with each use. 
 
0.5M EDTA, pH 8.0 
Dissolve 37.22g Na2EDTA·2H2O in 140ml distilled water, adjust pH to 8.0 with concentrated NaOH (~ 
10ml), adjust volume up to 200ml with distilled water and autoclave. 
 
Phenol:Chloroform:Isoamyl alcohol (25:24:1) 
Mix one part of phenol and one part of chloroform:isoamyl alcohol (24:1). 
 
7.5M Ammonium acetate, pH 7.6 
Dissolve 57.81g ammonium acetate in 50ml of distilled water, adjust pH to 7.6 with ammonia solution, 
adjust volume up to 100ml with distilled water and sterilize by filtration through a 0.45m filter. 
 
70% Ethanol 
140ml absolute ethanol 
Make up volume to 200ml with distilled water. 
 
TE buffer, pH 7.5 
200l 1M Tris-HCl, pH 7.5 
40l 0.5M EDTA, pH 8.0 

















10 × TBE 
108g Tris 
55g Boric acid 
40ml 0.5M EDTA, pH 8.0 
Make up volume to 1 litre with distilled water and autoclave. 
 
B.3 Cell Culture 
DMEM 
450ml DMEM media 
50ml FCS 













Adjust pH to 7.4 using 1N HCl or 1N NaOH if necessary, adjust volume up to 1 litre with distilled water 
and autoclave. 
 
1 × Trypsin-EDTA solution 
0.05% (w/v) trypsin 
0.53mM EDTA 
Prepare in a calcium- and magnesium-free salt solution such as 1×PBS. 
 
Cell freezing down solution (WHCO and KYSE series) 
70% foetal calf serum 
20% DMEM 












Cell freezing down solution (EPC-2) 




Weigh out 0.012g benzo[a]pyrene and add to 1ml pure DMSO. Heat to dissolve at 100°C, store at 4°C. 
Make 10mM working solution by mixing 20l 50mM stock solution with 80l pure DMSO. Treat cells 
with 10M BaP by diluting 10mM BaP stock 1:1000 with cell culture medium. 
 
B.4 MTT Assay 
MTT Solution 
Weigh 100mg MTT (dimethylthiazol diphenyltetrazolium bromide) in a 50ml tube; dissolve in 20ml 1 x 
PBS pH 7.4. Mix, vortex and incubate in a water bath at 37°C for 15min. In tissue culture, filter through a 
0.2µm filter. Store at 4°C. 
 
Solubilisation Reagent 
Dissolve 2.5g SDS in 25ml distilled water. Add 7.66ml HCl (32.64M) and mix. 
 
B.5 BrdU ELISA 
BrdU Labeling Solution  
Dilute BrdU labeling reagent (1000x BrdU, 10mM 5-bromo-2’-deoxyuridine in PBS, pH 7.4, filtered 
through 0.2m pore size membrane) 1:100 in sterile culture medium (working concentration 100M). Add 
10l labeling solution to each well. Final concentration: 10M BrdU. 
 
Anti-BrdU-POD 
Add 1.1ml ddH2O to lyophilized monoclonal antibody and dissolve for 10min. Store 20l aliquots of 
antibody at -20°C. Dilute antibody 1:100 in antibody dilution solution directly before use. 
 
B.6 RNA Work 
DEPC-treated water 
Add DEPC (diethylpyrocarbonate) to 0.01% (v/v) to distilled water, stir, let stand overnight and autoclave. 
 
10 × MOPS running buffer 
0.4M MOPS, pH 7.0 
0.1M Sodium acetate 











Dissolve 20.6g MOPS in 400ml 50mM sodium acetate (DEPC-treated), adjust pH to 7.0 with 10N NaOH, 
add 10ml 0.5M EDTA (pH 8.0, DEPC-treated), adjust volume up to 500ml with autoclaved DEPC-treated 
water. 
 
RNA loading buffer (25ml) 
                                                  Final concentration 
50l 0.5M EDTA, pH 8.0                 1mM 
62.5mg Bromophenol blue              0.25% (w/v) 
62.5mg Xylene cyanol                    0.25% (w/v) 
12.4ml Water 
12.5ml Glycerol                                 50% 
50l DEPC 
Stir overnight, then autoclave. 
 
75% Ethanol 
75ml absolute ethanol 
Make up volume to 100ml with autoclaved DEPC-treated water. 
 
B.7 Protein Work 
RIPA buffer 
150mM NaCl 
1% Triton X100 
0.1% SDS 
25mM Tris, pH 7.5 
1% Sodium deoxycholate 
1M DTT 
Dissolve 3.09g DTT (Dithiothreitol) in 20ml of 10mM sodium acetate (pH 5.2), filter sterilize and freeze 
aliquots at −20ºC. 
 
Proteinase K (10mg/ml) 




Dissolve PMSF (phenylmethylsulphonyl fluoride) in absolute ethanol to a final concentration of 100mM, 




















B.8 Western Blotting 
30% Acrylamide/0.8% Bisacrylamide solution 
30g acrylamide 
0.8g bisacrylamide 
0.1g SDS  
Make up to 100ml with distilled water and store at 4ºC. 
 
10% SDS 
Dissolve 10g SDS (sodium dodecyl sulfate) in 80ml distilled water; heat to 68ºC, adjust volume up to 
100ml with distilled water. 
 
1M Tris pH 6.8 
Dissolve 60.5g Tris base in 300ml distilled water, pH with concentrated HCl to 6.8, adjust volume up to 
500ml with distilled water, autoclave. 
 
1M Tris pH 8.8 
Dissolve 60.5g Tris base in 300ml distilled water, pH with concentrated HCl to 8.8, adjust volume up to 
500ml with distilled water, autoclave. 
 
5 × Protein loading buffer 
Dissolve 1.75g Tris in 10 ml distilled water, add 30ml of glycerine, adjust pH to 6.8 with concentrate HCl, 
add 5g SDS, adjust volume to 50ml with distilled water. 
 
5 × Protein loading dye 
200l 5 × protein loading buffer 
50l -mercaptoethanol 













10 × Running buffer 
Take 29g Tris, 144g Glycine and 10g SDS, adjust volume to 1 litre with distilled water. 
 
10 × Transfer buffer 
144g glycine 
38g Tris 
Make up volume to 1 litre with distilled water. 
 
1 × Transfer buffer 
100ml 10 × transfer buffer 
200ml methanol 
700ml distilled water 
 
TBST 
Mix 50ml 1M Tris, 30ml 5M NaCl and 500l Tween20. Adjust volume to 1 litre with distilled water. 
 
5% Non-fat milk blocking solution 
Dissolve 2.5g powder non-fat milk in 30ml TBST, make up volume to 50ml with TBST. 
 
27% Non-fat milk blocking solution 
Dissolve 3.5g powder non-fat milk in 30ml TBST, make up volume to 50ml with TBST. 
 
Coomassie blue staining solution 
500ml methanol 
0.5g Coomassie brilliant blue 
100ml acetic acid 




70ml acetic acid 
880ml distilled water 
 
1M Glycine pH 2.0 
Dissolve 37.535g glycine in 300ml distilled water, pH with concentrated HCl to 2.0 and adjust volume to 












1M Tris-HCl, pH 7.5 
Dissolve 24.22g Tris in 160ml of distilled water, adjust pH to 7.5 with HCl (~ 15ml), adjust volume up to 
200ml with distilled water and autoclave. 
 
Stacking gel (4%) 
Solution Volume 
ddH2O 3.65ml 
1M Tris pH 6.8 0.625ml 
30% acrylamide/bisacrylamide 0.650ml 
10% SDS 50µl 
10% APS 25µl 
TEMED 5µl 
Total volume 5ml 
 
Separating gel 
Solution 7% gel (nuclear protein) 10% gel (total protein) 
ddH2O 3.76ml 2.75ml 
1M Tris pH 8.8 3.75ml 3.75ml 
10% SDS 100µl 100µl 
30% acrylamide/bisacrylamide 2.33ml 3.35ml 
10% APS 50µl 50µl 
TEMED 5µl 5µl 




16% paraformaldehyde  
Add 80ml dH2O to 16g paraformaldehyde. Cover with foil, stir for 1h on heated stirrer. Do not let 
temperature exceed 60°C. Add a few drops of 10M NaOH, just until solution turns clear. Filter through 


















DAPI nuclear stain 
Add 50g DAPI (4’, 6-diamidino-2-phenylinole dihydrochloride) to 1ml dH2O. Store covered in foil at -
20°C. Dilute 1:200 in PBS before mounting. 
 
Mowiol 
Add 2g mowiol to 2ml glycerol. While stirring, add 4ml ddH2O. Leave at room temperature for about 4h, 
the longer the better. 
 
B.10 Microarray Hybridization 
Streptavidin-Cy3 
Prepare 1mg/ml stock solution by adding 1ml RNase-free water to 1mg streptavidin-Cy3 powder. Mix. 













Appendix C: Molecular Weight Markers 
 
 










































Appendix D: Cell Line Nomenclature 
 
 
Cell Line Origin 
A549 Lung adenocarcinoma cells 
ACHN Renal carcinoma cells 
BEP2D Immortalized bronchial epithelial cells 
Caco-2 Colon carcinoma cells 
CI41 Mouse normal epidermal cells 
EPC-2 Immortalized normal oesophageal epithelial cells 
F258 Normal rat liver epithelial cells 
FL Normal amnion epithelial cells 
H460 Lung cancer 
HeLa Cervical carcinoma cells 
Hepa1c1c7 Mouse hepatoma cells 
HepG2 Hepatocarcinoma cells 
HCT116 Colorectal carcinoma cells 
HIOEC Human immortalized oral epithelial cells 
HME87 Normal mammary epithelial cells 
HOSE Ovarian epithelial cells 
KYSE Oesophageal squamous cell carcinoma cells 
LS-180 Colon carcinoma cells 
MCF-7 Breast carcinoma cells 
MCF-10A Mammary epithelial cells 
MCF-10AT1 Breast carcinoma cells 
MSK-LEUK1 Oral leukoplakia cells 
MRC-5 SV2-immortalized lung fibroblasts 
NEC14 Testis embryonal carcinoma cells 
NHBE Normal human bronchial epithelial cells 
NHEK Normal human epidermal keratinocytes 
NHMEC Normal human mammary epithelial cells 
OVCA Ovarian carcinoma 
RL95-2 Endometrial epithelial cells 
SCC-9 Oral epithelial squamous cell carcinoma 
SCC-449 Oesophageal squamous cell carcinoma cells 
T24 Transitional cancer cells 
TK6 Lymphoblastoid cells 
WHCO1 Oesophageal squamous cell carcinoma cells 
WI38 Normal foetal lung fibroblasts 
 
 
 
 
 
